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ABSTRACT 
Dylan Michael Glatt: Monoclonal antibody-mediated tumor targeting and drug delivery  
to solid tumors 
(Under the direction of Russell J. Mumper) 
 
 Antibody-drug conjugates (ADCs) are an emerging class of targeted anticancer 
therapeutics.  Premised on Paul Ehrlich’s magic bullet hypothesis and clinical need to improve 
the tumor selectivity of anticancer drugs, ADCs marry the tumor homing properties of 
monoclonal antibodies (mAbs) with the cell-killing properties of cytotoxic agents like 
chemotherapy.  Conceptually, this is achieved by simultaneously improving the therapeutic 
effects and diminishing the toxic effects of the cytotoxic agent, thereby increasing the therapeutic 
index compared to standard chemotherapy.  Recent FDA-approvals of ADCETRIS® (2011) and 
KADCYLA® (2013), as well as the FDA breakthrough designation of inotuzumab ozogamicin 
(2015), inspire confidence in ADCs to continue advancing state-of-the-art cancer treatment.  
New research in cancer biology influences trends in ADC design.  Advances in antibody 
engineering, linker design, and bioconjugation continue to improve the chemistry, 
manufacturing, and control of ADCs.  Despite hurdles, herculean efforts brought ADCs from a 
research-phase concept to an FDA-approved clinical treatment in less than three decades.  The 
objective of this dissertation research was to develop an antibody-drug conjugate therapy for 
solid tumors cancer therapy.  Achieving that goal demanded a deep exploration of the many 
complex yet innately interdependent physical, chemical, and biological barriers that protect our 
 iv 
bodies from the daily barrage of pathogens but also shield diseases like cancer, HIV/AIDS, and 
Alzheimer’s from the drugs we use for treatment. 
Uptake and exposure of tumor-targeting mAb by solid tumors is influenced by specific 
molecular properties of the mAb, like antigen affinity, internalization rate, and circulating half-
life, the nature of tumor-associated antigen, and the unique tumor pathophysiology and its 
microenvironment.  Intermediate affinity tumor-targeting mAb were discovered to display 
superior tumor-targeting features than low- or high-affinity mAb to the tumor-associated antigen 
CD44, a novel cancer stem cell marker, and the epidermal growth factor receptor (EGFR), a 
hallmark tumor cell biomarker.  Pharmaceutical properties of tumor-targeting mAb were 
attenuated by fragmentation, yielding exceptionally sensitive EGFR tumor imaging agents, and 
chemical conjugation, enabling tumor-cell specific homing, internalization, and delivery of 
docetaxel to a solid tumor.  In a culminating study, an anti-EGFR mAb-docetaxel bioconjugate 
demonstrated tumor cell-specific anticancer activity in vitro and durable tumor regression in 
tumor-bearing mice in vivo. 
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CHAPTER 1: MONOCLONAL ANTIBODY AND ANTIBODY-DRUG CONJUGATES 
IN TUMOR TARGETING AND CANCER THERAPY 
 
“We have to learn how to aim chemically,” Paul Ehrlich once said [1].  He was speaking 
about the need to find or design molecules capable of targeting specific cells, cellular receptors, 
or pathogens infiltrating the human body.  Ehrlich came to this conclusion after years of studying 
how colorful dyes interact and localize within specific histological and cellular structures.  
Among many preeminent discoveries, Ehrlich demonstrated for the very first time that the 
biological effect of a chemical compound depended on its chemical composition and the cell on 
which it acts.  Thus, Ehrlich elucidated an inextricable connection between chemistry and 
biology that is the basis for modern drug discovery, design, and delivery. 
After shifting his focus to plant toxins, the development of high titer anti-diphtheria sera, 
and standardizing sera for determining antibody concentration, Ehrlich began musing about 
specific interactions that occur between toxins and anti-toxins.  He postulated the existence of 
receptors, first termed “side chains,” capable of binding toxins.  Ehrlich thought receptors 
associated with the cell or distributed broadly in the blood stream in response to an antigen.  He 
also believed various types of receptors exist, each compositionally and structurally unique with 
different binding groups that contribute to the nature, strength, and specificity of the interaction.  
Over time, Ehrlich’s receptor theory shifted from binding of toxins to binding – and later, 
pharmacological activity – of drugs. 
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Combining his studies visualizing the differential affinity of chemical dyes with specific 
biological structures and developing of a high titer anti-diphtheria serum, Ehrlich postulated that 
molecules exist or could be generated to bind specifically to a pathogen.  In a theory presented 
first in 1908, he called these molecules “magic bullets” and described their ability to home to a 
specific cell structural target.  Ehrlich believed “magic bullets” existing innately or synthesized 
chemically could efficaciously attack pathogens yet remain harmless to the healthy tissues of the 
host.  To test his “magic bullet” postulated, Ehrlich chemical altered and screened a library of 
compounds he hypothesized could treat syphilis spirochete.  In 1908, the same year he received 
the Nobel Prize for Physiology or Medicine, Ehrlich’s laboratory detected the anti-syphilitic 
activity of arsphenamine.  His methodological approach to optimize the biological activity of a 
chemical compound through systematic chemical modification was the first of its kind in drug 
discovery. 
Ehrlich also imagined his molecular “magic bullet” theory might apply to tumor cells and 
provided some of the earliest hypotheses on the treatment of cancer.  He was the first to suggest, 
boldly at the time, that small molecules might be used in the management of cancer.  The 
suggestion that the immune system can prevent tumors was perhaps the most controversial and 
yet least scientifically established of the theories Ehrlich promoted.  Naturally, this too turned out 
to be true.  With many of his controversial postulates resoundingly well established in current 
research, it should be no surprise that Paul Ehrlich is affectionately known as the founder of 
chemotherapy. 
Ehrlich eventually coined “magic bullets” as “antibodies” and writes, “antibodies are in a 
way magic bullets that identify their target themselves without harming the organism.”  Together 
with his contemporaries, Ehrlich searched in vain for immunogenic determinants on tumor cells.  
 3 
However, it was those who followed that succeeded in identifying receptors overexpressed 
preferentially on the surface of tumor cells.  In 1975, nearly seven decades after Ehrlich won the 
Nobel Prize, Kohler and Milstein developed hybridoma technology for the production of 
monoclonal antibody (mAb) [2], and Ehrlich’s 1908 theory of molecular “magic bullets” came to 
fruition.  The advent of hybridoma technology enabled the generation of immune-like molecules 
that bind with high affinity and exquisite specificity to any pharmacological target of interest, 
including pathogens, cell receptors, tumor cells, small molecule toxins, and more. 
Kohler and Milstein’s hybridoma technology and generation of a monoclonal antibody is 
perhaps the greatest discovery in the world of pharmaceutical research ever.  It has provided a set 
of research grade reagents that make up an estimated $1.6B worldwide market annually, $700M 
accounted for in the US alone [3], and nearly $30B market of therapeutic medicines in the US 
alone.  In fact, mAbs have become the leading biotechnology pursued for medical applications 
spanning therapy, drug delivery, and prophylactic vaccines.  To date, more than 30 mAbs have 
been approved by the FDA for therapeutic indications in immunology, cancer, cardiovascular 
disease, inflammation, and allergy. 
Owing to their molecular engineering and versatility, and critical to the themes explored 
in this dissertation, mAbs also serve as potent tissue- and cell-specific drug carriers and homing 
agents.  In fact, six mAbs have been FDA-approved in the field of drug delivery for anticancer 
indications.  Coined radioimmunoconjugates, three of the six mAbs are armed with a radioactive 
isotope, which emits high energy particles to kill nearby cells.  The other three mAbs carry 
potent small molecule cytotoxins.  These latter molecules are termed antibody-drug conjugates 
(ADCs) and represent the most advanced class of drug delivery agents in development today. 
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This introduction will outline the basic tenets in drug delivery, define key structural and 
functional attributes of the monoclonal antibody, and detail its novelty as a therapeutic and drug 
delivery agent, particularly for applications in tumor targeting and anticancer therapeutic drug 
delivery.  The development of monoclonal antibody for tumor targeting and anticancer drug 
delivery has successfully laid bare Paul Ehrlich’s century-old “magic bullet” for the world.  
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Cancer, treatment, and drug delivery  
Cancer is characterized by a rapid, uninhibited growth of malignant cells capable of 
infiltrating tissues and starving essential organs of the necessary nutrients to survive.  
Oncologists today have a number of tools to help a patient overcome the onslaught of cancer.  
The three most common approaches are surgery, radiation, and chemotherapy. 
 According the American Cancer Society, surgery is used to prevent, diagnose, stage, and 
treat cancer.  Curative surgery aims to completely remove the tumor mass from the body and 
results in the greatest effect when the tumor is localized (or isolated) to only one part of the 
body.  Chemotherapy and/or radiation complement curative surgery in a standard treatment plan.  
Other surgical approaches include palliative surgery, which focuses on treating cancer-associated 
pain; debulking or supportive surgery, which removes some of the tumor tissue or alters the 
tissue to be more susceptible to other forms of treatment; and preventative (or prophylactic) 
surgery, an elected procedure to remove a tissue with high likelihood to become cancer.  Surgery 
accounts for the vast majority of first line cancer treatment. 
 Radiation therapy utilizes high energy particles or waves to destroy or damage cancer.  
Radiation therapy comes in a variety of different forms and has been used in cancer treatment for 
many decades with success, as it offers access to precious or hard-to-reach tissues often 
inaccessible by surgical methods.  External beam radiation is the most common form of therapy.  
Like an X-ray, radiation is directed at the tumor from outside the body and can be applied for 
both superficial structures, like skin, or deep-seated tumors in tissues such as the bladder, 
prostate, lung, or brain.  Internal radiotherapy, also known as brachytherapy, relies on the local 
application of radioactive material to a tumor or tumor-bearing tissue that acts only over a short 
distance.  In contrast to external beam radiation, the radiation can be localized yet exposed over 
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long periods of time.  Brachytherapy has proven an effective treatment for cervical, prostate, 
breast, and skin cancer.  Unsealed source radiotherapy, or the administration of a radioactive 
isotope by injection or ingestion, can result in tumor growth inhibition or regression following 
exposure of the tumor to the radioactive agent.  Iodine-131 accumulates in the thyroid and works 
by beta radiation to destroy thyroid tissue and any thyroid cancer that takes up the radioactive 
iodine.  Other common unsealed source radiotherapy agents include yttrium-90, radium-223, 
strontium-89, and sarmarium-153.  Like other treatment options, radiation is often used in 
combination with surgery and/or chemotherapy to elicit complete response and eradication of the 
tumor. 
 Chemotherapy is a term to describe the administration of a molecule that kills cells 
(cytotoxins) or arrests cell growth (cytostatins).  Unlike radiation therapy and surgery, which 
remove, damage, or kill cell in a certain area, chemotherapy can act systemically to eradicate 
cancer cells throughout the whole body, even cancer cells that have metastasized to parts of the 
body far away from the primary tumor.  Besides killing cancer cells or arresting tumor growth, 
chemotherapy can also be used in palliative scenarios to ease pain or pressure caused by large, 
advanced stage tumors.  Chemotherapy is the most advanced traditional treatment option for 
cancer patients, especially those with advanced stage and metastatic cancer.  Significant 
advances in research have improved the selection of better drugs, particularly for a specific 
person with a phenotypically unique tumor, more precise drug dosing and scheduling, and the 
co-administration of complementary medications that improve the pharmacokinetic profile or 
biological activity of the chemotherapy. 
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Advances in cancer treatment 
Dr. Siddartha Mukherjee, author of New York Times best-selling book “The Emperor of 
all Maladies: A Biography of Cancer,” elegantly elucidates the impossible characterization of the 
archetypal cancer patient and archetypal cancer treatment.  Instead, he lauds the deeper 
molecular understanding of cancer and its inherent diversity – there is no single “cancer” but 
many diseases that are diverse, complex, and intermingled – and reveals a genuine anticipation 
that such understanding will improve cancer treatment and prevention.  Needless to say, cancer 
treatment has not significantly changed in the past century.  While surgery, radiation, and 
chemotherapy effectively eradicate cancer in some individuals, each approach has shortcomings 
that limit application, utility, and, ultimately, success in treating the cancer.  It is estimated on 
average that more than 99.9% of cells in the tumor must be killed to achieve remission in the 
patient. 
As the biological understanding of cancer pathogenesis and cancer treatment evasion 
matures, two emerging approaches represent the cutting-edge in cancer therapy today.  The first 
harnesses the power of the innate immune system to fight cancer at the cellular level, while the 
second targets specific phenotypes, pharmacological pathways, and metabolic pathways found 
upregulated and otherwise aberrant in cancer to fight the disease at the gene or protein level. 
Immunooncology (IO) describes a set of technologies and scientific approaches that 
leverage the body’s innate immune system to fight cancer.  Current IO strategies work by (1) 
promoting an immune response to a growing tumor, (2) modulating pharmacological pathways 
that enable cancer cells to resist immune detection and elimination, or (3) priming immune cells 
for tumor recognition ex vivo for subsequent combat against the tumor in vivo.  IO strategies 
have proven effective alone and in combination across cancer indications for many patients with 
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advanced, unresectable, or metastatic diseases for which no other therapy has proven effective.  
For example, recent FDA approvals of programmed death receptor-1 (PD-1) immune checkpoint 
inhibitors nivolumab (Opdivo®) and pembrolizumab (Keytruda®) join the cytotoxic T-
lymphocyte associated protein 4 (CTLA-4) inhibitor ipilimumab (Yervoy®) as effective immune 
modulating molecules used in anticancer regimens.  Moreover, a host of advanced adoptive T-
cell therapies designed to train the innate immune cells to become potent antitumor assassins are 
under current investigation in small clinical trials.  However, the application of adoptive T-cell 
therapy has proven challenging.  For example, on July 7, 2016 Juno Therapeutics halted the 
ROCKET phase 2 clinical trial of JCAR015 (NCT01044069) following two patient deaths.  
JCAR015 is a molecularly engineered chimeric antigen receptor (CAR) T-cell and arguably the 
most advanced IO technology in the clinic today. 
The second major advance in cancer treatment relies on phenotypically or 
pharmacologically targeted anticancer agents.  Receptor tyrosine kinase inhibitors (TKIs) and 
mAbs are the two most popular classes of targeted therapies, which together represent the most 
successful anticancer agents in the clinic today.  However, the effect of targeted therapies 
critically relies on the nature of cancer.  That is to say, cancers that do not overexpress a 
previously established cancer biomarker or upregulate the specific pro-growth/anti-apoptotic 
pathways targeted by the medicine are unaffected by targeted therapies.  Less patients are 
candidates for targeted therapy than standard treatment options, and targeted therapies can 
induce genetic mutations and resistance to the therapy over time.  Targeted therapies result in 
potent and specific pharmacological effects, yet by definition, targeted therapies fail to be an off-
the-shelf solution to help all patients fighting all cancers. 
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Drug delivery: exploiting tumor pathophysiology and phenotypic changes on cancer cells 
Chemotherapy can provide enormous benefits to patients with both solid and 
hematological cancers in early stage, late stage, and those with substantial, unlocalized 
metastases.  However, significant drawbacks in safety and toxicity limit the efficacy and utility 
of chemotherapy in many patients across a spectrum of cancer indications.  Specifically, limited 
accessibility of chemotherapy to the tumor tissues, the requirement of high dose, intolerable 
cytotoxicity, multiple drug resistance, and non-target tissue uptake impair the clinical use of 
chemotherapeutics in cancer therapy [4].  Addressing these shortcomings of standard 
chemotherapy treatment is the major charge of modern drug delivery. 
The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of 
physiologically imposed design constraints, as well as constraints dictated by the nature, size, 
location, stage, and phenotype of the tumor.  Drug delivery attempts to overcome, and in many 
instances exploit, these constraints.  The two main approaches to cancer drug delivery are 
summarized as passive targeting, using carrier systems to deliver drugs to cancerous tissue, or 
active targeting, exploiting genetic or phenotypic features of the cancer cell that differentiate it 
from other healthy cells of the body.  Generally, passive targeting relies on the pathophysiology 
of the tumor and the tumor microenvironment to improve tumor-specific drug delivery, whereas 
active targeting takes advantage high affinity, high specificity interactions unique to the targeting 
ligand and the tumor cell or cancerous tissue. 
As a solid tumor grows, it begins to cause physical, architectural, and biochemical 
changes in the local environment.  In fact, as it continues to grow these subtle changes propagate 
to local and global biological changes.  While oncologists and cancer biologists study these 
changes at the organ or molecular level, respectively, drug delivery scientists design and develop 
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systems that exploit the changes – the anatomical, metabolic, and phenotypic differences 
between normal tissues and tumor tissue. 
Tumor vasculature in particular differs from healthy, normal tissue vasculature.  Tumors 
exhibit high vascular density, and the vessels are larger in size, more permeable, and more leaky 
than the tight endothelium of normal blood vessels.  This vascular architecture results from 
elevated levels of vascular mediators, like the vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and prostaglandins, as well as the physical stress and 
consumptive energy needs of the rapidly proliferating cells within the tumor. 
The enhanced permeability and retention (EPR) effect is a phenomenon characterized by 
the impact of rapidly growing cancer cells on the junctions between epithelial cells of the local 
capillaries in concert with the impaired lymphatic drainage of macromolecules in solid tumors.  
In effect, when a solid tumor grows, it puts undue pressure on the nearby blood vessels.  That 
pressure stretches the local vessel, thinning out the epithelial cell wall and creating gaps between 
the epithelial cells.  These gaps result in a “leaky vessel.”  Depending on the size of tumor and 
architecture of the nearby vessel, “leaky vessels” allow entities as large as 1 µm to extravasate 
from the blood vessel and enter, and subsequently interact with, the extra-vascular tissue.  Solid 
tumors also exhibit poor lymphatic vascular density and slow draining rates, which can result in 
prolonged retention of high molecular weight drugs and drug carriers that accumulate in solid 
tumors.  The EPR effect has been extensively characterized in preclinical tumor models and is a 
primary driver of tumor uptake and retention of passive targeting drug carrier systems. 
Tumor tissue also greatly differs from healthy, normal tissues.  Solid tumors are 
heterogeneous and constitutively composed of highly interactive and cooperatively functioning 
cellular communities.  These cell populations modulate one another’s biological characteristics, 
 11 
including the growth rate, metastatic ability, and sensitivity to anticancer therapy, and together 
form a complex and dynamic environment of tumor vasculature, stroma, and parenchyma, each 
with unique features, growth needs, and contributions to the tumor microenvironment. 
Due to this dynamic and highly complex microenvironment within the tumor, tumors 
contain specific antigens coined tumor-associated antigens (TAAs) that are often found 
expressed on the surface of cancer cells.  Most function to support the rapid growth, highly 
proliferative cells that constitute the tumor mass.  TAAs vary in expression and function, but 
most are either selectively expressed or preferentially overexpressed at the tumor compared to 
normal, healthy tissues throughout the body.  While most TAAs function endogenously as 
growth-promoting cell surface receptors on the membrane of cancer cells, more recently TAAs 
have been identified on tumor-associated stroma and progenitor cancer cells called cancer stem 
cells (CSCs, also known as tumor initiating cells, or TICs).  Expression of these unique antigens 
within the tumor microenvironment and receptors on the surface of cancer cells provide the 
rationale for active tumor targeting, which takes advantage of the difference in the expression 
level of a TAA on the cancer cell (or within the tumor tissue) to preferentially accumulate at the 
tumor compared to healthy, normal tissues. 
 
Passive targeting: nanotechnology and the EPR effect 
Using nanotechnology to improve tumor targeting and therapeutic drug delivery is the 
most pursued approach in preclinical cancer treatment today.  Nanotechnology in cancer therapy 
refers to small particles, polymers, nanotubes, or other carriers that can encapsulate, bind, or 
complex a drug or drugs.  While the nanocarrier is primarily designed to increase drug 
accumulation at the tumor, they have also shown the ability to improve drug solubility, reduce 
toxicity to healthy organs, prolong circulation time, and protect the drug from premature 
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metabolism and degradation [5].  Advances in material science and basic studies of the colloidal 
properties of various materials and mixtures of materials have produced in an enormous diversity 
and versatility of nanocarrier systems for use in drug delivery, each designed and suited for a 
specific application. 
Nanocarriers improve tumor uptake by taking advantage of the pathophysiology of the 
tumor.  The EPR effect, in particular, results in high accumulation of molecules small enough to 
permeate the “leaky” tumor vessel, yet large enough to avoid rapid clearance by the draining 
lymphatic system.  Despite these advantages, nanocarriers must overcome serious drawbacks 
that limit its utility in tumor targeting and drug delivery.  Among the most commonly faced 
hurdles – which are generally described here, but many more hinder specific drug carrier systems 
– low drug encapsulation, poor control over drug release, limited tumor uptake, unacceptably 
high liver uptake, and rapid clearance by the mononuclear phagocyte system (MPS, a revised 
nomenclature for the reticuloendothelial system, RES) significantly impair the wide-spread 
pursuit of clinical grade nanotechnology-based medicines for cancer treatment. 
 A number of nanoparticle-based drugs have reached clinical development, though few 
have been FDA approved.  Doxil® was the first FDA-approved nanocarrier (1995), which is a 
liposomal formulation of doxorubicin.  Abraxane®, a formulation of containing albumin-bound 
paclitaxel, was approved in its first indication 2005.  Maqibo®, DaunoXome®, and Myocet® are 
other well-known FDA-approved medicines indicated in cancer. 
 
Active targeting: tumor-associated antigens and tumor-targeting ligands 
Cancer cells have cell membrane receptors that have been shown to be selectively 
expressed or preferentially overexpressed compared to healthy cells.  Active targeting takes 
advantage of the different expression levels of specific receptors to enable preferential 
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accumulation of the medicine at the tumor.  Importantly, this approach spares normal cells and 
healthy tissues from significant exposure to the medicine, thereby reducing the toxicity of anti-
cancer drugs to a patient.  The combined effect of increasing target tissue uptake while lowering 
exposure to healthy tissue results in a significantly improved therapeutic window. 
In general, phenotypic differences between cancer cells and the cancer microenvironment 
offer a host of targets to increase the accumulation of anti-cancer drugs to the tumor, as well as 
target drugs to the tumor stroma and pro-growth tumor factors at high concentration in the tumor 
microenvironment.  Active tumor targeting relies on high-affinity, high-specificity interactions 
between the TAA and the tumor targeting ligand.  TAAs exist primarily as cell-surface receptors 
found selectively expressed or overexpressed on the tumor cell surface.  Increasingly, soluble 
growth factors and receptors found on the tumor extracellular matrix and neovasculature of the 
tumor serve as effective TAAs.  Commonly pursued tumor targeting ligands include endogenous 
receptor ligands, recombinant proteins, RNA constructs, DNA aptamers, mAbs and various 
engineered mAb fragments.  Selection of the ligand for tumor targeting should take into account 
a variety of parameters, including amenability to chemical modification, drug loading, 
circulation time, internalization kinetics, size, charge, and access to the target antigen.  mAbs 
represent the most clinically advanced class of tumor targeting agents, and many different mAb 
formats have been pursued in an effort to increase selectivity, tumor uptake, penetration, 
distribution, and cell internalization by cancer cells [6]. 
 
 14 
Figure 1-1. Schematic of drugs and drug carriers used in cancer therapy.  A tumor cell (blue filled 
circle) can be treated by a toxic chemotherapeutic drug (red star) or a pharmacological agent (green 
arrow).  Pharmacological agents bind specific receptors on the cell surface (purple V) to induce 
antitumor activity.  Nanocarriers (black circle) can improve safety and efficacy and antitumor 
chemotherapeutics, particularly when targeted with an antigen-specific ligand (yellow arrow) to a 
tumor-associated antigen (black V). 
 
On the whole, nanoparticle-based drug delivery strategies have fallen short of their 
projected impact.  A 2016 analysis surveying the prior 10 years of  nanoparticle-based delivery 
to tumors found only 0.7% (median) of the administered nanoparticle dose accumulates at a solid 
tumor [7].  Endowing a drug carrier with an active targeting moiety seeks to improve the target 
tissue uptake of the carrier system.  Though active targeting of nanocarriers can improve target 
tissue uptake and drug delivery, gains have been notably modest. 
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Immunoglobulin and the monoclonal antibody 
Immunoglobulin (Ig, or antibody, Ab) are large, complex glycoproteins secreted by B-
cells in response to a foreign antigen.  Ig survey nearly every organ and tissue of the human 
body, including blood and mucus secretions, and serve to protect the body from invasion and 
propagation of foreign pathogens.  Antibodies recognize foreign antigens by binding to the 
antigenic epitope, a short amino acid structural sequence, and marking the foreign body for 
removal.  Once bound, the antibody recruits other immune cells to act on the foreign body.  
Thus, antibodies act specifically and efficiently to facilitate the removal of a foreign pathogen 
invading healthy tissues of the body.  Antibodies, particularly immunoglobulin gamma (IgG) and 
secretory immunoglobulin alpha (sIgA), also prevent pathogens from gaining access to healthy 
tissues or inhibit viruses from cell- or tissue-specific infiltration and access to intracellular 
machinery for replication and propagation within the host organism. 
Specific functional characteristics of Ig facilitate its ability to fight foreign viruses, 
bacteria, other pathogens.  For example, vaccines work on the principle of priming the body for a 
rapid and robust antibody response when the body is challenged by a foreign pathogen.  It is 
these unique properties – and the ability to manipulate, modulate, and otherwise engineer 
improved properties – that make Ig attractive molecules for applications in cancer therapy and 
drug delivery. 
 
Elements of immunoglobulin G structure and function 
Ig are composed of one or more units each consisting of four polypeptide chains: two 
identical heavy chains (HC), and two identical light chains (LC).  The polypeptide HC and LC 
come together to form heterodimer, and two HC-LC heterodimers come together to form an LC-
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HC-HC-LC homodimer. The Y-shaped four subunit protein of approximately 150 kDa is the 
characteristic base structure of Igs. 
 
 
Figure 1-2. Immunoglobulin, a homodimer of heterodimers, is composed of two identical heavy 
chains (grey), two identical light chains (orange), and an extensive network of inter- and intrachain 
covalent yet reducible disulfide bonds (black). 
 
In nature, the basic Y-shaped Ig structure can exist in various orientations and 
stoichiometry greater than one [8].  Igs of different classes serve specific functions and localize 
to specific tissues and fluids. For example, sIgA antibody is an Ig dimer primarily found in 
mucosal secretions, whereas IgM antibody is an Ig pentamer found in the blood and works as the 
first antibody defense to infection.  Five Ig classes – IgG, IgA, IgM, IgD, and IgE, distinguished 
by their constant regions – exist in humans, each with unique structural and functional attributes. 
This dissertation will focus exclusively on the immunoglobulin G (IgG) class, 
particularly IgG1 and IgG2 subtype human, humanized and mouse monoclonal antibody (mAb).  
This is because IgG is the most abundantly expressed antibody in the human body and the 
primary mediator of protection from pathogens.  It is also the most relevant Ig to mAb-based 
cancer therapy, tumor targeting, and drug delivery. 
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IgG quaternary, tertiary, secondary, and primary structure 
The macroscopic structure of IgG antibody is a dimer of dimers.  Heavy chain (HC) and 
light chain (LC) form a heterodimer known as “half IgG” or “reduced IgG” of approximately 
75,000 Da in molecular weight.  A homodimer of two HC-LC heterodimers forms full-length, 
intact IgG of approximately 150,000 Da in molecular weight.  The full IgG molecule contains, 
on average, approximately 25,000 atoms – four polypeptides totaling 1400-1600 amino acid 
residues (another word for amino acid).  Each HC-LC heterodimer is held together through a 
variety of non-covalent intermolecular forces, such as salt bridges, hydrogen bonding, and 
hydrophobic interactions, as well as an extensive network of covalent yet reducible interchain 
disulfide bonds.  For example, the two heavy chains of each HC-LC heterodimer are linked to 
each other by disulfide bonds, and each HC is linked to a LC by a single disulfide bond.  
Intrachain disulfide bonds further aid the structural integrity within each heavy and light chain 
domain.  Moreover, each domain within the HC (4 domains per HC) and LC (2 domains per LC) 
contains one intramolecular disulfide bond and two stacked antiparallel beta sheets.  The beta 
sheet found in each domain of an IgG antibody typically contains 4 antiparallel sheets stacked 
with 3 antiparallel sheets.  On the whole, IgG antibody are 40 – 70% beta sheet and 5 – 10% 
alpha helix. 
The HC of an IgG antibody is approximately 50 kDa, or 450 amino acid residues, and 
consists of four distinguishable regions, listed from the carboxy (COO-) terminus to the amino 
(NH3+) terminus: the constant heavy 3 domain (CH3), constant heavy 2 domain (CH2), constant 
heavy 1 domain (CH1), and variable heavy domain (VH).  The LC of an IgG antibody is 
approximately 25 kDa, or 215 amino acid residues, and consists of two distinguishable regions, 
the constant light domain (CL) located at the carboxy terminus (C-term) and the variable light 
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domain (VL) located at the amino terminus (N-term).  As the names suggest, the variable (V) 
domains differ them from the constant (C) domains of the IgG heavy and light polypeptide 
chains by distinguishable differences in amino acid composition. 
The HC and LC polypeptides differ in both structure and function.  For example, the 
class and effector function of an antibody is defined by the structure of the heavy chain.  The 
majority of interchain disulfide bonds reside in the IgG hinge region, a neck-like portion of the 
IgG molecule between the CH2 and CH1 domains of the HC.  Five types of HC exist, which 
define the various isotypes of Ig (IgA, IgG, IgD, IgE, and IgM), and two types of LC exist, 
lambda and kappa.  IgG antibody HCs exhibit various glycosylation patterns, which are mostly 
restricted to the CH2 domain.  Glycosylation is thought to improve aqueous solubility, enhance 
effector functions, especially the interaction and activation of the complement system, and 
improve serum half-life, but on the whole their function remains poorly understood. 
 
IgG Fab and Fc fragments 
IgG antibody can be further broken down and characterized by two main functional 
elements: the Fc fragment, “c” for constant or crystallizable, and the Fab fragment, “ab” for 
antigen-binding.  Each fragment (“F”) is characterized by a function, which together contribute 
to the protective activity of endogenous IgG in the body as well as the utility of IgG in cancer 
treatment and drug delivery.  IgG Fab and Fc fragments are commonly produced in cell culture 
using recombinant DNA technology, but can also be produced by post-translational digestion 
with a variety of peptidases, including pepsin, papain, ficin, trypsin, or IdeS, and/or full or partial 
reduction using common reducing agents like dithiothreitol (DTT), tris(2-
carboxyethyl)phosphine (TCEP), or 2-mercaptoethylamine (2-MEA).  Discussed later, small, 
multivalent IgG fragments are an active area of mAb-based therapy and drug delivery. 
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Pepsin and papain are the two most common IgG digestive enzymes.  Pepsin 
preferentially cleaves the N-term side of hydrophobic amino acids, especially aromatic amino 
acids like phenylalanine, tryptophan, and tyrosine.  These residues commonly reside in the lower 
hinge region of the IgG HC.  Therefore, treatment of IgG antibody with pepsin results in 
production of a divalent Fab dimer, connected via retained disulfide bonds within the HC hinge 
region.  This divalent molecule is coined (Fab’)2 and can be further reduced to monovalent Fab’ 
fragments by treatment with a mild reducing agent.  Papain, on the other hand, is a cysteine 
protease that generally cleaves IgG antibody above the hinge region.  Thus, treatment of IgG 
antibody with papain results in the production of two monovalent Fab fragments along with the 
intact, unmodified Fc fragment, which retains its hinge disulfide structure. 
The Fab fragment, which contains both domains of the LC along with the VH and CH1 
domain of the HC, is the portion of IgG responsible for binding to the antigen.  Critical to the 
Fab fragment are six short loops making-up the complementarity determining region (CDR).  In 
total, the 6 CDR loops, of which 3 reside within the VL chain and 3 reside with the VH chain, 
form the binding pocket that characterizes the affinity and specificity between IgG antibody and 
antigen.  The CDR loops – often described as 3 fingers from two separate hands – are also 
known as the IgG hypervariable regions, because these six short peptide segments demonstrate 
the greatest diversity in amino acid sequence, length, and flexibility of any other portion of the 
IgG molecule. 
 The Fc fragment is the portion of the IgG molecule responsible for mediating an immune 
response.  For example, IgG bound to an antigenic epitope exposed on the surface of the human 
immunodeficiency virus (HIV) particle membrane and coating its surface can initiate an immune 
response to the virion.  Specifically, the Fc receptor of IgG binds to the Fc gamma receptor 
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(Fc!R) and initiate signaling through immunoreceptor tyrosine-based activation motifs (ITAMs) 
or immunoreceptor tyrosine-based inhibitory motifs (ITIMs) during an antibody-dependent 
cellular cytotoxicity (ADCC) response.  The Fc can also recruit complement component 1q 
(C1q) to initiate the complement cascade, resulting in tumor cell lysis by the membrane attack 
complex (MAC). 
In addition to engaging the receptors on immune cells, the Fc also interacts with the Fc 
neonatal receptor (FcRn) found on the surface of epithelial cells in tissues throughout the body.  
Interaction between the Fc and the FcRn maintains high serum levels of IgG via endothelial cell 
recycling or, in select organs, mediates the transcytosis of IgG across epithelial barriers [9].  
FcRn-mediated recycling occurs due to the pH-dependence of the IgG Fc-FcRn interaction, 
which is high affinity at acidic pH but low affinity at neutral pH.  This phenomenon enables IgG 
to be bound to FcRn within the early endosome (pH < 6) yet dissociate at the cell surface when 
exposed to more alkaline conditions (pH 7) [10].  Moreover, high-affinity binding to the FcRn 
protects the mAb from intracellular catabolism [11].  FcRn expression also significantly impacts 
mAb tissue distribution [12].  Like with endogenous IgG, the Fc-FcRn interaction enable mAb 
for cancer therapy and drug delivery to circulate in the blood stream up to 3 weeks or longer, 
which offers a huge advantage to other platforms evaluated for applications in drug delivery. 
 
Monoclonal antibody 
Monoclonal antibody (mAb) is a special type of IgG.  Most IgG in humans is polyclonal 
(pAb), meaning it recognizes multiple epitopes on any one antigen.  mAbs, conversely, 
recognize only one epitope on an antigen.  Thus the nature of the mAb-antigen interaction is both 
more specific and higher affinity than a pAb-antigen interaction. 
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Antigen binding affinity and specificity of mAb separate it from most all other 
biochemical interactions observed in nature.  Moreover, the production of hybridomas and 
application of recombinant DNA technology allow for the precise engineering of mAb that not 
only bind a specific epitope on an antigen, but whose pharmaceutical, physicochemical, and 
biological properties can be precisely tuned.  The range of engineering, modification, and 
manipulation afforded by mAbs –from the modulation of FcRn affinity to the removal of 
hydrophobic residues in place of hydrophilic ones or incorporation of non-canonical amino acids 
that allow bioorthogonal chemistry within living cells – have established mAbs as leading 
molecules in medicine, drug delivery, and assay reagents.  Protein engineering for improved 
properties of mAb in drug delivery will be discussed in a future section. 
 
mAbs as therapeutics 
 mAbs have and continue to be one of the fastest growing classes of pharmaceutical 
products today.  In 1986, Orthoclone OKT3® became the first FDA-approved mAb for sale in 
the US.  In 2007, a total of 26 FDA approved therapeutic mAbs were valued at more than $13.B 
[13] and spanned indications in cancers and immunological disease.  By 2015, there were 47 
FDA-approved therapeutic mAbs with a total market value of nearly $40B [14] and increased 
disease targets of cardiovascular disease, pulmonary disease, neurodegeneration, and pain 
treatment.  It is estimated that mAb therapeutics will enter the market at a rate of four per year, 
reaching a total of 70 therapeutic mAbs by 2020 with an estimated market value above $125B 
[15]. 
Due to their complexity, mAb-based therapeutics require large amounts of time, money, 
and expertise to develop, estimated in 2010 as 85.7 months in the clinical phase, 12.8 months in 
the FDA approval phase, and on average between $1.2 and 1.5B from discovery through FDA-
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approval [16].  Regardless of these considerable resource investments, mAbs were 5 of the top 
10 drugs sold in 2014 and the pipeline continues to diversify and expand. 
 Data compiled from Janice M. Reichert’s annual “Antibodies to watch” series shows 
mAbs reaching phase 3 clinical trials between 2010 and 2015 (Figure 1-3) [17-23].  As of 
November 2015, 53 novel antibody therapeutics were in Phase 3 clinical development (data not 
included).  This number represents a 36% and 104% increase compared to the number of 
antibody therapeutics in Phase 3 in 2014 and 2009, respectively [24].  Non-traditional indications 
and immunological indications are the fastest growing molecules as of late, but the 17 of 53 
antibody therapeutics in Phase 3 clinical study represent a significant uptick in anticancer 
antibody therapeutics from 2015. 
 
 
Figure 1-3. Clinical indications of the 28 FDA-approved mAb-based therapeutics in July 2010, 
and mAbs reaching Phase 3 between 2010 and 2015 in anti-neoplastic, immunomodulatory, anti-
infective and non-traditional indications between 2010 and 2015. [17-23, 25] 
 
 The increase in mAbs entering clinical trials over the past two decades is in part due to 
significant technology advancements in the generation, manufacture, manipulation, and 
application of mAbs in therapy and drug delivery, but also due to the significant knowledge 
improvements in the biology and progression of diseases.  Different diseases manifest and 
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present differently.  mAbs offer a unique pharmaceutical platform that can feature specific yet 
diverse pharmacological properties. 
 
Mechanism of action of mAbs in cancer therapy 
Anticancer mAbs operate through four main mechanisms to abate tumors and quell the pro-
growth, anti-regulatory environment of cancer in the human body [26].  Some mAbs function by 
(1) binding cancer-associated receptors and ligands expressed at high concentration on tumors 
and within the tumor microenvironment to antagonize pro-growth or pro-angiogenic pathways.  
Other mAbs (2) agonize receptors on cancer cells to activate pro-apoptotic pathways within the 
cancer cell, or disrupt signaling between extracellular environmental stimuli and intracellular 
anti-apoptotic pathways.  Like endogenous mAbs, many therapeutic mAbs (3) are capable of 
binding to a cancer-associated antigenic epitope found selectively expressed or overexpressed on 
the cancer cell surface, coat that cell surface, and induce immune-mediated responses of 
antibody-directed cellular cytotoxicity (ADCC) or (4) complement-dependent cytotoxicity 
(CDC).  Known as effector functions, or immune-mediated mAb response to cancer, ADCC and 
CDC occur primarily for the IgG1 isotype mAb.  Inducing these effector functions is the only 
direct cell death pathway of therapeutic mAbs. 
 Studying the differences between the anti-epidermal growth factor receptor (EGFR) 
mAbs panitumumab and cetuximab, as well as the anti-vascular endothelial growth factor 
(VEGF) mAb bevacizumab, helps to demonstrate the various pharmacological mechanisms of 
mAbs used in cancer therapy.  All three mAbs are indicated for the treatment of metastatic 
colorectal cancer.  Cetuximab (Erbitux®) is an IgG1 isotype anti-EGFR chimeric mAb.  It was 
approved in 2004 and antagonizes the EGF receptor, inhibiting binding of the epidermal growth 
factor (EGF) with a stated binding affinity (described by the equilibrium dissociation constant, 
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Kd) of 390 pM.  Panitumumab (Vectibix®) is an IgG2 istoype anti-EGFR human mAb.  It was 
approved in 2006 and antagonizes EGFR with Kd of 50 pM.  Bevacizumab (Avastin®) is an 
IgG1 isotype anti-VEGF humanized mAb approved in 2004.  Unlike panitumumab and 
cetuximab, which antagonize a cell surface receptor, bevacizumab antagonizes the ligand of the 
cell surface vascular epithelial growth factor receptor (VEGFR).  VEGF is a secreted protein and 
therefore found extracellular, soluble and freely circulating in the bloodstream and tumor 
microenvironment. Bevacizumab binds VEGF with a Kd of 1.1 nM, thereby inhibiting agonism 
and subsequent activation of VEGFR. 
 
Table 1-1. MAbs currently indicated for treatment of metastatic colorectal cancer 
 Bevacizumab Avastin® 
Cetuximab 
Erbitux® 
Panitumumab 
Vectibix® 
Dose 
5-10 mg/kg every 2 
weeks; 7.5-15 mg/kg 
every 3 weeks 
400 mg/m2 loading 
dose, 250 mg/m2 
weekly thereafter 
6 mg/kg every 
biweekly 
Cost $814.42 / 100 mg $629.88 / 100 mg $1144 / 100 mg 
FDA approval date 2004 2004 2006 
Target VEGF EGFR EGFR 
Kd (pM) 1100 390 50 
mAb class Humanized Chimeric Fully human 
Isotype IgG1 IgG1 IgG2 
 
 In the 2013 ASPECCT trial, a head-to-head comparison of cetuximab and panitumumab 
for the treatment of metastatic colorectal cancer (mCRC) concluded they confer similar overall 
survival advantages [27].  This might be unexpected, due to the order of magnitude difference in 
binding affinity between the two mAbs; however, increased efficacy of cetuximab in the trial 
could be due to its unique mechanism of action compared to panitumumab.  In particular, the 
IgG1 framework of cetuximab induces effector function activity, like ADCC and CDC, against 
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cancer cells.  These immune-mediated tumor cell killing mechanisms might improve anti-tumor 
activity of cetuximab compared to its higher binding anti-EGFR competitor panitumumab. 
 Bevacizumab is also an effective agent against metastatic CRC.  Rather than 
antagonizing the receptor, which is expressed on the surface of a cancer cell, bevacizumab 
antagonizes the VEG factor ligand.  Bevacizumab works not directly on the cancer cell itself but 
rather on the supporting vascular architecture that feeds the tumor blood, oxygen, and other 
nutrients required to rapidly proliferate. Ready access to its soluble and extracellular target 
antigen enables the unique activity observed with bevacizumab compared to the higher binding, 
direct action of cetuximab and panitumumab in mCRC.  Other differences between the three 
mAbs will be discussed later, including mAb humanization, role of antigen affinity on target 
tissue uptake, and the impact of target antigen expression level and distribution on the safety and 
efficacy profile of mAbs in clinical study. 
It is finally important to note that therapeutic mAbs are rarely indicated as stand-alone 
agents.  The most notable exception is ipilimumab, which activates the immune system by 
binding to CTLA-4 and exhibits sufficient activity to be used as a single agent in the treatment of 
solid tumors.  Only mAbs indicated for hematological cancers are administered as stand-alone 
single agents.  All remaining FDA-approved mAbs for solid tumors display only modest 
antitumor activity alone and are thus administered in combination with chemotherapeutic agents.  
Moreover, in nearly 35 years since the first mAb was evaluated in the clinic, only 8 mAbs have 
been approved for the treatment of cancer, and only two cell surface targets (HER2 and EGFR) 
have been successfully targeted by mAbs for treatment of solid cancers [28].  Therefore, 
development of mAbs administered as single-agent therapies to solid tumors would be a huge 
step forward in solid tumor cancer management using a mAb-targeted drug delivery. 
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mAb development trends 
 A number of technology improvements continue to drive innovation and improve clinical 
success of mAb-based therapeutics.  Recombinant DNA technology has revolutionized the 
selection, humanization, and production of antibodies, superseding hybridoma technology and 
allowing the design of antibody-based reagents of any specificity and for very diverse purposes 
[29].  These and other mAb development trends are captured and embedded in Reichert’s 
“Antibodies to watch” series but also discernible in the preclinical pipeline studies found in the 
peer-reviewed literature of mAbs.  The four major trends in mAb development are (1) 
humanization, (2) fragmentation, PEGylation, or other post-translational modification, (3) amino 
acid-level engineering, and (4) organ- and cell-specific drug targeting and delivery. 
 
Humanization 
 Early mAb-based therapeutics were generated in mice following administration of tumor-
associated antigen immunogen.  While mAbs are generally well tolerated in humans, 
hypersensitivity and immunogenicity reactions plague murine-derived mAb therapeutics, which 
significantly limit their safety and pharmacological activity, and remain a notable challenge for 
all mAb-based therapeutics.  For example, muromonab-CD3 (Orthoclone OKT3®) is a mouse 
murine mAb against human CD3 indicated for renal allograft rejection.  Upon administration, it 
can cause cytokine release syndrome (CRS), an acute infusion reaction, as well as cause severe 
influenza-like symptoms due to an immunogenic response with human anti-mouse IgG 
antibodies.  The development of human anti-mouse antibodies, also known as anti-drug 
antibodies (ADAs), can render mAb therapy completely ineffective.  Replacing murine derived 
amino acid sequences with human amino acid sequences has been demonstrated to reduce 
immune reactions to mAb therapeutics.  Because of these observations, murine sequences of 
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mAbs have been replaced with human sequences in an iterative process termed humanization.  
The first step generated chimeric mAbs, which were part human part mouse.  The next step 
generated humanized mAbs, which contain fully human sequences with only retained murine 
sequences in the CDR regions of the VL and VH regions.  Substituting murine-based amino acid 
sequences for human ones is a technologically challenging process, yet generally yields 
molecules with improved pharmaceutical properties.  Like with other mAb development trends, 
wider access to the technology and the realization of clinical benefits has prompted companies to 
focus on humanization prior to commercialization of mAb-based therapeutics.  In fact, 48 of the 
53 (91%) mAb-based therapeutics currently in Phase 2/3 clinical development are humanized or 
fully human [24], compared to only 56 of the 86 (65%) in development between 1990 and 1999.  
The species of the mAb is inferred from its name, for example: antibody ending in “-momab” is 
of murine origin, “-ximab” is chimeric (human mAb with murine variable domains), “-zumab” is 
humanized (human mAb with mouse CDR sequences), and “–mumab” is human (100% human 
IgG sequence homology). 
 
 
Figure 1-4. Humanization of mAb pipeline.  FDA-approved mAbs in July 2010 and phase 3 
clinical trial data from 2010 through 2015. [17-23, 25] 
 
 28 
Studies of engineered mAbs have shown that immunogenicity is not simply a matter of 
sequence homology with fully human antibody.  In fact, alterations in particular amino acids at 
certain positions can also influence immunogenicity of mAb-based therapeutics. 
 
Fragmentation, PEGylation, and other post-translational modifications 
 Monoclonal antibody fragments confer unique properties to molecules of interest in 
pharmaceutical development [30].  Not only are they smaller in size than intact IgG, fragments 
offer tunable molecular properties and decreased sensitivity to physical or chemical perturbation 
[31, 32].  Etanercept (Enbrel®) and certolizumab pegol (Cimzia®) showcase the utility of the 
and IgG Fc fragment and Fab fragment, respectively, in the development of mAb-based 
therapeutics, though many others have reached clinical trials and gained FDA approval.  
Certolizumab pegol also highlights a particular modification, coined PEGylation, which can 
endow recombinant proteins, mAbs, and mAb fragments improved pharmaceutical features like 
higher aqueous solubility, lower opsonization, and an extended circulating half-life [33-38].  
Though IgG fragments confer many improved properties, their clinical success remains stymied 
by the lack of proof of concept studies and continued successes of their fully intact IgG 
counterparts [39]. 
 Etanercept is an Fc-fusion protein indicated for treatment of autoimmune diseases like 
rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis.  It works by 
inhibiting activity of tumor necrosis factor alpha (TNF"), a master regulator of inflammatory 
responses in many organ systems.  Etanercept was produced using recombinant DNA 
technology.  The DNA coding sequence for soluble tumor necrosis factor receptor 2 (TNF-R2) 
was joined to the DNA coding sequence of the Fc fragment of human IgG1.  The fused molecule 
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serves as decoy receptor for TNF" and showed phenotypic effects in vivo comparable to deletion 
of the TNF receptor [40]. 
 Etanercept displays exceptionally improved pharmaceutical properties compared to 
recombinant TNF-R2.  The fusion, originally developed as human TNF-R2 fused murine IgG Fc, 
was shown to be highly active and unusually stable for blockade of TNF in vivo [40, 41].  It also 
circulated much longer in the blood stream, owing to its increase in molecular weight and FcRn-
mediated endothelial cell recycling.  Many other Fc-fusion proteins have advanced through 
clinical trials since the first clinic trials and subsequent FDA approval of Etanercept.  Aflibercept 
is an Fc-fusion protein comprised of the extracellular domains of human VEGF receptors 1 and 2 
fused to the Fc portion of human IgG1.  It is indicated for wet macular degeneration and more 
recently as a combination therapy for mCRC.  It is therefore a direct competitor, in both 
indication and mechanism of action, of the mAb-based VEGF antagonist bevacizumab. 
Another approach to TNF" therapy employs an anti-TNF" Fab fragment covalently 
modified with a 40-kDa branched polymer chain of poly(ethylene)glycol.  Certolizumab pegol is 
a PEGylated anti- TNF" Fab fragment that binds with high affinity and specificity to TNF".  
Unlike etanercept, which serves as a TNF" receptor decoy, certolizumab pegol antagonizes 
soluble TNF" and prevents its binding to endogenous TNF receptors.  Though different in 
approach, etanercept and certolizumab pegol achieve the same pharmacological effect – lowering 
the concentration of free, active TNF" in the bloodstream. 
Fab fragments differ from their full-length mAb counterparts in a variety of ways that 
offer both advantages and disadvantages.  For one, Fab fragments are one-third the size and 
molecular weight of full-length, intact mAb.  Smaller in size, Fab fragments diffuse faster, 
extravasate more, and can access tissues and cells that are difficult to reach for mAbs.  In tumor 
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targeting studies, Fab fragments exhibit deep tumor penetration and often exhibit significantly 
improved distribution throughout a solid tumor than mAb.  However, their smaller size and lack 
of Fc fragment result in significantly faster clearance rates than mAb due to renal filtration and 
abolished FcRn recycling. 
Moreover, the anti- TNF" Fab fragment of certolizumab pegol is PEGylated, a covalent 
modification of the Fab fragment with the polymer, poly(ethylene)glycol).  PEGylation can 
significantly improve the pharmaceutical properties of a protein.  PEGylation of anti- TNF" Fab 
was performed by site-specific covalent modification of the hinge free thiol of anti- TNF" Fab’ 
with a 40-kDa branched PEG polymer.  PEGylating the Fab’ fragment of anti- TNF" Fab 
improved its circulating half-life, nearly matching the half-life of intact IgG.  It is thought that 
PEGylation improves the pharmacokinetic (PK) profile of mAb fragments because it increases 
the size and hydrodynamic radius of molecule, in addition to increasing hydrophilicity and 
mitigating protein opsonization.  Lysine-based PEGylation of fully intact mAbs can increase 
resistance to proteolytic degradation, albeit with a reduced ability to bind to Fc receptors or fix 
complement [42].  Conjugating PEG to partially reduced interchain disulfides yields more 
homogeneous PEGylated IgG without alteration of FcRn recycling or Fc!R induction.  
PEGylation is one of the most common modifications utilized to increase the pharmaceutical 
properties of drugs and drug carriers, particularly for engineered proteins and nanocarriers used 
in drug delivery.  Recent studies showing an abated effect of PEGylated therapy in a particular 
individual have sparked concern for immune stimulation of PEG and the generation of anti-PEG 
antibodies (APAs).  It is hypothesized that APAs form after onset of PEGylated therapy, but they 
could also be present and the immune system primed for response due to the wide use of PEG in 
consumable products.  The presence of APAs alters the PK, biodistribution (bioD), safety, and 
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efficacy of PEGylated drugs and nanoparticles, mAbs, and engineered fragments like 
certolizumab pegol. 
 
Engineering for improved physical, chemical, and biological properties 
 Deletion or substitution of amino acids along the polypeptide chain enable modification 
of the mAb at the most fundamental level.  Such changes are used to engineer mAbs with 
improved physical stability, added chemical handles for functionalization or biorthogonal 
conjugation, and enhancing biological properties. 
One of the most common applications of protein engineering to mAbs is the removal or 
substitution of amino acids for improved physical or chemical stability in vivo [43, 44].  mAbs 
contain 2 to 8 aggregation-prone motifs per heavy and light chain pair, usually comprised of a 
string of solvent-exposed hydrophobic amino acids [45].  “Hot spots,” as their known, can 
induce aggregation during storage, especially when formulated at high concentration, or result in 
opsonization, degradation, and rapid clearance upon administration in vivo [46, 47].  Regions 
prone to physical or chemical instability also occur at pockets of charge-charge repulsion within 
the mAb secondary or tertiary structure.  Removing “hot spots” from the amino acid sequence 
can improve the structural stability of the molecule [44].  Often, single point mutations within a 
hot spots can improve solubility, lower opsonization, and improve the overall PK profile of the 
mAb [43].  In other examples, reducing the disulfide bond heterogeneity of an IgG4 molecule 
increased the Fab thermal stability [48], and single oligosaccharide modifications to the Fc – in 
this case, removing core N-glycan residues – significantly enhanced Fc!R binding and mediated 
higher antibody-dependent cellular cytotoxicity against human tumor cells [49]. 
The incorporation of chemical handles within the mAb primary structure allows site-
specific conjugation of drugs, toxins, polymers, radionuclides, or particle-based drug carriers 
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without significant impact on native amino acid of the mAb.  This is a critical technology 
advancement, as the integrity of the basic amino acid sequence is often fundamental to the 
chemical, physical, and biological activity of the mAb.  Site-specific antibody-drug conjugates 
(ADCs) provide the best example of amino acid substitution or incorporation for the purpose of 
bioconjugation.  For example, Schultz and colleagues were one of the earliest groups to 
demonstrate the incorporation of a non-canonical oxime-functionalized phenylalanine into the 
amino acid backbone of a tumor-targeting human IgG [50, 51].  By incorporating the non-
canonical amino acid into the primary structure of the mAb, the team was able to site-specifically 
ligate the mAb with a drug at a specific location on the mAb using the biorthogonal chemistry of 
an azide [50].  In this way, both the location and number of drugs could be controlled with 
exquisite precision and conjugation performed in the cell without concern for modification to 
non-target protein – an enormous feat in the world of protein chemistry in general, and the 
generation of homogenous antibody-drug conjugates in particular [51-60].  The site-specifically-
modified conjugate outperformed a non-specific conjugate carrying the same number of drugs 
[50, 61, 62].  Other more common methods to include the addition of a non-native cysteine or 
selenocysteine, methods spearheaded by Genentech and the National Institute of Health, 
respectively. 
 Modest changes to the amino acid sequence that yield a change in biological function are 
perhaps the most alluring of protein engineering feats applied to mAbs.  Many recent studies 
modulate the affinity of the Fc to the FcRn neonatal receptor in an attempt to alter residence time 
or mAb bioD [63, 64].  Therapeutic mAbs that rely on long residence time in the blood to 
accumulate at the target and exhibit pharmacological action might be engineered for higher 
affinity to the FcRn, whereas antibody-drug conjugates, whose payload may be prematurely 
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cleaved during FcRn recycling might desire completely abated affinity from the FcRn without 
change in activation of effector function.  Point mutations within the CDR loops of Fab can 
increase or decrease in binding affinity between the mAb and the target antigen.  Reducing the 
affinity of a bispecific antibody for the transferrin receptor resulted in improved the brain uptake 
and subsequent access to therapeutics targets within the brain parenchyma [65]. 
Given the state of technology in protein engineering, mammalian expression, and 
purification, the diversity of mAb-based molecules with improved physical, chemical, and 
biological activity will only continue to grow in the decades to come. 
 
MAb used in tumor targeting and cell-specific intracellular drug delivery 
 Of the massively wide array of technologies aimed to improve the delivery of drugs and 
other pharmaceutical agents at high concentration and pharmacologically active form to tumor 
cells within the body, mAbs, mAb fragments, and engineered derivatives together represent the 
most clinically advanced and proven vectors to date.  The reason is because mAbs are so 
versatile, having successfully carried drugs, toxins, and radionuclides to tumors and efficiently 
facilitating internalization by the target cell and subsequent intracellular release of the payload.  
Moreover, mAbs have permeated the blood brain barrier, one of the most impenetrable barriers 
in the human body, and homed immune cells to cancer cells (blinotumomab), enhancing 
immune-mediated anticancer cytotoxicity.  The number and diversity of mAb-based constructs 
under investigation for tumor targeting and drug delivery is unprecedented today.  These 
technologies and their impact on tumor targeting, drug delivery, and cancer management will be 
the focus of the remaining discussion in this chapter.  
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Receptor-ligand interactions 
 MAb binding to cancer cells and accumulating at antigen-overexpressing tissues is 
biochemically governed by Clark’s theory of receptor-ligand interactions.  In this case, mAb is 
represented by the ligand, L, and the TAA is represented by the receptor, R.  At equilibrium, 
Clark’s theory states: # + % ↔ [#%] where, #  is equal to the concentration of free (or unbound) receptor %  is equal to the concentration of free (or unbound) ligand, and [#%] is equal to the concentration of the receptor-ligand bound complex 
Clark’s theory requires five assumptions be satisfied: 
1. The interaction is reversible; the association reaction is bimolecular while the 
dissociation reaction is unimolecular. 
2. All receptor molecules are equivalent and independent. 
3. The biological response is proportional to the number of occupied receptor sites. 
4. The interaction and response are measured after the reaction has reached equilibrium. 
5. The ligand does not undergo degradation, does not participate in other reactions, and only 
exists in either a free (unbound) or bound (to the receptor) form. 
Equilibrium is defined as the state in which the concentration of both the reactants and 
products have no further tendency to change.  In another way, equilibrium is achieved when the 
forward reaction proceeds at the same rate as the reverse reaction.  When the reaction rates are 
equal, but never zero, the concentration of the reactants and/or products will not change and 
equilibrium has been achieved. 
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Law of mass action and Kd 
 Clark’s theory of receptor-ligand interactions is able to relate kinetics and 
thermodynamics using the law of mass action.  For, 
# + % )*↔)+*[#%] ),→ .//.01 
the kinetic parameters )*, )+*, and ), are defined as follows: )* is the forward rate constant, )+* is the reverse rate constant, and 
 ), is the proportionality constant relating the biological response to receptor occupancy 
The forward (association, or “on”) and reverse (dissociation, or “off”) rates can be calculated by 
multiplying the rate constant by the concentration of the reactants.  Therefore, 
Forward rate = )* # [%], and 
Reverse rate = )+*[#%] 
At equilibrium, the forward rate equals the reverse rate, )* # % = )+*[#%] 
and the law of mass action can be written, # [%][#%] = )+*)* = 34 
The law of mass action allows calculation of the all-important equilibrium dissociation constant, 34, which is a measure of affinity between the mAb and the tumor-associated antigen.  Because 
the forward rate constant )*, also known as the kinetic on rate, is largely dependent on the 
diffusion of ligand to the receptor, the equilibrium dissociation constant 34 is predominantly 
governed by the reverse rate constant )+*, also known as the kinetic off rate. 
  
 36 
Fractional occupancy and determination of Kd 
 If #  is redefined as: # = [#]5 − #%  where, [#]5 is the total receptor concentration, 
then the law of mass action can be rewritten: ([#]5 − #% )[%][#%] = 34 
and rearranged: 
#% = [#]5( % + 34) 
and further rearranged to its final form: / = 9:[9]; = [:]( : <=>) where, / is the fractional occupancy 
In this final form, a regular hyperbola with a horizontal asymptote, the law of mass action 
expresses the fractional occupancy, 9:[9];, as a function of ligand concentration, [%], and the 
equilibrium dissociation constant, 34.  At 100% saturation of [#]5, such that #% = [#]5, the 
number receptors that are ligand-bound is equal to the total number of receptors, and the curve 
plateaus at a value 1.0.  Moreover, plotting the fractional occupancy, /, as a function of [%] 
enables a graphical (and thus experimental) determination of 34.  The apparent equilibrium 
dissociation constant, 34, is defined as the concentration of free ligand at which 50% of the 
receptor sites are occupied (/ = 9:[9]; = 0.5). 
 Clark’s theory describes the nature of the interactions between receptor and ligand in 
both kinetic and thermodynamic terms.  For mAbs designed to home tumors and deliver drugs, 
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the affinity and specificity of that interaction is critical to its in vivo behavior.  The equilibrium 
dissociation constant, more than any other parameter, is used to screen and select mAb for 
applications in tumor targeting and drug delivery.  When 34 is very large (µM or mM), the 
binding affinity between mAb and antigen is very weak, dissociating within seconds or 
milliseconds.  However, when 34 is very small (nM or pM) the binding affinity between mAb 
and antigen is very strong, and the mAb will remain bound to the antigen for hours or longer.  
The next section reviews the impact of other critical molecular properties of mAbs, including the 
circulating half-life, internalization rate, and dynamic interaction with the TAA, that contribute 
to the complex and, in some cases, unpredictable in vivo behavior of tumor targeting mAbs. 
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Barriers to mAb tumor targeting and drug delivery 
 MAb-based tumor targeting literature is rich with promising technologies to increase 
tumor uptake and accumulation of anticancer drugs.  However, studies investigating the effect of 
antigen affinity, internalization rate, antigen expression level, mAb circulating half-life, or other 
molecular properties on cumulative tumor exposure often report puzzling, complex, and 
contradictory results.  For example, molecules that bind with high affinity and specificity in vitro 
do not always result in high tumor uptake and prolonged tumor exposure in vivo – in fact, low 
affinity mAb variants have been shown to exhibit higher tumor uptake and exposure than high 
affinity variants in the same tumor model [66-68].  Observations in the field underscore the 
complex and dynamic environment of biological systems, the diversity of organs we describe 
singularly and guilelessly as “tumor” and “cancer”.  A deeper understanding of the complex and 
interdependent processes governing tumor uptake, penetration, and distribution within a solid 
tumor helps illustrate the barriers to predictable tumor uptake and explain the shortcomings of 
the widely accepted, yet frequently disproved, notion that increasing antigen affinity will 
increase tumor uptake and cumulative exposure.  
High, predictable tumor uptake of mAb is also limited by the complex biological 
environment in which they operate.  For example, mAb evaluated for solid tumor targeting and 
drug delivery regularly reach tumor uptake values of 30 % administered dose per gram of tumor 
tissue or higher in preclinical tumor uptake and bioD studies in mice.  However, the same 
molecules studied in humans show tumor uptake of 0.01% – 0.003 % of the administered dose 
per gram tumor tissue [69].  This observation is an artifact of the dynamic interplay between (1) 
the target antigen, (2) the molecular properties (physical, chemical, and biological) of the tumor 
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targeting mAb, and (3) the starved environment in and surrounding a solid tumor.  These barriers 
will be discussed throughout this next section 
 
Ideal properties of the target antigen 
 No one thing influences tumor uptake, target cell internalization, circulating half-life and 
pharmacokinetics of mAb-based tumor targeting agents as much as the target antigen itself.  
Characteristics of a “good” target for cancer therapy overlap most features that define a “good’ 
target for tumor detection.  Target antigens should exhibit the following four properties: (1) be 
abundant and accessible, (2) selectively expressed or preferentially overexpressed, (3) expressed 
homogenously and consistently, and (4) exhibit minimal or no shedding. 
 
Expression profile: target tissue vs non-target tissue 
The target antigen should be abundantly expressed and accessible by the tumor-targeting 
ligand.  Externally administered mAbs lack access to the cytoplasm, nucleus, or other subcellular 
components of the target cell; therefore, accessible targets are predominantly cell-surface or 
extracellular antigens.  Targeted receptors should have a cell-surface copy number of 105 or 
greater.  Mylotarg®, a high-affinity anti-CD33 antibody-drug conjugate indicated for acute 
myeloid leukemia, was modestly effective at killing the target cell due to only 5000-10000 
copies of CD33 on the acute myeloid leukemia (AML) cell surface. 
Moreover, the target antigen should be selectively expressed or overexpressed at the 
cancer cell.  The vast majority of tumor-associated antigens are preferentially overexpressed on 
cancer cells.  Few receptors (if any) exhibit absolute selective expression on cancer cells.  
Therefore, it is the preferential overexpression of target antigen at the tumor, coupled with the 
accessibility and affinity of the tumor-targeting mAb, that dictates the total amount of mAb able 
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to accumulate at the tumor, rather than accumulate at low antigen-expressing tissues.  
Bivatuzumab mertansine, an antibody-drug conjugate targeting a splice isoform of CD44 
(CD44v6) and indicated for incurable squamous cell head and neck cancer or esophageal cancer, 
was discontinued from a Phase 1 dose escalation study after a patient experienced toxic 
epidermal lysis and died [70].  Post-mortem characterization showed orders of magnitude higher 
CD44v6 expression in the keratinocytes of the deceased patient compared to other patients in the 
study, many of whom received a much higher dose. 
 
Target antigen turnover rate and endogenous function 
Turnover rate and endogenous function of a target receptor are critical parameters during 
the selection of target antigen for tumor targeting.  Previous studies have tactfully demonstrated 
that both expression level and turnover rate of the target antigen impact the uptake [71] and 
penetration [72] of mAb by a tumor.  Moreover, mAb binding to a receptor can alter or abate the 
function of that receptor, which in some instances may be a key player in pro-apoptotic cell 
signaling or immune-mediated anti-cancer cell response. 
The target antigen should exhibit minimal or no shedding from the cell surface to the 
extracellular space.  A shed receptor acts as a decoy, which prevents engagement of mAb with 
the target cell.  This, in turn, reduces uptake of mAb in the target tissue.  Selection of antigen 
whose endogenous function or turnover rate can be exploited for enhanced tumor targeting or 
cell uptake is a future direction of considerable interest in the field, particularly so if it bestows 
the mAb localization or exposure characteristics that improve its activity against a cancer cell. 
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Drug resistance, PgP induction, biomarker and stroma changes 
The target antigen ought to be expressed homogenously and consistently at the target 
tissue.  Receptor expression can decrease due to genetic driver mutations or environmental 
stimuli, including the targeted therapy itself.  Repeated administrations of a targeted therapy can 
induce a cancer cell to suppress receptor expression on the target cell, also known as drug 
resistance, o induce genetic driver mutations and changes to transcriptional activators. 
 
MAb radiolabeling and radionuclides used for treatment and imaging 
Historically, mAb-based tumor targeting studies are performed using radiolabeled 
material.  Radiolabeled mAb and engineered fragments (also known as radioimmunoconjugates 
or RICs) offer a diverse set of reagents to probe how size, shape, charge, valency, affinity, 
avidity, and specificity impact tumor uptake.  As reagents, RICs offer an exceptionally low level 
of detection for PK and bioD studies.  They can additionally offer imaging capabilities, which 
allow for dual-modal data acquisition when studying tumor uptake and bioD of tumor-targeting 
mAb.  RICs are regularly used in cancer detection, diagnosis, and treatment monitoring, but 
some prepared with nuclides, like iodine-131 or yttrium-90 that emit high energy particles or 
waves of energy, are capable of killing cells.  A handful of these RICs have been FDA-approved 
for cancer therapy. 
RICs are formed via covalent attachment (direct) or through chelation (indirect) of the 
radionuclide with the tumor-targeting mAb.  Indirect labeling, the most common approach, of 
mAb requires covalent modification of mAb with a chelator followed by complexation of the 
radionuclide with the chelator. The types of radionuclides used in imaging and diagnostics vary 
widely, each with unique set of advantages and disadvantages.  Tumor targeting and uptake 
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studies often employ immunoPET imaging agents, which are positron-emitting radionuclides 
that can also emit gamma or beta particles. 
 
Table 1-2. Properties of common radionuclides used in preclinical bioD and PET imaging studies 
[73] 
Radionuclide t1/2 (h) Positron yield (%) Additional considerations 
68Ga 1.1 89 Generator-produced 
18F 1.8 97 Common, cyclotron 
64Cu 12.7 19 Also beta 
86Y 14.7 33 Also gamma 
76Br 16.2 23 Also gamma 
89Zr 78.5 23 Also gamma 
124I 100.3 23 Also gamma 
 
 Critically, both covalent modification of mAb by direct attachment with the radionuclide, 
as is the case with radioactive iodine, and indirect modification of mAb by direct attachment of a 
chelator followed by complexation with the radionuclide, as is the case for zirconium-89, 
copper-64, and indium-111, will ultimately impact the physical, chemical, and biological 
properties of the mAb.  Because the method of radiolabeling and selection of the radioisotope 
can impact the properties of the mAb [74], different radionuclides and conjugation techniques 
have been developed to offer versatile labeling and manage negative impacts as much as 
possible.  The selection of the radionuclide, in particular, will result in significantly different 
measurements of tumor uptake and retention due to the unique processing mechanisms 
associated with residualizing isotopes compared to non-residualizing isotopes [68, 75].  For 
example, the catabolites of a cell-internalized radioiodinated mAb – free iodine-125 if 
dehalogenated or radioiodinated tyrosine if degraded enzymatically within the lysosome, 
respectively – are effluxed from the target cells, whereas heavy metals like indium-111, 
zirconium-89, and copper-64 will remain contained within the cell following internalization.  
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The conjugation chemistry and linker selection of radiolabeled antibody also impact mAb 
cellular processing and tissue distribution.  As an example, intracellular iodine-125 radioactivity 
was nearly 3-fold higher for mAb conjugates radiolabeled with the SIPC method or TCB method 
compared with conjugates prepared by the Iodogen method [76]. 
 
Molecular properties of mAb that improve target engagement, solid tumor uptake and 
distribution, and cancer cell internalization 
The list of unsuccessful first-generation imaging agents used in cancer detection offer a 
glimpse into the evolution in approach to mAb-based tumor targeting.  Of the mAb-based 
imaging agents FDA-approved in the 1990s, including satumomab pendetide (Oncoscint®), 
capromab pendetide (Prostascint®), arcitumomab (CEA-Scan®), and nofetumomab merpentan 
(Verluma®), only Prostascint® remains on the market in the US.  These first-generation imaging 
agents were limited by a number of shortcomings, including the murine origin of the antibodies, 
inconvenience of delayed imaging due to long serum persistence of intact antibodies, sub-
optimal choice of targets, and limited detection and sensitivity of the agents [73].  Many of these 
shortcomings have been ameliorated with the recent advances in mAb engineering; however, 
issues related to the choosing a tumor-associated target antigen and optimizing target 
engagement persist. 
MAb used in tumor targeting and drug delivery should exhibit a variety of properties, 
including high avidity to the receptor, rapid internalization upon receptor binding, exquisite 
specificity to the target antigen, compatibility for chemical modification, physicochemical 
stability and retained binding after modification, limited immunogenicity, and produced in 
sufficient quantity.  The role of high avidity, molecular size, and cell uptake kinetics on tumor 
uptake, retention, solid tumor penetration, and cancer cell uptake are discussed below. 
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High avidity 
Avidity describes the cumulative strength of binding, accounting for multiple affinities of 
individual non-covalent binding interactions, between mAb and the tumor-associated antigen.  A 
study of monovalent engineered short-chain variable fragments (scFv) and Fab’ fragments 
exhibited 8-fold lower binding affinity to the pan-carcinoma antigen tumor-associated 
glycoprotein 72 (TAG-72) compared to dimeric F(ab’)2 and intact IgG [77].  Separately, short 
chain variable fragments (scFvs) binding the same human epidermal growth factor receptor 2 
(HER2) epitope showed that a high affinity mutant (1 nM) displayed a significantly higher 
fraction of cell-surface binding to antigen-expressing tumor cells in vitro than low affinity 
mutants, more than 7-fold higher tumor retention in vivo than a mutant with 320-fold lower 
affinity, and more than 2-fold higher tumor retention in vivo than a mutant with 16-fold lower 
affinity [78].  Homodimerizing a tumor-targeting scFv led to an increase in avidity that tripled 
tumor uptake compared to the same monovalent scFv or a heterodimerized scFv with one tumor-
specific scFv and one non-specific scFv [79].  In a separate study, bivalent IgG and F(ab’)2 
displayed higher antigen affinity than a monovalent Fab specific to the same epitope on 
fibroblast growth factor receptor 4 (FGFR4); however, dimerizing the Fab and F(ab’)2 fragments 
increased antigen affinity only modestly, whereas dimerizing the intact IgG increased the 
binding affinity more than 3-fold [80]. 
 
Molecular size: balancing tumor penetration with long circulation 
 Each of the more than 1013 cells in the human body are within a few cell diameters of a 
blood vessel, an organizational structure that efficiently facilitates delivery of oxygen, glucose 
and other essential nutrients to tissues [81].  However, the delivery, penetration, and distribution 
of a drug within a solid tumor mass is notoriously poor.  Like drug delivery to well protected 
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organs like the brain defensed by the blood-brain barrier, and the pancreas, characterized by poor 
vascularization and extremely tight cell packing, many features of a solid tumor limit the uptake, 
penetration, and distribution of drugs, including large distances between blood vessels, the 
composition of extracellular matrix, cell-cell adhesions, high interstitial fluid pressure, lack of 
convection, drug metabolism, and non-target protein binding. 
 Convective-based diffusion is the principle driver of tumor uptake of macromolecules.  In 
a tumor accumulation study using fluorophore-labeled dextran ranging in size from 3.3 kDa to 2 
MDa, reducing the molecular weight of dextran improved its vascular permeability by nearly two 
orders of magnitude [82].  Smaller 3.3 kDa and 10 kDa dextran resulted in deep tumor 
penetration, more than 35 µm from the nearest blood vessel, and also distributed homogenously 
through the tumor bass.  Contrarily, 40 kDa to 70 kDa dextran’s modestly penetrated the tumor, 
accumulating 15 µm from the nearest blood vessel, and 2 MDa dextran poorly penetrated the 
tumor mass, accumulating only 5 µm from the nearest blood vessel.  Dextran’s between 40 kDa 
and 70 kDa resulted in the greatest tumor uptake, even though they were largely concentrated 
near the vascular surface. 
Smaller, engineered mAb fragments effectively evade these hurdles.  In studies 
comparing scFv (ca 25 kDa), Fab’ (ca 50 kDa), F(ab’)2 (ca 100 kDa), and IgG (ca 150 kDa), 
intact IgG mostly concentrated at the tumor in the region of or directly adjacent to vessels, 
whereas the scFv evenly distributed throughout the tumor mass, and the distribution of Fab’ and 
F(ab’)2 showed intermediate penetration in a size-dependent manner [83].  Moreover, the scFv 
demonstrated maximum tumor penetration at 0.5 h while intact IgG reached an equivalent tumor 
penetration at 48 to 96 h after administration.  Comparing tumor penetration of anti-FGFR4 IgG 
and fragments at the time of maximum tumor uptake also showed that increased avidity 
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decreased penetration into the solid tumor [80].  Non-specific IgG traveled 100 µm from the 
vessel, compared to 65 µm for monomeric IgG and 35 µm for dimeric IgG.  Likewise, F(ab’)2 
monomer traveled 50 µm from the vessel compared to 30 µm of the dimer, and Fab, the smallest 
and lowest affinity fragment studied, traveled 130 µm from the vessel compared to 35 µm of the 
dimer. 
However, what lower molecular weight fragments gain in tumor penetration and 
distribution, they lose in circulating half-life.  Importantly, macromolecules greater than 
approximately 60 kDa are not subject to glomerular filtration, which has a very well established 
(and extensively reviewed) size and charge selectivity [84].  Moreover, described in detail above, 
IgG constructs void of the Fc fragment are not subject to FcRn recycling.  Taken together, 
engineered mAb fragments smaller than 60 kDa and void of the Fc fragment clear much more 
rapidly than larger fragments and intact IgG.  In the study comparing anti-TAG-72 engineered 
fragments to intact IgG, the intact IgG reached a maximum tumor uptake of 18% injected dose 
per gram (%ID/g) at 48 h compared to 2.6 %ID/g at 4 h and 0.7 %ID/g at 48 h for the scFv [77].  
By comparison, the tumor uptake of F(ab’)2 was 20.8 %ID/g at 4 h and 13.9 %ID/g at 48 h, 
compared 6.2 %ID/g and 2.7 %ID/g for the Fab’ at 4 h and 48 h, respectively.  Kidney uptake at 
4 h was 5 %ID/g for intact IgG, 15.8 %ID/g for dimeric F(ab’)2, 37.0 %ID/g for the monomeric 
Fab’, and only 1.7 %ID/g for the scFv, which had been largely filtered and cleared.  The blood 
concentration versus time curves of anti-FGFR4 intact IgG, dimeric F(ab’)2, and monomeric Fab 
in Swiss Webster mice demonstrate the stark pharmacokinetic differences observed between IgG 
and its smaller fragments [80]. 
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Rapid receptor-mediated uptake 
Receptor-mediated endocytosis following binding of mAb or engineered fragments to the 
target cell can significantly alter tumor uptake, tumor retention, and the circulating concentration 
of tumor targeting mAb.  The impact of cell uptake on the tumor targeting and drug delivery 
features of mAbs depends on the internalization pathway and fate within the cell, factors dictated 
by the nature and strength of the mAb-antigen interaction, as well as the endogenous function of 
the receptor and its response to mAb activation. 
In many cases, bivalent binding is required for receptor-mediated endocytosis to occur.  
This is the case for the tumor-associated antigens CD44 and FGFR4.  In the case of FGFR4, 
negligible cell uptake is observed when FGFR4-expressing Huh-7 cells are incubated with 
monomeric Fab at low or high concentration; however, once dimerized, cell uptake of the Fab 
homodimer incubated at 100 nM is nearly identical to the cell observed with monomeric IgG or 
dimeric F(ab’)2 incubated with cells at a lower 10 nM concentration [80].  Moreover, dimeric 
IgG and F(ab’)2 each resulted in greater fractions internalized than their monomeric counterparts 
or non-specific controls.  The extent of cell uptake of tumor-targeting mAb was also shown to be 
largely influenced by the incubation concentration.  Incubation with 100 nM intact IgG or 
fragments led to significantly higher cell uptake than cell uptake with10 nM preparations 
measured after equal incubation time.  Together, these data highlight the effect of concentration 
and valency on cell uptake in vitro. 
Perhaps more importantly, uptake and cellular processing significantly impacts mAb-
based tumor targeting agents in vivo.  While rapid receptor-mediated uptake is an ideal property 
for antibody-drug conjugates, which must internalize to release the payload within the target cell, 
it can at the same time limit efficacy and safety if cell uptake is not isolated to the target tissue.  
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The various biological and pathophysiological mechanisms limiting mAb tumor targeting and 
drug delivery in mAb in vivo will be discussed in the following section.  
 
Biological phenomena that limit tumor accumulation and retention of molecularly engineered 
mAb-based tumor targeting and drug delivery agents 
Much to the chagrin of researchers in the drug delivery field, mAbs curated with the 
precise critical molecular properties thought to improve tumor targeting and drug delivery 
largely fell short of expectations in clinical trials.  High-affinity mAb selected during standard 
screening and selection campaigns can exhibit poor tumor penetration, poor tumor retention, 
unacceptable off-target tissue uptake, rapid catabolism and clearance [66-68, 85, 86].  While 
advances in mAb engineering superseding hybridoma technology addressed many hurdles mAbs 
face in general, transport phenomena unique to the complex and dynamic biological system of 
solid tumors limit the wide-spread implementation of fully intact, high-affinity mAbs for tumor-
targeting and drug delivery [87].  In fact, solid tumor uptake and retention of mAb can be limited 
by many of the same properties engineered into the mAb for use in tumor targeting and drug 
delivery in the first place [81].  With the exception of Kadcyla®, mAbs used in drug delivery – 2 
of 3 FDA-approved ADCs and 2 of 2 FDA-approved RICs– are indicated for hematological 
cancers. 
Setting individual differences in the expression profile (e.g., target versus non-target) of a 
specific tumor antigen aside, the next section will describe the two main phenomena that plague 
wide-spread use of tumor-targeted mAb in drug delivery.  Phenomena coined the binding-site 
barrier and target-mediated drug disposition reduce tumor uptake, solid tumor penetration, and 
efficacy of mAb-targeted therapies. 
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MAb extravasation, penetration, distribution, and the “binding-site barrier” impacts 
Vascular permeability of the tumor is well-established as the critical mediator of high 
tumor uptake of macromolecular drug carriers like mAbs.  Yet, access and affinity to the target 
antigen largely govern tumor penetration and distribution.  Described above, tuning the 
molecular properties of mAb can help achieve preferential uptake at the target tissue, and early 
studies demonstrated that high-affinity mAbs and engineered fragments improved tumor uptake 
compared to lower affinity counterparts [78].  However, further critical review of these studies 
revealed low tumor penetration and distribution of high-affinity mAbs in solid tumors [66].  It 
was discovered that high affinity molecules that successfully extravasate from the blood vessel to 
the tumor interstitium largely remain localized to the perivascular region of the tumor.  This 
phenomenon, mediated by the high-affinity nature of the mAb to the TAA constitutively 
expressed by the tumor cells nearest the blood vessel, is known as the binding-site barrier (BSB). 
BSB predicts the diffusion of high-affinity mAb into tumors is limited by the low local 
concentration of diffusible, free antibody due to slow rates of antibody-antigen dissociation [87-
90].  Evidence continues to mount showing intermediate affinity mAb (1 – 100 nM) can result in 
greater tumor uptake, improved tumor penetration, and enhanced target engagement than high 
(<1 nM) or low (>100 nM) affinity mAbs binding to identical epitopes on the same target cell 
[66-68].  In one tumor uptake study, scFv variants ranging between 0.01 and 100 nM showed 
that tumor uptake did not to improve significantly with affinity enhancements beyond 1 nM, and 
the lowest affinity scFvs exhibited diffuse tumor staining while high affinity clones were 
primarily restricted to the perivascular regions of the tumor [66].  A comparative study of 125I-
radiolabeled mAb demonstrated that low affinity mAb penetrated a tumor spheroid much more 
deeply and evenly than high affinity mAb binding the same antigen [85].  In a head-to-head 
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study with a series of highly engineered mAb, higher tumor uptake was observed for an 
intermediate affinity mAb (23 nM) compared to a low-affinity mAb (270 nM) or high-affinity 
mAb (0.56 nM) (D). [66, 68]. 
Studies probing the relationship between antigen affinity and tumor penetration informed 
the engineering of a bispecific mAb designed to exploit the transferrin receptor to transcytose the 
blood-brain barrier.  The high-affinity clone failed to dissociate from the receptor following 
transcytosis.  Reducing affinity to the transferrin receptor led to greater brain uptake and 
increased concentrations of the bispecific mAb reaching the brain parenchyma [65]. 
The BSB phenomenon is also observed clinically.  Three patients with metastatic renal 
cell carcinoma were administered 124I-labeled anti-carbonic anhydrase IX (CAIX) mAb.  
PET/CT images of tumor uptake among the three patients showed dramatically different 
distribution behaviors of the same tumor targeting mAb [91].  One patient showed homogenous 
distribution of the mAb in the tumor mass; a second patient showed heterogeneous distribution 
of mAb, localized only to periphery of the tumor, at the interface between the tumor mass and 
the extracellular space; a third patient showed homogenous distribution of the mAb in the 
metastatic nodes but heterogeneous distribution with the primary mass.  However, these clinical 
data require further interrogation.  Current studies cannot with confidence separately attribute 
differences in mAb distribution between patients to the affinity or specificity of the tumor 
targeting mAb separate from expression differences of the target antigen within the target tissue. 
 
Target engagement and target-mediated drug disposition 
Target engagement is defined as the total amount of tumor targeting mAb binding to the target 
antigen and accumulating at the target tissue.  It is critical that tumor targeting mAb binds with 
high affinity and specificity to the target antigen expressed at the target tissue rather than target 
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antigen expressed ubiquitously throughout the body.  Even modest levels of target antigen 
expression on healthy tissues will result in some non-target tissue uptake of high-affinity tumor 
targeted mAb.  The result – less target engagement and more target-mediated drug disposition – 
will thwart the improved safety and efficacy profiles of mAb-targeted therapy compared to 
traditional chemotherapy, as was observed with the CD44v6-targeted antibody-drug conjugate 
bivatuzumab mertansine described earlier [70]. 
Target-mediated drug disposition (TMDD) reduces tumor exposure and accelerates 
systemic clearance of tumor targeting mAb due to antigen expression on non-target tissues as 
well as rapid uptake, catabolism, and efflux within the target tissue [92].  A recent study 
elegantly showed that the presence of a tumor – and tumor size –enhanced the plasma clearance 
of an anti-carcinoembryonic antigen (CEA) mAb.  Moreover, in a blinded follow-up study, the 
authors successfully identified and categorized tumor versus non-tumor-bearing mice simply by 
measuring plasma concentration of the tumor specific anti-CEA mAb [93].  Clearance of tumor 
targeting mAb decreases when dose is increased [94, 95], perhaps due to a saturating effect on 
the target receptor. 
TMDD alters the PK properties of mAb, and the TMDD model posits that altered plasma 
PK of tumor targeted mAb in tumor-bearing mice results from tumor consumption and 
associated catabolism of the mAb in the tumor by the antigen-expressing cancer cells.  In 
landmark cancer cell uptake and retention studies with 125I-labeled mAb, it was observed that 
antibody labeled with 125I (by the Peirce iodination method) proteolytically degraded in the 
lysosome following endocytosis and rapidly released radioiodinated tyrosine into the cell 
supernatant [74, 96, 97].  Studies with 125I-labeled anti-HER2 mAb in HER2-overexpressing SK-
OV-3 cells demonstrated that high affinity mAb both internalized and degraded faster and to a 
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greater extent than low-affinity or non-binding mAb [68].  In addition to reduced plasma 
concentrations, high-affinity, rapidly internalizing tumor targeting mAbs display inferior 
retention of radioactivity in the tumor compared to antibody-antigen systems exhibiting slow 
rates of endocytosis. 
TMDD also alters uptake and retention of mAb within the target cell – a significant 
parameter in design of ADCs.  While TMDD can reduce the efficacy of therapeutic mAbs and 
utility of mAbs in tumor detection and imaging, ADCs for the most part benefit from TMDD to 
aid in the rapid and complete delivery of drug to cancer cells [98, 99].  Lower plasma 
concentrations of the ADC can usually be offset by increasing the dosing frequency or otherwise 
shortening the time between doses.  ADCs exploiting TMDD and will be discussed in the last 
sections of this review. 
 
Impacts of the tumor microenvironment  
 Besides the BSB and TMDD, specific physiological phenomena characteristic of solid 
tumors limit the uptake, retention, and distribution of mAb [87].  Some examples include the 
high interstitial fluid pressure, poor blood flow, poor vascularity, and heterogeneous antigen 
expression within the tumor [90].  Attempts to make the tumor microenvironment more 
amenable to drug delivery [100] have seen only limited success.  For example, one such 
approach attempted to increase the vascularity of the tumor by conjugating VEGF to a tumor-
targeting mAb [101].  Tumor uptake was modestly improved at very high doses only after a pre-
treatment with the VEGF conjugate prior to the administration of the VEGF-tumor targeting 
conjugate. 
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Novel approaches improve tumor targeting, uptake, drug delivery, and in vivo efficacy 
MAbs offer an unparalleled platform to target tumors with radionuclides and drugs that 
enable robust diagnosis and treatment of cancer.  However, heuristics guiding the principle 
design of efficient and selective tumor targeting mAbs remains elusive.  Moreover, predicting 
the in vivo behavior of tumor targeting mAb against a diversity of biological targets, all while 
incorporating highly variable biological data like inter-patient variability and the expression level 
and turnover rate of the target receptor in non-target tissues, continues to be a significant 
challenge in the field.  Tumor targeting models in quantitative pharmacology probe the 
underlying mechanisms that limit mAb tumor uptake and predict distribution, circulating half-
life, and target cell uptake [102-105].  These models also contribute to a greater appreciation of 
the complex interplay between antigen and antibody and can accelerate screening and selection 
campaigns of tumor-targeting mAb with specific localization and exposure requirements.  
Integration of more biological data into these models will improve the outcome and 
predictability of mAbs for applications in tumor-targeting and safe, effective drug delivery. 
A number of novel approaches are currently under investigation to improve mAb tumor 
targeting, penetration, distribution, selectivity, and drug delivery.  For example, more important 
than specificity to the target antigen, the mAb should exhibit selectivity to the target antigen on 
the target cell.  One way to approach this is to develop an orthogonal, dual-modal mAb-based 
targeting agent.  Orthogonal targeting takes advantage additional attributes unique to the tumor 
tissue or cancer cell, separate from phenotypic expression of the target antigen. 
For example, one mechanism of resistance to trastuzumab therapy in HER2-
overepxressing patients is the upregulation of other human epidermal growth factor receptor 
family members, like EGFR.  To better tune tumor cell targeting, a dual-receptor targeted 
 54 
radioimmunotherapy was generated to study tumor targeting and efficacy in cancers co-
expressing human epidermal growth factor receptor-2 (HER2) and epidermal growth factor 
receptor (EGFR) [106].  By linking the Fab fragment of trastuzumab to the soluble endogenous 
EGF ligand, the authors showed specific binding and subsequent cell death to HER2- and EGFR-
expressing tumor cells, whereas the monospecific Fab or EGFR bound and killed tumor cells that 
predominantly expressed only HER2 or EGFR, respectively.  Orthogonal, dual-modal therapies 
could also be designed and tunable by external stimuli, like heat, ultrasonic waves, or radiation-
induced activity. 
Bispecific antibodies (biAbs) have been explored for a variety of applications in drug 
delivery.  BiAbs retain the structure of an intact IgG; however, rather than containing two 
antigen binding fragments that each bind the same antigenic epitope, biAbs contain two unique 
antigen binding fragments that each engage a unique antigenic epitope.  BiAbs have commonly 
been engineered with one arm one binding a tumor-associated antigen and the other arm 
exhibiting some pharmacological activity on a molecule in the local environment.  For example, 
a series of papers describe the development of a biAb engineered to exploit the expression of 
transferrin at the apical membrane of the blood-brain barrier to transcytose the classically 
impenetrable membrane and exhibit activity against the Alzheimer’s causing beta-site APP-
cleaving enzyme 1 (BACE1) [65, 107-110].  In addition to enhancing targeting specificity, 
pharmacologically activity, and access to classically inaccessible tissues, cells, and subcellular 
compartments, biAbs can alter the localization behavior of antigens of cells and aggregate 
molecular entities together in a biological medium.  Blinatumomab (Blincyto®) contains one 
anti-CD3 arm and one anti-CD19 arm to home CD19+ leukemic or lymphomic cancer cells with 
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CD3+ T cells.  Blincyto® is used to treat some types of acute lymphocytic leukemia and is 
thought to work by proximally-mediated T-cell attack against the cancer cell. 
There is no shortage or diversity in engineered mAb constructs with enhanced physical, 
chemical or biological capabilities designed specifically to overcome barriers to tumor-specific 
drug delivery, advance understanding in research, and improve capabilities in the clinic.  
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MAb-mediated drug delivery and the antibody-drug conjugate (ADC) 
Patients diagnosed with inoperable, metastatic, advanced stage cancers often face limited 
treatment options in cancer management.  An unlimited dose of chemotherapy would 
successfully kill all cancer cells in that patient but may have lasting, potentially fatal, effects to 
the patient.  The natural challenge with cancer, however, is that it grows within a generally 
healthy human, whose body contains mostly healthy cells and healthy tissues, many of which are 
susceptible to the toxic effects of chemotherapy.  The goal of a chemotherapy treatment regimen 
is to dose as much as possible as often as possible to a point that may cause discomfort or acute 
tissue damage but will not kill or cause severe, unmanageable, or chronic damage to the healthy 
organs and tissues of the body.  Unfortunately, there are situations when no dose is high enough 
to eradicate the cancer cells without causing intolerably high damage to healthy tissue.  Non-
small cell lung cancer, which is often diagnosed as late-stage, inoperable, and metastatic, has no 
more than a 14% 5-year survival rate [111].  Survival rates of some cancers of the brain [112] 
and pancreas [113] are even more dismal.  It is in these situations that an oncologist may 
advocate to forgo treatment and focus instead on palliative care. 
MAb-mediated drug delivery attempts broaden the therapeutic window of the drug to be 
delivered.  The therapeutic window is described as the difference between the maximum 
tolerated dose (MTD) and the minimum effective dose (MED).  Prior sections of this review 
attempted to convince the reader that mAbs are the most versatile drug delivery platform today – 
tailored, tunable, and engineered in almost any way imaginable.  MAbs are also arguably the 
world’s most successful biotechnology product and the only clinically consistently proven safe 
and effective drug carrier.  Drugs, toxins [114], and radionuclides [115] are three of the most 
common cytotoxic agents conjugated to a tumor-targeting mAb.  All three conjugates – 
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antibody-drug conjugates (ADCs), immunotoxins (ITs), and radioimmunoconjugates (RICs) – 
have been studied in clinical trials and successfully gained FDA approval.  
Future use of “ADC” in this text will refer to an anticancer chemotherapeutic covalently 
attached to a tumor-targeting mAb.  Conjugation of the cytotoxic molecule to a mAb broadens 
the therapeutic window of the cytotoxic molecule.  The mAb endows the cytotoxic molecule 
improved selectivity, which lowers its MED, and simultaneously reduced systemic exposure, 
which increases its MTD [116].  ADCs are the most advanced cancer therapy and most 
promising tumor targeting agent in drug delivery today.  Synthesis, design, characterization and 
clinical development of ADCs will be the focus of the remainder of this review. 
 
ADC anatomy 
An antibody-drug conjugate is comprised of three basic elements: a tumor-targeting 
mAb, a cytotoxic molecule, and a linker [117].  This molecular format marries the homing 
properties of an antibody with the cytotoxic properties of a chemotherapeutic. 
ADCs components work together in harmony to yield a safe and effective anticancer 
agent.  However, from the three basic elements of an ADC, there are five molecular attributes 
that impact safety, efficacy, and behavior of ADCs in vivo.  Those five components are the (1) 
target antigen, (2) tumor-targeting mAb, (3) payload, (4) linker between the toxic drug and tumor 
targeting mAb, and (5) bioconjugation chemistry to attach the linker to the mAb.  The ideal 
features for selecting a tumor-targeting mAb and target antigen for ADC therapy overlap many 
of the features of an ideal tumor targeting therapy (reviewed above).  Basically, the antibody 
should impart long circulation, antigen localization, and intracellular delivery to the target cell.  
The linker should remain stable in circulation yet rapidly cleave once internalized by the cell.  
The inherent potency of the released drug must be sufficient to kill the tumor cell at low 
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concentrations, and its site of action should be within the TAA-expression target cell.  While the 
antibody accumulates the payload at the tumor and the toxin mediates the activity, the linker 
uniquely impacts both accumulation and potency.  The molar loading of drug on the mAb can 
also be tuned to achieve the desired potency.  Each of these elements will be discussed in more 
detail below. 
 
ADC mechanisms of action 
ADCs operate through variety of primary and secondary mechanisms to exhibit a 
cytotoxic effect on the target cell [118].  Intracellular delivery of the payload is the primary 
pharmacological activity of an ADC.  The mAb component of an ADC can induce immune-
mediated responses, which serves as a secondary, yet still direct, mechanism of antitumor 
activity.  Finally, drug delivered to the target cell can exhibit activity on other neighboring 
cancer cells  [119, 120].  This is coined the bystander effect, and is a demonstrated indirect 
method by which ADCs home potent toxins to tumors. 
 
 
Figure 1-5. ADCs induce cytotoxic activity against cancer cells through multiple, direct and 
indirect independent mechanisms of action. 
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First generation antibody-drug conjugates 
The concept of an ADC first evolved from the need to improve the tumor selectivity of 
anticancer drugs, whose clinical doses were limited by undesired off-target toxicities.  Thus, the 
first ADCs were prepared with the anticancer drugs already in the clinic, such as methotrexate 
[121], vinblastine [122], doxorubicin [123], and melphalan [124, 125].  A conjugate of murine 
KS1/4 antibody with the cytotoxic drug methotrexate linked through an amide bond was 
evaluated in two Phase I clinical trials in patients with non-small cell lung cancer (NSCLC) 
[126].  Immunohistochemical (IHC) staining of tumor biopsies provided evidence of tumor 
localization of the conjugate, yet little evidence of therapeutic benefit or clinical response was 
observed in either study.  The same KS1/4 antibody was later linked to desacetylvinblastic 
through either an esterase-labile hemisuccinate linker or acid-labile hydrazone bond.  Both were 
evaluated in clinical trials with patients with adenocarcinoma of the lung or colon.  Direct 
evidence of tumor localization was observed, but therapeutic activity was not noted with either 
conjugate in the trials [127]. 
BR96-DOX, a Lewis-Y-targeted mAb conjugated with doxorubicin via an acid-labile 
hydrazone bond, was the first proof-of-concept ADC to pave the way for subsequent generations 
[128].  BR96-DOX was tested in Phase II trials in  patients with metastatic breast cancer [129].  
While toxicity of the conjugate was markedly different than the control group of unconjugated 
doxorubicin, the conjugate failed to demonstrate clinically meaningful therapeutic activity.  It 
was discontinued soon thereafter. 
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Antibody-drug conjugates (ADCs): synthesis and design 
 Design and synthesis of antibody-drug conjugates (ADCs) is one of the most exciting and 
yet challenging aspects of the field today.  ADCs in clinical and preclinical pipelines are diverse, 
each designed with specific components for a very specific action.  Yet when taken together, 
ADCs target a wide variety of antigens using a diversity of mAb-based tumor targeting 
constructs linked with exquisitely designed linkers to a handful of therapeutics through an ever-
increasing set of bioconjugation chemistries.  The result: a set of molecules that treat tumors with 
drugs no other vehicle can safely or effectively deliver in humans.  Without exception, ADCs in 
clinical trials are under evaluation as antineoplastic therapies.  ADCs historically target cancers 
of the blood, but the 2013 FDA approval of Kadcyla® re-invigorated ADC development for 
solid tumors, whose pipeline has never been more robust and diverse than today.  Like tumor-
targeting mAb and other drug delivery vehicles, ADCs must overcome a series of physical, 
chemical, and biological barriers to exhibit a safe and potent effect on the target tissue [130]. 
 
Selection of Antigen 
 The features of an ideal antigens for an ADC therapy overlap many of the features of an 
ideal tumor-targeting therapy, with one significant yet semi-controversial property.  At a 
minimum, target antigen should (1) be abundant and accessible, (2) selectively expressed or 
preferentially overexpressed, (3) expressed homogenously and consistently, and (4) exhibit 
minimal or no shedding.  Additionally, binding of the mAb component of an ADC to the target 
receptor expressed at the surface of the cancer cell should trigger rapid and complete 
internalization of the receptor-ADC complex.  Following internalization, the receptor should 
avoid lysosomal degradation and its re-expression on the target cell surface should be high.  
Moreover, internalization of the receptor should not adversely affect target cell proliferation, 
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survival, or resistance to drug.  Like with tumor-targeting mAb, the selection of the target 
antigen is the most critical feature to the safe and successful design of an antineoplastic ADC. 
 Targeting a well-known internalizing receptor or engineering the mAb component of the 
ADC to trigger internalization upon binding is not always necessary.  For one, the rate of 
diffusion of the ADC to the cell surface is likely much faster than the rate at which the ADC can 
enter the cell.  In this case, cell uptake would be influenced by dose, ADC diffusivity, and access 
to the cell-surface receptor, rather than internalization rate after binding.  Whether the ADC must 
undergo receptor-mediated endocytosis (RME) in order to exhibit potent and specific activity 
against the target cell [131] is an area of controversy and studies with other TAAs currently 
explore the topic. 
 
Tumor-associated cell surface receptors 
The most common target antigens for ADC therapy are cell-surface receptors found 
selectively expressed or overexpressed on the cancer cells located within the primary tumor.  
ADCs targeting cell-surface tumor-associated antigens such as CD19, CD20, CD22, CD30, 
CD33, and HER2 represent that vast majority of ADCs in preclinical and clinical development.  
MAbs and ADCs targeting cell-surface receptors for drug delivery has been extensively 
reviewed. 
 
Antigens in the tumor microenvironment 
Antigens of ADCs can be found directly expressed on the cancer cells, on tumor stroma 
cells, on cells of the extracellular matrix, and on progenitor cancer stem cells, which give rise to 
both primary tumor cells and migratory metastatic cells [132].  The tumor microenvironment, 
including stroma and architectural features that enable the migration and proliferation of cancer 
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cells, is a new and exciting antigen pool targeted by ADC therapies.  Similar to anti-angiogenic 
therapies, which starve the tumor of essential nutrients to survive, divide, and proliferate, ADCs 
targeting the tumor stroma and other elements of the tumor microenvironment are hypothesized 
to (1) localize drug within the tumor microenvironment and (2) degrade the architecture that 
enables solid tumor growth, vascularization, and metastases.  ADCs in development for 
extracellular matrix target fibronectin, tenascin, or periostin, or vascular targets, like integrins, 
prostate-specific membrane antigen (PSMA), and vascular endothelial growth factor receptor 
(VEGFR-2) [133]. 
Targeting the tumor mass microenvironment with a cleavable ADC has proven to be an 
effective treatment and promising new approach against drug-resistant cancers.  An ADC 
targeting the alternatively-spliced extra domain A of fibronectin accumulated in the sub-
endothelial extracellular space of the tumor, not on the primary cancer cells themselves, and 
mediated potent antitumor activity [134].  The DM1 payload was linked to the mAb by a labile 
disulfide bond, which was cleaved as free drug and released in the extracellular environment.  
Improved tumor uptake and faster drug release were observed when DM1 was linked to the 
smaller SIP mAb fragment rather than intact IgG, which enhanced the therapeutic activity of the 
non-internalizing ADC [135].  Historically, disulfide-linked ADCs against cell-surface receptors 
demonstrate lower efficacy and diminished safety in solid tumor models due to premature drug 
release [120, 136]. 
 
Antigens overexpressed by cancers stem cells (aka tumor initiating cells) 
Data increasingly demonstrate that cancer stem cells (CSCs, aka tumor initiating cells, 
TICs) underlie tumor growth, recurrence, and resistance to therapies [137].  Like primary tumor 
cells, cancer stem cells harbor a set of receptors that phenotypically differentiate them from 
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healthy cells, including CD44, epithelial cell adhesion molecule (EpCAM), and the delta-like 3 
receptor (DLL3).  A recent set of preclinical studies using an ADC targeted to DLL3 
demonstrated complete eradication of the CSC cells while also inducing durable tumor 
regression across multiple patient-derived xenograft (PDX) models [138]. 
 
Selection of Antibody 
 As with the target antigen, the ideal features of antibody for an ADC does not 
significantly differ from the ideal features of antibody for tumor targeting.  MAb used for 
anticancer drug delivery should exhibit high avidity to the receptor, rapid internalization upon 
receptor binding, exquisite specificity to the target antigen, compatibility for chemical 
modification, physicochemical stability and retained binding after modification, limited 
immunogenicity, and produced in sufficient quantity.  Above all, its key feature is to 
preferentially bind to the antigens expressed on the target cell and concentrate the cytotoxic 
agent at the tumor site.  It can be advantageous to select antibody that itself possesses functional 
anticancer activity, which might confer additional therapeutic benefit.  
 
Selection of Linker 
Antibody-drug conjugates function as a prodrug.  Effectively, intact ADCs are benign 
when in circulation yet activated once internalized by the target cell, releasing its cytotoxic 
payload within the cell at the precise site of action.  The efficiency of the ADC drug delivery – 
the number of cytotoxic molecules reaching the pharmacological target divided by the total 
number administered – is largely determined by the linker cross-linking the drug to the mAb.  
Premature release of drug in circulation, or inefficient release of drug within the target cell, could 
lead to systemic toxicity, lower efficacy, and all-around lower therapeutic index of the ADC.  
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Current ADC assembly strategies rely on bifunctional linkers and specific molecular or 
mechanistic processes to release active free drug.  Selection of linker and conjugation chemistry 
(discussed more below) are inherently connected and have been extensively reviewed [133]. 
Selection of linker between the drug and tumor-targeting antibody is one of the most 
critical design elements in the generation of safe and potent antibody-mediated drug delivery.  
Effective cancer treatment requires systemic stability of the conjugate as well as selective drug 
release at the target tissue.  Prior to mAb and targeted delivery strategies, early explorations 
evaluated the use of polymers as carriers of anticancer drugs.  Attaching cytotoxic anticancer 
drugs to high molecular weight polymers showed reduced systemic toxicities, longer in vivo 
circulation times, improved biodistribution, and enhanced therapeutic efficacy.  While these 
advantages are not to be disregarded, polymer-drug conjugates suffered from two critical 
disadvantages:  
1) Modest uptake at target tissues  
2) Inefficient, uncontrolled, or non-specific drug release from the polymer support, 
typically mediated by simple aqueous hydrolysis or by proteolytic enzymes (e.g., 
esterases) 
Ideal linkers for targeted drug delivery remain stable at circulation but rapidly cleave at 
the target site.  Selective linker cleavage and subsequent drug release relies on identifying 
conditions or molecules isolated or specific to the target tissue or site of drug action.  
Foundational cell biology studies discovered that endosomes and lysosomes are acidic (pH 5–7) 
compared to the cytosol and the extracellular environment (pH 7–7.5).  The endosomes and 
lysosomes also contain specific cellular digestive enzymes known as capthepsins that are 
expressed at orders of magnitude higher concentration within the lysosome than cytosol or 
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extracellular fluid.  Glutathione is also expressed at 1000 times higher concentration within the 
cell than outside the cell. 
These discoveries in basic cell biology guided linker design and hypotheses regarding 
targeted intracellular drug delivery.  Three classes of ADC linkers exploit these conditions to 
selectively cleave drug within the target cell. 
 
Acid-sensitive cleavable linkers 
 Acid-sensitive linkers are thought to remain stable in circulation and then cleave 
following receptor-mediated endocytosis and acidification during endosome to lysosome 
maturation.  Hydrazone-based linkers constitute the most prominent acid-sensitive linker used in 
ADC drug delivery and linker design.  In fact, the anti-CD33 ADC Mylotarg® took advantage of 
hydrazone to link calicheamicin to an anti-CD33 mAb.  Only small fractions of calicheamicin 
were cleaved during ADC circulation.  However, even small fractions of the highly potent 
compound resulted in some cases of myelosuppression and hepatic veno-occlusive disease. 
 
Lysosomal enzyme-sensitive cleavable linkers 
Acid-sensitive hydrazone linkers were the preferred linker choice in the early days of 
immunoconjugate design and synthesis. However, hydrazone bonds show limited hydrolytic 
stability, resulting in a significant amount of free drug released in circulation prior to entering the 
target tissue.  Lysosomal-specific linkers addressed the issues associated with hydrazone linkers 
by exploiting the specific expression profile of enzymes within the lysosome.  Cathepsin B was 
identified as a candidate target for linker substrates due to its high activity and exclusive 
intracellular localization.  Cathepsin B is a cysteine protease predominantly localized to the 
lysosome of cells.  It’s concentration in blood is below current methods of detection.  Taken 
 66 
together, conjugates prepared with a cathepsin B-cleavable linker are likely stable in circulation 
and yet selectively and rapidly cleaved upon cell internalization and ADC accumulation in the 
lysosome.  
Prior to the application of cathepsin B-specific substrates for use in ADC linker 
technologies, Gly-Phe-Leu-Gly [139] and Ala-Leu-Leu [140, 141] peptides were used as drug 
carrier linkers for targeted lysosomal cleavage.  These peptides were considered impractical for 
use in ADC linkers due to their observed slow drug release and hydrophobic nature.  It was 
previously established that Z-Phe-Arg-X is a general substrate for the assay of cathepsins B and 
L [142].  After preparing a series of model compounds to determine structure requirements for 
efficient enzyme-mediated drug release and plasma stability [143], Dubowchik and colleagues 
used the simple sequence as a model to identify two novel compounds for use as cathepsin B-
specific linker compounds for antibody–drug conjugate preparation.  Two linker compounds 
composed of Phe-Lys or Val-Cit were used to conjugate the anticancer drug doxorubicin (DOX) 
to the chimeric, internalizing Lewis-Y-specific monoclonal antibody [144].  The study 
demonstrated that DOX release was 30-fold faster form the Phe-Lys linker than the Val-Cit 
linker with cathepsin B but released at identical rates in a rat liver lysosomal preparation.  Both 
conjugates showed excellent stability in human plasma and potent, antigen-specific cytotoxic 
activity.  Moreover, the additional incorporation of a self-immolative p-aminobenzyloxycarbonyl 
(PABC) spacer in both linkers was required for rapid and quantitative generation of free DOX, 
which had been previously described in other prodrug designs [145].  Of particular interest for 
lysosomal enzyme-sensitive linkers, this group also developed the methods to quantitate the total 
accumulation of ADC accumulated within the cell by the lysosomal pathway [146].  
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ß-lactamase-sensitive linkers have also been explored for antibody-drug conjugate 
design.  For example, doxorubicin-derivatized PEG carriers containing a ß-lactamase-sensitive 
cephalosporin moiety released free doxorubicin upon ß-lactamase-catalyzed hydrolysis with a 
tumor-targeting mAb-ß-lactamase conjugate [147]. 
 
Disulfide linkers sensitive 
Many immunoconjugates employ disulfide linkers to control the payload release.  
Disulfide linkers offer preferential cleavage at the target cell, simple chemistry and tunability in 
release kinetics.  Reducing agents have long been used to cleave disulfide bonds to two 
individual sulfhydryls, or free thiols.  Nisonoff and colleagues led early studies exploring the 
disulfide bond structure within antibodies, as well as the conditions to reduce and recombine 
univalent fragments.  In systematic studies, reducing agents like 2-mercaptoethylamine (2-MEA) 
were used to study time- and temperature-dependent reduction of IgG disulfide bonds and 
recombination of univalent fragment of rabbit antibody. 
 Disulfide linkers exploit the finding that glutathione (GSH) in the cell is 100-1000 times 
the concentration in the circulation.  It has long been assumed that intracellular conditions of 
endocytic vesicles are reducing environments.  However, Austin some conflicting studies have 
shown that endocytic compartments are oxidizing, not reducing, and comparable with conditions 
in the endoplasmic reticulum [148].  These findings add to the novelty of specific and tunable 
ADC linker design. 
 
Non-cleavable linkers 
Linkers do not necessarily need a specific cleavage mechanism to effectively deliver 
drugs to the intracellular space of the target cell.  Non-cleavable linkers, designed without a 
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specific payload release mechanism, have shown effective target cell uptake and payload 
delivery to antigen-positive tumor cells.  Ado-trastuzumb-DM1 in its final clinical form 
Kadcyla® is the first and only FDA-approved ADC using a non-cleavable linker design. 
Non-cleavable linkers do not contain a specific, chemically labile structure.  Thioethers 
formed by the reaction of maleimide electrophiles with endogenous and engineered cysteine 
residues were initially thought to form stable, non-cleavable bonds.  This was a promising 
approach for ADCs, which carry drugs that are 10–10,000 times more potent than standard 
chemotherapies. The two currently FDA- approved ADCs both utilize a maleimide moiety to 
link to a cysteine residue on the antibody (Adcetris®) or an incorporated sulfhydryl on the drug 
(Kadcyla®). 
It should be noted that the term non-cleavable does not indicate complete in vivo stability, 
so this terminology can be somewhat misleading.  Increasing evidence has shown that 
maleimide-based ADCs are prone to payload loss via a retro-Michael type reaction (fast) or 
hydrolysis (slow).  The regenerated maleimide can be trapped by free cysteine, glutathione, or 
albumin has been observed, and active drug conjugated to mAb via a thioether bond can be 
chemically exchanged from the mAb to cysteine-34 of albumin [149, 150].  Transfer to serum 
albumin can be blocked by preparing the conjugate using bromoacetamide (bac) chemistry in 
place of the maleimide chemistry.  However, while maintaining a constant DAR over the 14-day 
study, the bac-conjugated ADC demonstrated minimal improvement. 
Premature cleavage of the toxin from the antibody can result in two significant issues: (1) 
systemic exposure of the toxin to nontarget tissues, which can affect safety and dose-limit the 
ADC, and (2) the remaining ADC in circulation may have reduced efficacy owing to the reduced 
number of drugs per antibody.  
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Selection of drug 
 Only a select few drugs have reached clinical studies as the payload for an anticancer 
ADC.  ADC payloads must exhibit a variety of features that exclude that vast majority of drugs.  
Because ADCs must overcome a series of biological barriers (many described in detail above), 
and very few molecules reach the intracellular targets of ADC payloads, it is widely accepted 
that ADC payloads should exhibit cytotoxic effects at 100–1,000 times higher potency than 
traditional chemotherapy.  In addition to outstanding potency, ADC payloads should also be 
amenable to covalent modification, stable in aqueous conditions, soluble in aqueous conditions, 
chemically benign to the antibody, and non-substrates for PgP [118, 151] 
 
Anthracyclines 
 Doxorubicin (DOX) was an attractive starting point for ADCs due to the ease of covalent 
bioconjugation to the mAb and satisfactory aqueous solubility.  DOX is an anthracycline that 
stops DNA replication by intercalating DNA and inhibiting the progression of DNA 
topoisomerase II.  Antibody-DOX conjugates were some of the very earliest ADCs studied for 
cancer therapy, with the first reported conjugate prepared in 1983 and characterized for its 
activity against a panel of brain cancers [123].  BR64-DOX and BR96-DOX were heavily 
researched DOX-based ADCs in the 1990s.  BR96-DOX even entered clinical trials, though its 
development was halted in Phase II for low drug potency, antigen-mediated off target toxicity, 
and premature drug cleavage [129].  Despite its challenges, a CD74-targeted DOX-based ADC is 
currently in Phase I/II clinical trials for hematological cancers [152]. 
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Antimitotic agents: taxanes 
Many of the earliest ADCs prepared delivered antimitotic agents.  Taxanes (like 
docetaxel and paclitaxel) stabilize altered microtubule structures and inhibit their normal 
degradation during cell division, whereas vinca alkaloids (auristatins and maytansinoids) bind to 
the vinca alkaloid binding domain to inhibit tubulin polymerization and disrupt normal tubulin 
formation and dynamics.  A literature search of antibody-docetaxel conjugates today yields no 
results.  However, a series of paclitaxel conjugates were prepared and characterized in vitro and 
in vivo.  The first description of an antibody-paclitaxel ADC was reported in 2001 and described 
its preferential cytotoxic activity on a panel of ovarian cancer cell lines compared to healthy cells 
[153].  A cetuximab-paclitaxel conjugate (PTXC225) improved in vitro cytotoxicity compared to 
paclitaxel alone,  cetuximab alone,  or a mixture of the two; however, no improvement in 
antitumor efficacy was observed [154], likely attributed to the relatively low dose of cetuximab-
delivered paclitaxel or an untimely release of paclitaxel, or both.  Follow-up studies confirmed 
rapid release of paclitaxel from C225 (t1/2 < 2 h), which was improved by replacing the succinate 
linker with glutaric acid.  The improved cetuximab-paclitaxel conjugate resulted in enhanced 
antitumor activity and a more than 16-fold increase in paclitaxel half-life [155].  Studies also 
assessed an anti-EGFR Fab linked to paclitaxel, as well as a trastuzumab-paclitaxel conjugate 
[156].  No antibody-taxane conjugates have reached clinical study. 
 
Antimitotic agents: vinca alkaloids 
Two main ADC payload classes exhibit antineoplastic activity by inhibiting tubulin 
polymerization: auristatins, synthetic analogues of the cytostatic peptide dolastatin 10, and 
maytansinoids, synthetic analogues of the benzoansamacrolid macrocyclic maytansine.   
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Together, tubulin binding auristatins and maytansinoids are the most common ADC payloads 
today. 
 The powerful antineoplastic activity of the microtubule inhibitor dolastatin 10 was first 
described in 1987 [157].  When exposed to cells, dolastatin 10 leads to mitotic cell cycle arrest 
and apoptosis, with picomolar level cytotoxicity in cancer cell proliferation assays [158].  Since 
then, many research groups have actively developed a suite of synthetic analogues (auristatins) 
that serve as the payload of more than 30 ADCs undergoing clinical trials today, including the 
FDA-approved ADC brentuximab vedotin (Adcetris®) [159].  While dolastatin 10 showed 
impressive in vitro activity and preclinical efficacy, toxicity was observed in preclinical species 
[160], clinical efficacy was uninspiring in patients with melanoma [161] or advanced breast 
cancer [162], and significant toxicity was observed in a study of patients with recurrent or 
metastatic soft tissue sarcomas [163].  Two significant discoveries led auristatins to the forefront 
of the ADC payload field.  First, removal of one N-methyl group of dolavalin at the N-terminus 
only slightly attenuated potency  Second, the new, only slightly attenuated analogue, contained a 
secondary amine, which could be attached to a linker and subsequently conjugated to mAb [164].  
Together, these advancements led to the generation of highly potent and efficacious ADCs, and 
eventually resulted in the FDA-approval of brentuximab vedotin for treatment of Hodgkin 
lymphoma (HL) and systemic anaplastic large cell lymphoma (SALCL) [165].  [166].  
Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are the most common 
auristatins selected for mAb conjugation.  MMAF is approximately 100-times less potent than 
MMAE in in vitro, yet its methyl ester derivative (MMAF-OMe) is 100-times more potent [167], 
a result attributed to the poor cell permeability of MMAF.  Antibody-auristatin conjugates are 
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typically prepared with a protease-specific dipeptide linker attached to a para-aminobenzyl 
moiety and linked to a mAb free thiol via noncleavable thioether bond. 
 A maytansine derivative (DM1) was developed as the payload on Kadcyla®, also known 
as ado-trastuzumab emtansine or T-DM1, the second of the three currently FDA-approved ADCs 
and indicated for HER2-overexpressing breast cancer [168].  First isolated in 1972 [169], 
maytansine was discovered to exhibit antineoplastic activity by binding tubulin near the vinca 
alkaloid binding site and suppressing microtubule dynamic instability [170].  Like dolastatin 10, 
maytansine was extensively evaluated in human clinical trials but failed to demonstrate a 
therapeutic effect at tolerable doses [171, 172].  Though not possessing a native functional group 
for chemical conjugation, maytansine exhibits other properties attractive to ADC payloads, such 
good aqueous stability and reasonable aqueous solubility [28].  S-methylated thiol-bearing 
maytansinoids exhibit potencies between 1 and 30 pM against KB and SK-Br-3 human cancer 
cells.  Antibody-maytansinoid conjugates have been prepared with both cleavable disulfide and 
non-cleavable thioether linkers which yield different forms of active drug [173]. 
 
DNA agents 
 Calicheamicins are the most prominent DNA scission agents, exerting activity by binding 
tightly within the minor groove of DNA and launching a nucleophilic attack that abstracts 
hydrogen atoms from both strands of duplex DNA.  Next, oxygen cleaves the DNA diradical, the 
double stranded DNA breaks, and the cell dies.  Minor groove binding is facilitated by an aryl 
tetrasaccharide targeting moiety, and a methyl trisulfide performs the nucleophilic attack that 
mediates double strand DNA scission.  Calicheamicin is recognized to be among the most potent 
antitumor agents ever discovered.  In vivo, calicheamicin,!1 possesses potency against a variety 
of tumor types at doses as low as 0.15 ug/kg [174].  calicheamicin,!1 was modified to N-acetyl-
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!-calicheamicin, a 20 times less potent and toxic analogue, and the trisulfide was converted to a 
disulfide to add a functional group for antibody conjugation [175].  Antibody-calicheamicin 
conjugates are generally prepared with hydrazone or amide linkages [176, 177]. 
 Duocarmycins exert high potency through a sequence specific alkylation of DNA 
resulting in cell death [178].  An analogue of duocarmycin (DC1) was shown to exhibit near 
equal potency as duocarmycin yet exhibit significantly improved stability.  After the addition of 
a thiol-containing linker to the terminal pyrroloindole subunit of DC1, antibody-DC1 conjugates 
containing 3 to 4 DC1 molecules per antibody linked by disulfide bonds showed excellent in 
vitro cytotoxicity and antigen-specificity, but poor solubility and aqueous instability precluded 
further development [179].  Incorporating a phosphate group into the phenol group of DC1 
significantly enhanced the solubility and aqueous stability of the antibody-DC1 conjugate 
without altering in vitro potency or specificity [180].  Two ADCs containing duocarmycin 
derivatives are currently under clinical development: MDX-1203 targets CD70-positive solid 
tumors and SYD985 targets HER2 positive solid tumors [152]. 
 Camptothecin, a potent DNA topoisomerase I inhibitor, possesses significant antitumor 
activity and causes apoptotic cell deal of tumor cells [181].  Similar to the duocarmycins, 
camptothecin is poorly water soluble and exhibits very low aqueous stability.  Subsequent 
modifications aimed at improving these attributes led to the generation of topotecan, irinotecan, 
and ultimately SN-38, the active metabolite of irinotecan.  While 1-2 orders of magnitude less 
potent than other ADC payloads, SN-38 has been linked to antibody and shown potent antitumor 
activity [182].  A number of ADCs are currently under investigation using SN-38, including 
IMMU-130 and IMMU-132.  Contrary to its competitors, SN-38 ADCs offer an improved 
therapeutic index specifically due to the moderate cytotoxicity of SN-38 [183]. 
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 Pyrrolobenzodiazepine (PBD) is the newest DNA damaging agents in the ADC arena.  
PBDs react within the guanine residue within the minor groove of DNA, which blocks cell 
division without distorting the DNA double helix [184].  PBD dimers further improve the 
potency and sequence specificity of PBD, forming irreparable DNA crosslinks that result in 
exquisite in vitro potency (1–10 pM) and good in vivo antitumor activity [185].  ADCs linked 
with the PBD dimer were found to be highly potent against both normal and multi-drug resistant 
cancer cells lines (5–20 pM), even those that express very low levels of antigen (4 pM), and yet 
exhibit relatively low cytotoxicity against non-antigen expressing cells (> 1 nM) [186, 187].  
Three ADCs currently use PBD payloads: SGN-CD70A targets CD70 for solid tumors, SGN-
CD33 targets CD33 for hematological cancers, and SC16LD6.5 targets the DLL3 receptor on 
CSCs of solid tumors [152]. 
 
New drugs under investigation 
The vast majority of clinical and FDA-approved ADCs utilize just two payloads, 
auristatin and maytansine analogues.  Though clinically proven and effective, he next generation 
of ADCs has the potential to make use of novel payloads with the potential to address current 
shortcomings, such as poor selectivity, drug resistance, limited potency, and poor 
physicochemical properties.  Two newly investigated ADC payloads are described below.  
Exatecan is a water soluble derivative of camptothecin that is highly effective against P-
glycoprotein (PgP)-mediated multi-drug resistant cells [188].  Exatecan was conjugated to 
trastuzumab and showed selective cytotoxicity against HER2-positive KPL-4 cells and negligible 
cytotoxicity to HER2-negative MCF7 cells; moreover, the trastuzumab-exatecan conjugate 
demonstrated potent efficacy in mouse bearing HER2-positive trastuzumab-resistant JIMT-1 
tumors [189]. 
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 Cryptophycins isolated from cyanobacteria display potent activity against cancer cell 
lines.  Like the vinca alkaloids, cryptophycins bind microtubules at the vinca binding site and are 
also toxic stand-alone agents.  Developed as an ADC, cryptophycins exhibit potent activity 
against antigen-positive human cancer cells, by one to two orders of magnitude compared to 
auristatin or maytansine derivatives evaluated [190]. 
 
 Table 1-3. Potency, linker compatibility, and current clinical status of clinical-grade ADC payloads 
Natural Product Payload Potency, IC50 (M) MOA Clinical Status 
Ansamitosin P-3 
Maytansine 
DM1 
DM4 
 
10-10 – 10-11 
10-11 – 10-12 
Antimitotic: tubulin depolymerization 
 
Market 
Phase II 
Calicheamicin Calicheamicin 10-9 – 10-10 DNA cleavage Phase III 
Camptothecin SN-38 10-8 Topoisomerase I inhibition Phase II 
Dolastatin 10 
Auristatin 
MMAE, 
MMAF 
 
10-9 – 10-11 
10-8 – 10-10 
Antimitotic: tubulin depolymerization 
 
Market 
Phase II 
Doxorubicin Doxorubicin 10-7 DNA intercalation and topoisomerase II inhibition Phase II 
Duocarmycin MGBA 10-9 DNA alkylation Phase I 
Pyrrolobenzodiazepine PBD dimer 10-11 – 10-12 DNA cleavage Phase II 
Taxane paclitaxel 10-7 – 10-8 Antimitotic: tubulin stabilization Preclinical 
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ADC synthesis and first generation conjugation chemistry 
The bioconjugation methods linking drugs to antibodies is one of the most exciting areas 
of ADC research today.  Many reviews explore he topic in detail, and the field continually 
progresses as new linkers are developed and modifications to the antibody become more 
technologically feasible.  
The vast majority of ADCs under evaluation for cancer therapy are synthesized following 
standard methods described in Hermanson’s foundational protein chemistry text Bioconjugate 
Techniques, originally published in 1996 and now on its 3rd edition [191].  These methods rely 
on non-specific alkylation of lysine residues of the mAb, coined 1st generation conjugation 
chemistries, and is the most common technique employed to conjugate drugs, toxins, and other 
therapeutic agents to a mAb.  New methods in site-specific chemistry and orthogonal chemistry 
rely on the addition of non-native or non-canonical amino acids to the primary amino acid 
sequence.  Termed 2nd generation conjugation chemistries, site-specifically modified ADCs with 
unique number and location of drugs and assessed by binding, in vitro cytotoxicity and in vivo 
efficacy display superior properties to 1st generation  [192]. 
Lysine accounts for 40-80 residues within an IgG1, 8-20 of which are readily solvent 
exposed and amenable to chemical conjugation.  Early studies in mAb-based bioconjugation 
resulted in conjugates with a heterogeneous number of modifications at heterogeneous locations, 
which yield complex, heterogeneous mixtures of more than 106 unique conjugates with different 
numbers of drugs at a variety of locations. 
 
Second generation conjugation chemistry: reduction-alkylation and regioselective techniques 
In the past two decades, a number of selective methods have been described to introduce 
molecules of interest onto mAbs. The ability to control the location and stoichiometry of 
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conjugation can significantly improve the properties of mAb conjugates.  While the most 
common chemically “specific” approach is the alkylate drug to full or partially reduced disulfide 
sulfhydryls, other site-specific methods include alkylation to the N-terminus, C-terminus, and 
specific sugars within the carbohydrates on the Fc CH3 domain [116].  Second generation 
approaches, such as disulfide partial reduction alkylation, yield complex mixtures that contain as 
many as 103 unique conjugates with different numbers of drugs – usually in even pairs – at 
significantly fewer locations than first generation conjugations. 
 
Third generation conjugation chemistry: unnatural and non-canonical amino acid incorporation 
Third generation conjugation approaches yield very finely controlled number and 
location of drugs, usually on the order or 1–10 molecules, often with more than 95% or more as a 
single drug-loaded species.  Increased control in drug loading, including the site, location, and 
DAR, can dramatically improve the properties of the resulting conjugate, which can be modified 
with drug without any significant loss in affinity, specificity, and other secondary properties of 
mAbs, like FcRn binding and the ability to induce antibody-mediated cellular cytotoxicity.  For 
example, Schultz and colleagues at Salk Institute have developed a method to incorporate non-
canonical amino acids into proteins within a living cell.  This integrated system can produce 
soluble protein, including IgGs and mAbs, with chemical residues that enable biorthogonal 
chemical conjugation within cells, and precisely control both number and location of molecules 
attached to the tumor-targeting mAb. 
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Structure-activity relationships of ADCs 
 Antibody-drug conjugates are large, complex molecules.  Attributes of their molecular 
design impact the overall activity, safety, efficacy, and mechanism of action of the conjugate.  
Significant papers highlighting the critical attributes of ADC design are listed in the table to 
follow and detailed later in this section. 
 
 Table 1-4. Critical attributes of ADC design and key papers linking ADC design to activity, safety, efficacy, and mode of action 
ADC attribute Properties studied 
mAb 
(Antigen) Drug Key papers 
Drug-to-antibody 
ratio (DAR) 
In vitro potency, 
in vivo activity, 
MTD, PK 
 
In vitro potency, 
in vivo activity, 
MTD, PK 
 
 
cAC10 
(CD30) 
 
 
cAC10 
(CD30) 
 
 
 
MMAE 
 
 
 
MMAE 
 
 
 
 
Hamblett, et al. Clin Cancer Res 2004 
 
 
 
McDonagh, et al. Prot Eng, Design & Selection 2006 
 
Location or site of 
drug attachment 
In vitro potency, 
in vivo activity, 
MTD, PK 
 
Efficacy and 
tolerability 
 
Stability, 
toxicity, efficacy 
 
Stability and 
therapeutic 
activity 
 
(Linker) Stability 
 
 
cAC10 
(CD30) 
 
 
3A5 
(MUC16) 
 
C16 (M1S1) 
 
 
Trastuzumab 
variants 
(HER2/neu) 
 
C16 (M1S1) 
 
 
 
MMAE 
 
 
 
MMAE 
 
 
MMAD 
 
 
MMAE 
 
 
 
Aur0101 and 
MMAD 
 
 
McDonagh, et al. Prot Eng, Design & Selection 2006 
 
 
 
Junutula, et al. Nat Biotech 2008 
 
 
Strop, et al. Chem & Biol 2013 
 
Shen, et al. Nat Biotech 2012 
 
 
 
Dorywalska, et al. Bioconjugate Chem 2015 
 
 
 
Conjugation 
chemistry 
Ag binding, Fc 
binding, thermal 
stability 
mouse H10 
and aHIS 
 
Biotin 
 
 
Acchione, et al. mAbs 2012 
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 Linker 
Ag binding, Fc 
binding, thermal 
stability 
 
Stability, 
potency, and 
efficacy 
 
 
Activity and 
efficacy 
 
Stability, 
efficacy, PK, 
safety 
 
Stability and 
drug release 
 
Activity and 
efficacy 
 
Activity, MTD, 
Efficacy, Drug 
delivery 
mouse H10 
and aHIS 
 
 
BR64 (Ley) 
 
 
 
cAC10 
(CD30) 
 
 
cAC10 
(CD30) 
 
 
BR96 (Ley) 
 
 
(HER2) 
 
 
AC10 
(CD30), 1F6 
(CD70), 1F6-
C4v2 (CD70) 
biotin 
 
 
 
DOX 
 
 
 
DOX, 
MMAE, 
MMAF 
 
MMAE 
 
 
 
DOX 
 
 
Maytansine 
 
 
MMAF 
Acchione, et al. mAbs 2012 
 
 
 
Trail, et al. Cancer Res 1997 
 
 
 
Doronina, et al. Bioconjugate Chem 2006 
 
 
 
Lyon, et al. Nat Biotech 2014 
 
 
 
Dubowchik, et al. Bioconjugate Chem 2002 
 
 
Albers, et al. Eur J Med Chem 2014 
 
 
Alley, et al. Bioconjugate Chem 2008 
PC properties 
(hydrophobicity of 
linker)  
PK and efficacy 
 
 
 
h1F6 (CD70) 
 
BR96 (Ley) 
MMAF 
 
 
DOX 
Lyon, et al. Nat Biotech 2015 
 
 
King, et al. J Med Chem 2002 
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Drug-to-antibody ratio 
Drug-to-antibody ratio (DAR) is one of the most important design parameters in the 
development of safe and effective antibody-drug conjugates.  There were two main hypotheses 
related to increasing the potency of ADCs in vitro and in vivo: first, to increase the amount of 
ADC that reaches the target tissue.  More ADC yields more drug, and more drug yields higher 
activity.  Second, it was hypothesized to increase the payload per antibody, or DAR.  Because 
early work in ADC development used relatively benign drugs like doxorubicin, efficacy required 
extremely high doses compared to what is seen today. 
Increasing the amount of drug at the site of action results in increased activity and/or 
potency of the conjugate.  Besides increasing the amount of the ADC at the tissue, increasing 
DAR has been shown in increase the cytotoxic activity against antigen-overexpressing cell lines.  
For example, ADCs prepared with high drug loading using he cAC10 antibody against CD30-
positive malignant cells were found to be more potent than low drug loading counterparts [164].  
Subsequent reports demonstrated the relationship between drug loading on in vitro 
characteristics of the ADC, where high DAR conjugates exhibit high toxicity in vitro, but 
moderate DAR conjugates exhibit better efficacy than low or high DAR conjugates in vivo [179, 
193].  The effect of drug loading on ADC therapeutic potential was assessed conjugates using the 
cAC10 anti-CD30 ADC containing different DAR ratios in vitro and in vivo.  ADCs with two 
(E2), four (E4), and eight (E8) drugs per antibody were prepared following reduction-alkylation 
of interchain disulfides and purification using hydrophobic interaction chromatography.  While 
potency was directly associated with drug loading (IC50 values E8 < E4 < E2), in vivo antitumor 
activity of the E4 conjugate was comparable with E8 at equal mAb doses – and thus, half the 
dose of MMAE [194]. The maximum tolerated dose of E2 in mice was double that of E4, which 
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was in turn twice that of E8.  It was found that MMAE loading affected plasma clearance, as E8 
cleared 3-fold faster than E4 and 5-fold faster than E2.  Therefore, it was discovered that 
decreasing the drug loading per antibody in fact increased the therapeutic index of the CD30-
targeted ADC. 
Another strategy to increase DAR uses branched peptide linkers to conjugate multiple 
drugs to the mAb [193].  It was hypothesized that less modification to the mAb framework 
residues might improve the PK and in vivo stability losses observed with heavily drug decorated 
ADCs.  This approach continues to be pursued today.  Mersana has successfully linked up to 20 
drugs using a proprietary Fleximer® polymer technology, and evidence suggests potent activity, 
safety and efficacy across a series of cancer indications using different payloads, different tumor-
targeting mAbs, and unique payload release mechanisms. 
 
Location 
Location of the drug attached on the antibody has significant implications on the activity 
of the antibody.  Optimizing the conjugation location at ideal residues, or avoiding particular 
disadvantageous residues, is a serious design concern when synthesizing antibody drug 
conjugates. An elegant study on the Adcetris precursor molecule, dating back to 2006, provides 
one of the most extensive interrogations of location and stoichiometry on the in vitro and in vivo 
characteristics of ADCs.  Interestingly, it was recently shown that the drug release rate from 
vcMMAE-based ADCs is neither dependent on the location nor the local environment, dictated 
by the sequence and structure of the antibody carrier [195]. 
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Linker 
Early studies demonstrate the significant impact of linker selection on in vitro and in vivo 
attributes of antibody-drug conjugates. Comparing a non-cleavable thioether linker head to head 
with a cleavable disulfide linker demonstrated that the ADC linker can have clear impacts on the 
pharmacokinetics and the chemical nature of the catabolites formed [120]; however, in this 
particular example which used the same against studied in the same TAA-expressing cell line, 
both linkers offered the same payload delivery to the tumor. 
ADC linkers containing hindered disulfide bonds release maytansinoid at a slower rate 
than less hindered linkers.  Antibody-maytansine conjugates prepared with various degrees of 
steric hindrance surrounding the disulfide bond demonstrated that steric hindrance impacts many 
properties of the ADC, including PK, drug release, potency, and efficacy.  The most hindered 
conjugate released maytansinoid over 22,000 times more slowly than the least hindered 
conjugate. 
Quaternary ammonium linkers, which allow for the incorporation of tertiary amine 
functional compounds, were used with a !-glucoronidase cleavable auristatin E (AE) construct 
to study drug delivery to CD30 overexpressing cancer in vitro and in vivo [196].  These linkers 
expand the available payloads to incorporate into tumor-homing antibody-drug conjugate 
designs. 
 
PK/PD of ADCs 
Quantitative pharmacology continues to unveil specific attributes of ADC in vivo 
behavior, including target tissue uptake, metabolism, and clearance.  On one hand, macroscopic 
PK/PD models have been used to develop trends in the safety, efficacy, systemic exposure, and 
tumor exposure of mAb and relevant metabolites.  On the other hand, uptake, catabolism and 
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processing has been explored on the cellular level.  Such explorations drive design and of ADC 
that require specific localization or exposure requirements to meet safety and efficacy 
benchmarks. 
These studies also enable specific interrogation of ADC properties on observed 
macroscopic behavior.  For example, internalization rate and efflux rate were found to be key 
parameters to determine how much payload is delivered to a cell by a trastuzumab-maytansinoid 
antibody-drug conjugate [197]. 
 
Methods to characterize antibody-drug conjugates 
Methods to characterize ADCs span classic assays oriented toward both large molecule 
proteins and antibodies as well as small molecules.  Additional methods probe the safety, 
stability, and mechanism of drug release by the linker.  Because ADCs facilitate uptake and 
delivery of drug to antigen positive cells, the various catabolism events that take place within the 
cell can modify, degrade, or other alter the properties of the ADC.  Standard analytical 
characterization techniques for ADCs are described below in Table 1-X. 
 
Table 1-5. Quality attributes and analytical characterization of ADC 
Quality attributes Assays Analyte 
Size heterogeneity SDS-PAGE, CGE mAb + ADC 
Size heterogeneity (aggregates) SE-HPLC, SEC-MALS mAb + ADC 
Charge heterogeneity ICE, IEF, CEX mAb + ADC 
Drug load UV, HIC, HPLC ADC 
Drug-load distribution HIC, MS ADC 
Residual drug ELISA, HPLC ADC 
Potency (for drug) Cytotoxicity ADC 
Potency (for mAb) Antigen binding mAb + ADC 
 
SDS-PAGE – sodium dodecyl disulfide poly(acrylamide) gel electrophoresis 
CGE – capillary gel electrophoresis 
SE-HPLC – size exclusion high pressure liquid chromatography 
SEC-MALS – size exclusion chromatography multi-angle light scattering 
ICE – imaged capillary electrophoresis 
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IEF – isoelectric focusing 
CEX – cationic exchange chromatography 
UV – ultraviolet spectroscopy 
HIC – hydrophobic interaction chromatography 
HPLC – high pressure liquid chromatography 
ELISA – enzyme-linked immunosorbent assay 
Cytotoxicity – cell viability 
Antigen binding – binding and functional activity loss in competitive equilibrium binding 
 
 
Thorough analytical analysis of ADC structure, particularly the liabilities, has helped 
frame hypotheses in ADC design that may lead to improved molecules and a priori prediction of 
safety, efficacy, and in vivo ADC behavior [198]. 
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State-of-the-art ADCs and development frontiers 
The first ADCs to be FDA approved would fail to meet the basic criteria required by 
almost every other drug in the history of the FDA.  ADCs are prepared as heterogeneous 
mixtures comprised of molecules with a various number of drugs loaded at various locations on 
the mAb.  Only recently has the FDA started to offer guidance on the experiments required to 
show safety of efficacy of an ADC in the clinical setting [199].   
Four groups should be credited with advancing ADCs from the bench to the clinic over a 
span of three decades beginning in the 1980s.  These were major research efforts spearheaded by 
Bristol Myers Squibb, Seattle Genetics, ImmunoGen, and Pfizer [133, 200].  Genentech, 
Immunomedics, Amgen and others have become players only within the last decade.  While only 
two of the four early projects reached clinical development, the advances established in these 
decades laid the groundwork for the vast majority of methods and approaches taken in ADC 
research and development today.  
Basic research in cancer biology, medicinal chemistry, and antibody engineering fuel the 
diversity and vitality of the ADC pipeline.  ADCs under investigation today demonstrate 
improved efficacy, selectivity, and enhanced pharmaceutical properties compared to earlier 
generation molecules, including the two FDA approved ADCs ADCETRIS® and KADCYLA®.  
Frontiers in ADC research and development address current limitations, such as the limited 
number of cytotoxic drugs suitable as ADC payloads.  However, all three components of the 
ADC must be optimized to create a successful conjugate.  Once optimized, the ADC should 
avoid resistance mechanisms that shorten the time the ADC can be used, and ADC payloads 
should evade the powerful efflux pump P-gP, which can significantly reduce the accumulation of 
drug within the target cell.  The future of ADCs used in oncology will depend on our ability 
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tackle these challenges and others, which can interfere with ADC efficacy and result in ADC-
mediated nontarget cell toxicity.  Additionally, there is great hope in applying the lessons of 
ADCs used in oncology to broader patient sets, other diseases, and technology settings beyond 
medicine. 
 
Improved antigens and tumor-targeting strategies 
The selection of the antigen target is critical to enabling a therapeutic window for an 
ADC and has proven to be surprisingly complex [201].  In fact, a recent review describing ADC 
target selection was unable to formalize any generally applicable, optimal parameters for an 
ADC target [202].  The once straightforward approach to target selection – (1) higher expression 
in tumor versus normal tissues, (2) localization to the plasma membrane of the cancer cell, and 
(3) internalization into cells to trigger drug release – has largely failed to yield consistent and 
predictable results [203].  While the historic criteria to target selection still apply, a more 
sophisticated, integrative approach to target selection, incorporating clinical data and complex 
quantitative pharmacological models, offers improved insights for the antigen selection process 
today [99, 105].  For example, antigens that display minimal susceptibility to mutations, and 
therefore resist drug resistance, have become increasingly attractive targets for ADC therapy 
[204].  While some researchers continue seeking the holy grail tumor antigen, that one receptor 
selectively, homogenously, and consistently expressed on all cancer cells within the tumor tissue 
[205], others have identified antigens in the tumor stroma [101] and tumor extracellular matrix 
[131, 134, 135] that effectively localize payload delivery to the tumor and improve therapy.  
Emerging platform technologies and novel biological insights are expanding the ADC target 
space and transforming strategies for target selection. 
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ADCs targeting highly aggressive cancer stem cells (CSC, or tumor initiating cells, TICs) 
have been explored recently.  CSC are hypothesized to be the driver progenitor cells responsible 
to tumor growth, metastasis, and may be the primary cause of recurrence [206-208].  An anti-
5T4 ADC linked to the tubulin inhibitor MMAF exhibited potent preclinical in vivo antitumor 
activity in a variety of tumor models [209], and subsequently entered a phase I dose escalation 
study.  Separately, an anti-DLL3 ADC that showed strong and durable antitumor efficacy in a 
series of patient-derived xenograft models [138] recently entered phase I/II clinical trials. 
Other strategies to improve tumor targeting of ADCs have been explored with other 
mAb-based modalities.  Tumors pretargeted with tumor-targeting mAb can be treated with a 
small, rapidly cleared ligand-drug conjugate that binds specifically to the mAb.   Together the 
antibody-ligand-drug complex internalizes by the target cell to release the drug within the target 
cell.  This strategy improves tumor-to-nontumor ratios compared to directly modified mAbs, 
permits rapid drug delivery to the tumor, and reduces systemic exposure of the drug due to its 
rapid clearance.  A second strategy removes or shields antigen positive nontarget cells from 
engagement with the ADC prior to ADC administration.  Removal requires the filtration of cells 
or antigen from the patient’s blood prior to administration of the ADC, whereas shielding utilizes 
a predose or co-administration of unconjugated Ab before or with ADC treatment to block ADC 
binding to low antigen expressing nontarget cells and promote ADC accumulation at the high 
antigen-expressing target tissues [118].  A third strategy masks the mAb from antigen binding 
until it the mAb becomes activated locally by proteases common to the tumor microenvironment 
[210].  This strategy not only enables safer ADCs with longer serum half-lives, it could also 
effectively release ADC payloads in the local tumor microenvironment.  
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Finally, targeting ADC to specific tumor-homing immune cells is a separate but related 
“frontier” approach to improve tumor targeting.  Tumor-infiltrating lymphocytes (TILs) are 
white blood cells that leave the blood stream and travel to the tumor.  Generated against an 
antigen overexpressed on TIL, rather than directly at the tumor, TILs could traffic the ADCs to 
the tumor and increase payload delivery to hard-to-reach, metastatic tumors that would otherwise 
avoid drug exposure.  TIL backpacking and tumor uptake has been demonstrated recently with 
radioimmunoPET imaging agents with exciting success.  
 
Improved mAbs and trends in antibody engineering 
Dosimetry studies with radiolabeled mAbs in cancer patients indicate that tumor uptake 
ranges from 0.003% to 0.1% of injected dose per gram tumor [69, 211].  Lack of specificity to 
the target antigen can result in nontarget toxicities, while poor internalization or inadequate 
antigen binding impact the therapeutic benefit of the ADC.  Moreover, the solid tumor 
environment remains a formidable foe to mAb and ADCs tumor uptake [212], and designing 
mAb that effectively accumulate yet permeate a solid tumor environment remains a critical 
challenge.  Key advances in antibody engineering attempt to address limitations. 
Changes in amino acid sequence can improve many features of the tumor targeting mAb.  
Effector function enhancements within the Fc of mAbs hold tremendous promise in eliciting 
robust secondary immune responses in cancer patients and may ultimately elicit more durable 
remissions in the clinic.  In addition to increasing complement activation and enhancing ADCC, 
sialylated glycans on the Fc can enhance anti-inflammatory properties.  Moreover, many studies 
have shown specific amino acid changes in the Fc can increase or decrease FcRn binding, which 
in turn impacts half-life and mAb volume of distribution.  The mAb hinge can be modified to 
alter stability and flexibility.  Modifications to the variable region of the mAb impact 
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immunogenicity, binding affinity and specificity, and lower the isoelectric point to decrease 
elimination. [118] 
Size and tumor permeability hinder intact mAb in tumor targeting studies, which suggests 
their use in ADCs platforms could be improved.  Engineered antibody fragments likes scFvs, 
diabodies, and minibodies exhibit improved tumor penetration but shorter half-lives compared to 
intact mAbs [213].  Tumor binding of engineered fragments is also improved due to their 
increased number of antigen binding sites per unit area.  Bispecific antibodies increase the 
specificity of targeting and thereby increase tumor uptake due to their dual-modal nature of 
interaction [214].  Many formats exist, including the scFv-IgG, BiTE, dAB, DVD, and DAF, 
though only the standard bispecific antibody format has been evaluated in drug delivery [215].  
Recently, mAbs specific to vasculature proteins were fast-tracked within tumors through 
caveolae-mediated transcytosis, and yet remained absent in normal tissues [216]. 
Acquired resistance is significant hurdle to mAb-based ADC development [217].  In 
December 2013, Roche announced an alliance with Molecular Partners AG to discover, develop 
and commercialize DARPin-drug conjugates for the treatment of cancer [218].  DARPins are 
small, non-mAb-based targeted proteins that can demonstrate improved tumor targeting and 
pharmaceutical properties to mAbs.  DARPin might prove less immunogenic than intact mAb or 
mAb derivatives.  Separately, high affinity molecules like folic acid and growth hormones show 
promise as non-mAb based toxin-targeting carriers. 
Solid tumors are composed of phenotypically and functionally heterogeneous malignant 
cells.  This heterogeneity interferes with the effectiveness of targeted molecular cancer therapies. 
Rather than ADCs with direct action on the tumor, one group recently demonstrated the utility of 
a PanitumumAb-IR700 conjugate to both eliminate EGFR+ tumor cells and increase tumor 
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permeability [219], coined the super-enhanced permeability and retention effect, leaving the 
tumor more susceptible to combination or follow-on treatments. 
 
Improved linkers and site-specific conjugation chemistries 
Conventional conjugation methods of the ADCs currently on the market and in clinical 
studies result in heterogeneous mixtures of different molar ratios of conjugates species 
comprising antibody linked to drugs at different sites.  Kadcyla® carriers an average of 3.5 DM1 
warheads per antibody distributed among the 80 – 95 lysine residues found on both light and 
heavy chains of the IgG.  The resulting mixture contains > 106 unique ADC species with 0-8 
molecules attached to the mAb.  Adcetris® carries an average of 4 MMAE warheads per 
antibody distributes between four reduced disulfides, two between the heavy chains and one 
between each heavy chain-light chain pair.  The resulting mixture contains > 100 ADC species 
with either 0, 2, 4, 6, or 8 MMAE molecules attached to the mAb.  Recent studies have also 
shown that ADCs conjugated by reduced disulfides by a thioether bond can undergo maleimide 
exchange, which can transfer the payload from the antibody to circulating albumin.  Hydrolyzed 
maleimides can overcome this exchange  
In these two conventional strategies, each species produced can demonstrates distinct 
biological properties, and batch to batch consistency of ADCs produced by conventional 
methods can be challenging [211].  Site-specific conjugation, in which a defined number of 
linker-payloads consistently are conjugated to specific sits on the mAb,  can yield ADCs with 
improved properties and enhanced efficacy and safety profiles [116, 220]. 
Antibodies with engineered cysteines enable thiol conjugation at the specific sites.  This 
process was pioneered by Junutula and colleagues at Genentech and resulted in the THIOMAB 
drug conjugates [221].  The resulting conjugate was nearly homogenous and possessed 
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comparable antitumor activity as conventionally conjugated ADCs, despite having a lower DAR.  
THIOMAbs of anti-HER2 antibody trastuzumab, the same IgG element used in the clinically-
approved Kadcyla®, demonstrate homogenous drug loading, better PK, improved efficacy at 
lower doses (ADC or drug), and improved stability in circulation than T-DM1 in head-to-head 
preclinical studies [149, 222]. 
In a series of studies headlined as “expanding the genetic code” Schultz and colleagues at 
the Salk Institute pioneered methods to insert biorthogonal reactive handles into the amino acid 
sequence of proteins [55, 59, 60].  The twenty first amino acid, selenocysteine (Sec), and the 
unnatural amino acid, p-acetylphenylalanine (pAcPhe), have been inserted into mAbs for the 
purpose of generating site-specific ADCs.  Selenocysteine conjugates were shown to retain their 
binding properties and Fc-mediated effector function capacities [223, 224].  ADCs prepared by 
orthogonal oxime ligation to pAcPhe demonstrate improved in vitro cytotoxicity, superior 
efficacy, and increased PK stability relative to conventional conjugates, and they were well 
tolerated in preclinical toxicology studies [50, 61, 225].  Unnatural amino acid incorporation has 
also yielded site-specific antibody-polymer conjugates functionalized with therapeutic siRNA 
[226], antibody-LXR agonists for atherosclerosis [62], and antibody-dasatinib conjugates for 
immunosuppression [227].  Besides the novelty and improved properties of the conjugates, the 
utility to this method is the ability to perform chemistry within a cell or biological system that is 
unambiguously inaccessible by any of the biochemical machinery of the living cell. 
Two enzymatic approaches enable site-specific modification have been explored for 
ADC cancer therapy.  In the first approach, a mutant glycotransferase conjugates a chemically 
active sugar moiety to a site of glycosylation on a mAb.  In the second, more pursued, approach, 
transglutaminase (mTG) catalyzes the formation of a covalent bond between an inserted, non-
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natural glutamine side chain and any molecule with a primary amine [228].  The recognizable 
glutamine tag, LLQG, must be inserted into the antibody sequence before the conjugation can 
occur.  LLQG has been engineered into anti-EGFR, anti-HER2, and anti-M1S1 mAbs and has 
achieved homogenous drug loading [229, 230].  Like with THIOMAbs and the unnatural amino 
acid-conjugates, LLQG tags produce ADCs with similar in vitro and iv vivo activity as 
conventionally conjugated ADCs with higher DARs [230].   
In addition to controlling the location and chemistry of attachment, the drug-to-antibody 
ratio (DAR) influences the biological activity and pharmaceutical properties of ADC.  High 
DAR (> ~ 4) ADCs have been shown to exhibit shorter circulating half-lives, decreased antigen 
binding efficiency, and reduced physicochemical stability compared unconjugated mAb.  For 
these reasons, DAR 3 – 4 is the ideal range.  New platforms of antibody-polymer conjugates 
enable site-specific drug loading as high as 10 or 20 drugs to the mAb, which result in improved 
drug delivery and very high potency in preclinical studies [231].  The hypothesis posits that less 
modification to the IgG primary structure will improve its pharmaceutical properties, and the 
addition of the polymer, too, can improve the pharmaceutical properties of the drug and at the 
same time the pharmaceutical properties of the ADC.  
While site-specific ADCs have made huge advances in the ADC, antibody engineering, 
and bioconjugation fields, their transition to the clinic appears fettered.  There are concerns 
related to immunogenicity and stability, as well as drug loading, tumor exposure, and potential 
catabolite toxicities [211].  Next generation ADCs may be able to capitalize on the development 
of novel linker-payload designs that are activated specifically in the tumor microenvironment to 
enhance antitumor activity.  Non-covalent antibody-drug conjugates could localize drugs to 
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tumors without compromising the intact structural properties of the mAb.  Studies evaluating 
these approaches in the ADC arena were not identified from the current literature. 
 
Improved ADC payloads, dual warhead ADCs, and overcoming P-gP 
The list of cytotoxins amenable for use in ADCs is short and has not changed much in the 
past two decades.  Finding soluble, stable, and linkable drugs with the potency needed to be an 
effective ADC payload presents a formidable challenge to ADC development.  However, this is a 
vibrant area of research in medicinal chemistry – the synthesis of new analogues of old 
cytotoxins or identification of novel drugs amenable for use in an ADC [232].  Drugs with higher 
potency, selectivity, and improved pharmaceutical properties pave the way for high potency 
ADCs with higher DARs. 
While the prevailing view in ADC synthesis is to attach the most potent drug amenable to 
conjugation in a fashion that balances drug loading with drug stability, ADCs carrying 
moderately potent drugs like SN-38 have proven to be efficacious therapeutic agents in clinical 
trials [152] and have shown to improve the therapeutic index compared to ADC with more 
potent payloads [183].  In addition to payload potency, spatiotemporal delivery within the cell 
also impacts the activity of an ADC payload.  Several natural products target vacuolar adenosine 
triphosphatases, a membrane-bound proton pump of the lysosome [211].  Inhibiting this pump 
disrupts lysosome function and results in a cascade of pharmacological changes within that cell 
[233], processes that can be exploited for future ADC payload development. 
Increasing evidence implicates that drug efflux pumps like P-gP and MRP1 decrease the 
intracellular drug accumulation and retention of cytotoxic agents within the target cell.  Studies 
demonstrated that both P-gP and MRP1 expressed at the target tissue mediate resistance to 
gemtuzumab ozogamicin (Mylotarg®), and to a lesser extent ado-trastuzumab emtansine 
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(Kadcyla®); no reports of resistance to brentuximab vedotin (Adcetris®) have been published 
[234].  The sensitivity of cytotoxic agents to multidrug resistance mechanisms is a factor to 
consider in selecting the optimal payload for an ADC.  Reducing the effects of active 
transporters, and thereby increasing intracellular concentrations of the cytotoxic agent, is a major 
priority in the ADC field [235, 236].   
Substrates to P-gP and MRP1 are small, planar, hydrophobic, and weakly cationic [234].  
Therefore, selecting molecules that are poor substrates for efflux [237] or protein toxins that are 
too large for P-gP efflux [238] can overcome P-gP mediated resistance.  Other approaches to 
limit P-gP efflux of ADC payloads rely on ADC prodrug strategy [180, 239]; design of drug-
linker components such that, upon degradation in the lysosome, the payload is not a substrate for 
transporters [240]; or, modulate size, charge, shape, or hydrophilicity into the linker component 
to alter the properties of the drug [159, 167, 176, 240, 241].  Pre-dosing or co-administering a P-
gP inhibitor or decoy with the ADC could be tested for inhibition of P-gP efflux of ADC 
payloads.  Preparing a dual warhead ADC with both drug and a P-gP inhibitor could also show 
promise as long as the release profile of the two drugs was controlled and distinct. 
In general, codelivery of two mechanistically different payloads is a reasonable approach 
to increasing the durability of clinical benefit of ADC [242].  Dual-warhead ADCs could 
overcome drug resistance or lack of sensitivity intrinsic to the heterogeneity of tumor tissues and 
allow the use of the dual-cytotoxic ADC across different cancer indications.  Two independent 
cleavage mechanisms would allow controlled and distinct exposure of the drugs within the tumor 
tissue.  Molecules whose release profile and subcellular exposure can be finely tuned should be 
vigorously pursued as ADC payloads.  One approach is to use a double prodrug strategy, 
wherein a prodrug attached to the mAb requires additional chemical or enzymatic activation at 
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the target site.  The secondary activation step could leverage an external stimulus (e.g., 
photoactivation, ultrasound, or thermoresponse) for particularly localized delivery. 
 
Improved ADC characterization and CMC 
Conjugation of drugs to a mAb increases the structural complexity of the resulting 
molecule, which necessitates improved characterization methods than what suffice for the mAb 
alone or drug alone.  Of greatest interest is determining the number and location of drugs 
conjugated to the mAb, describing the mechanism and rate of drug cleavage, characterizing 
impurities, identifying and characterizing catabolic, proteolytic and metabolic processes 
responsible for ADC degradation, and screening for the induction of anti-therapeutics antibodies 
[198].  Multiple, complementary methods in liquid chromatography, electrophoresis, and mass 
spectrometry are used to characterize ADCs in all stages of development [243, 244]. 
These methods are mostly published within the last 5 – 10 years and require significant 
training and specialized instrumentation to perform.  The early use of analytical characterization 
in ADC research helps one associate the pharmaceutical properties of an ADC with 
pharmacological or PK/PD findings, which subsequently improve ADC design, reduce the CMC 
liabilities, and can help achieve maximal activity in patients [218]. 
 
ADCs as monotherapy and potent combination therapies 
While ADCs have already proved their clout as effective monotherapies, improvements 
in antibody engineering, linker design, drug selection, conjugation chemistry, and the process 
engineering have produced more potent and homogenous ADCs than ever before.  As such, the 
landscape of indications for ADCs is growing both as single agents and in combination 
strategies.  Results from combination treatments of ADCs with FDA approved checkpoint 
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inhibitors have shown encouraging results due to combined cellular toxicity and robust immune 
response [245].  Combination treatments of ADCs with conventional chemotherapies or other 
targeted therapies, like modified AVD, PI3K inhibitors, or neratinib, are currently undergoing 
clinical evaluation with encouraging preliminary data [246].  With strong clinical data showing 
efficacy and safety in dual mAb combination strategies, even those targeting the receptor [247, 
248], ADCs seem well positioned to prove potent add-ons to current mAb-based regimens or 
achieve synergy with enhanced activity mediated by the payload or antibody.  Anti-HER2 T-
DM1 is currently under investigation with the anti-HER2 mAb pertuzumab with encouraging 
early clinical results [249].  Likewise, patients receiving a combination therapy of anti-CD22 
brentuximab vedotin with AVD, a modified SOC for Hodgkin lymphoma, achieved complete 
remission with no side effects [250].  Anti-5T4 and anti-DLL3 ADCs targeting the cancer stem 
cell niche may prove especially potent combination agents with a variety of standard of care 
(SOC) regimens, though this remains to be explored.  
ADCs will improve as companies with two complementing technologies merge.  For 
example, Sorrento Therapeutics 2013 acquisition of Concortis Biosystems primed the generation 
of tumor targeting mAbs from Sorrento’s G-MAB® library system with Corcortis’ proprietary 
site-specific conjugation chemistry and library of novel toxins [218].  The combination enables 
multifunctional ADCs, such as dual warhead ADCs and bispecific ADCs. 
 
Applications outside oncology 
Within the last 5 years, the FDA has approved Adcetris® (2011) and Kadcyla® (2013), 
and granted FDA breakthrough designation to inotuzumab ozogamicin garnered (2015).  The 
pharmaceutical properties unique to ADCs are not necessarily unique to indications in oncology.  
For example, an anti-CD163 mAb conjugated with dexamethasone has demonstrated 
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macrophage-specific delivery for treatment of inflammatory and autoimmune conditions [251].  
ADCs could also be developed against invading pathogens, like bacteria or viruses. A 
Pennsylvania woman was recently infected with colistin-resistant E. coli.  While she was 
successfully treated with another antibiotic, the emergence of multidrug resistant 
microorganisms should spur novel approaches to antibiotics.  A similar approach could be 
envisioned for new pathogens for which no drugs exist, like the Zika virus currently ravaging 
much of South America and stoking superbug worries in the US and around the world. 
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CHAPTER 2: SUMMARY OF DISSERTATION RESEARCH, AIMS, STATEMENT OF 
PROBLEM, AND RESEARCH HYPOTHESES 
 
Summary of dissertation research 
Several complex, interdependent barriers limit target tissue uptake of tumor-targeting 
mAb and antibody-drug conjugates.  Overcoming these delivery barriers requires a deep 
understanding as to the specific physical, chemical, and biological circumstances of the mAb, the 
TAA, and the tumor microenvironment.  The dissertation work presented herein 1) identifies key 
barriers to efficient, predictable tumor uptake and exposure of tumor-targeting mAb and the 
critical molecular properties of mAb that improve cumulative tumor exposure, 2) describes the 
synthesis of novel anti-EGFR antibody-drug conjugates that enhance selectivity of the pan-acting 
chemotherapy docetaxel to EGFR-positive cells, and 3) evaluates the antitumor efficacy and 
combined effect of anti-EGFR ADC therapy in mice bearing an EGFR-overexpressing tumor. 
Aim 1 
Characterize the critical features of tumor-targeting mAb for solid tumor drug delivery using 
CD44 and EGFR as model TAAs. 
Problem 
Across an array of solid tumor TAAs, mAbs with high antigen affinity yield inconsistent 
and unpredictable tumor targeting properties in vivo. 
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Hypothesis 
While high affinity mAb bind and internalize rapidly in vitro, intermediate affinity mAb 
can display high tumor targeting, deeper tumor penetration, and improved tumor 
exposure compared to low- or high-affinity variants.  Intermediate mAb demonstrate 
these improved features due to their ability to avoid off-target tissue uptake, as well as 
rapid target cell uptake and catabolism. 
Aim 2 
Synthesize an EGFR-targeted antibody-docetaxel conjugate and characterize its activity against 
differentially expressing EGFR-positive human cancer cells. 
Problem 
Many chemotherapies, including docetaxel, fail to offer clinical benefit due to their 
imprecise delivery to the target tissue. Moreover, off target tissue uptake and subsequent 
toxicity can limit safety and efficacy of administered doses. 
Hypothesis 
Covalent conjugation of docetaxel to an anti-EGFR mAb will improve docetaxel 
selectivity to EGFR overexpressing cells in vitro. 
Aim 3 
Demonstrate antitumor efficacy and durable tumor regression of anti-EGFR ADC in mice 
bearing an EGFR-positive tumor compared to equimolar docetaxel, equimolar anti-EGFR mAb, 
and combination docetaxel plus anti-EGFR mAb. 
Problem 
Anti-EGFR mAbs like panitumumab and cetuximab must be dosed in combination with 
chemotherapy due to their lack of therapeutic activity as a monotherapy. 
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Hypothesis 
Covalent conjugation of docetaxel to the anti-EGFR mAb panitumumab or cetuximab 
will improve the activity of anti-EGFR mAb against EGFR-overexpressing cancer cells 
and, simultaneously, specificity of docetaxel to EGFR-expressing tissues in vivo 
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CHAPTER 3: THE INTERPLAY OF ANTIGEN AFFINITY, INTERNALIZATION AND 
PHARMACOKINETICS ON CD44-POSITIVE TUMOR TARGETING OF 
MONOCLONAL ANTIBODY1 
 
Introduction  
Improved molecular understanding of cancer pathogenesis has inspired a renaissance in 
the treatment of cancer.  Most notable is the arsenal of targeted therapies, like receptor tyrosine 
kinase inhibitors and monoclonal antibodies (mAbs), which exhibit activity on specific cells and 
cellular pathways of cancer overexpressed or upregulated in an individual.  Aside from their 
therapeutic potential, mAbs can be engineered to bind any pharmacological target with exquisite 
precision and specificity and offer access to classically “undruggable” targets within cells or 
hard-to-reach tissues like solid tumors [252, 253].  For example, mAbs engineered to bind 
tumor-associated antigens (TAAs) like CD20, CD22, CD30, CD33, and HER2 effectively target 
cancer cells and enable tumor cell-specific, intracellular drug delivery [6, 254].  Antibody-drug 
conjugates (ADCs), which leverage the tumor homing properties of mAb with the cytotoxicity of 
chemotherapeutics, represent the most advanced class of mAb-targeted cancer therapy to date. 
                                                
1 This chapter previously appeared (in part) as an article in the June 6, 2016 issue of Molecular 
Pharmaceutics.  The original citation is as follows:  
Glatt DM, Beckford Vera DR, Parrott MC, Luft JC, Benhabbour SR, Mumper RJ. The interplay 
of antigen affinity, internalization, and pharmacokinetics on CD44-positive tumor targeting of 
monoclonal antibodies. Molecular Pharmaceutics. 2016 Apr 14. DOI: 
10.1021/acs.molpharmaceut.6b00063 
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Even with monumental advances in engineering highly tailored TAA-specific mAbs, the 
promise of tumor-specific drug delivery has not yet been realized.  MAbs against the same cell 
surface antigen often demonstrate unique mechanisms of action and different in vitro and in vivo 
characteristics [255].  Antigen affinity is the primary and often singular parameter used to screen 
and select mAb for use in tumor targeting and drug delivery.  Increasing mAb binding affinity 
and valence improves tumor uptake [78-80].  Moreover, high affinity, bivalent binding mAbs can 
lead to greater in vitro potency than their lower avidity counterparts that recognize an identical 
epitope [256].  However, critically, high affinity mAb selected during standard screening and 
selection campaigns can exhibit poor tumor penetration, poor tumor retention, off-target tissue 
uptake, rapid catabolism and clearance [66-68, 85, 86].  These observations are attributed to two 
phenomena.  The first phenomenon is coined the binding site barrier (BSB), which predicts the 
diffusion of high affinity mAb into tumors is limited by the low local concentration of diffusible, 
free antibody due to slow rates of antibody-antigen dissociation [87-89].  The second 
phenomenon limiting mAb tumor uptake is coined target-mediated drug disposition (TMDD).  
TMDD limits target tissue uptake and accelerates clearance due to antigen expression on non-
target tissues [75, 92].  Consistent, predictable tumor targeting, sans rapid blood clearance and 
significant uptake in non-target tissues, remains a challenge in the field in part due to a lack of 
heuristics describing the ideal properties of the tumor targeting mAb, but more importantly, the 
ideal properties of a tumor targeting mAb given a specific biological target. 
Complexity in screening and a priori selection of an optimal mAb for tumor targeting is 
also an artifact of the diversity of biological targets.  Desirable biological targets for mAb-
targeted therapeutics are cell-surface receptors selectively expressed or orders of magnitude 
overexpressed at the tumor, readily accessible, consistently expressed and minimally shed, and 
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typically, internalize upon mAb binding.  CD44 (also commonly referred to as HCAM, homing 
cell adhesion molecule, or Pgp-1, phagocytic glycoprotein-1), the endogenous cell surface 
receptor for hyaluronic acid (HA), is a cell surface receptor involved in cell survival, 
proliferation, differentiation, migration, adhesion, signaling, angiogenesis, presentation, and 
docking of proteases at the cell membrane [257].  It is overexpressed in a variety of primary 
tumors and implicated as a prognostic indicator for progressive disease and cancer metastases 
[258-260].  CD44 is also the characteristic biomarker of cancer stem cells, a new and promising 
target for drug therapy [261].  Targeting CD44 with HA has shown to facilitate cell uptake and 
drug delivery to CD44-overexpressing cancers in vitro and in vivo [262-264].  However, HA-
targeted therapies used to treat CD44-overexpressing cancers must overcome serious limitations 
in vivo, including competition with ubiquitously expressed endogenous HA and the modest 
specificity, low affinity, and heterogeneity of the HA polymer. 
For these reasons, it was hypothesized that a CD44 mAb could efficiently target CD44-
overexpressing A549 cancer cells in vitro and in vivo and overcome the limitations of the HA-
targeted approach.  We further hypothesized A549 tumor uptake to be a function of CD44 mAb 
antigen binding affinity, uptake kinetics, and pharmacokinetic profile in tumor-bearing mice.  A 
panel of CD44 mAb was used to identify and assess critical attributes of the mAb that promote 
tumor uptake by CD44-positive A549 tumor-bearing mice. 
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Materials and methods 
Cell Culture  
A549 human non-small cell lung cancer (NSCLC) cells were purchased from the 
American Type Culture Collection (ATCC) and cultured in RPMI 1640 (Gibco 11875-093) 
supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma F2442) and 100 U/mL penicillin-
streptomycin (PS, Gibco 15140-122). 
 
Antibodies and chemicals 
Eight (8) mouse monoclonal antibodies specific to human CD44 and the respective FITC-
labeled conjugate were purchased from Abcam (ab2212 and ab9524), Santa Cruz Biotechnology 
(sc-7297, sc-9960, sc-53298, sc-52535, sc-65412), or Invitrogen (MA54).  Two CD44 mAbs 
were expressed and purified by standard methods from B lymphocyte hybridomas (HB-257 and 
HB-258).  Immunohistochemistry was performed using a biotinylated goat anti-mouse IgG 
(Jackson 155-065-166) followed by an avidin-based peroxidase (VECTASTAIN Elite ABC PK-
6100) and DAB substrate (Thermo TA-125-QHDX).  Iodine-125 was purchased from 
PerkinElmer and conjugated to mAb using Pierce pre-coated iodination tubes (Thermo 28601) 
following standard procedures.  Phosphate buffered saline (PBS, Gibco 14190-144) and 16% 
(w/v) paraformaldehyde (PFA, Alfa Aesar 43368) were used as received. 
 
CD44 mAb cell-surface binding, saturation, competition and internalization by A549 cells  
Cell-surface binding to A549 cells was determined by fluorescence-activated cell sorting 
(FACS).  A549 cells at 80-85% confluency were harvested from Corning T-225 flasks, counted, 
resuspended in ice cold 2% (v/v) FBS/PBS (FACS buffer) to a final concentration of 2x107 
cells/mL and subaliquoted into 50 µL samples of 1x106 cells.  Each cell sample was incubated 
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with 50 µL of 4 µg/mL CD44 mAb in 4% FBS/PBS (100 µL, 2 µg/mL final concentration) for 1 
h on ice at 4°C.  After three washes with FACS buffer, the cells were stained with 2 µg/mL goat 
anti-mouse IgG (H+L)-Alexa 488 secondary antibody (Thermo A-11001) prepared in FACS 
buffer for 30 min on ice at 4°C.  Cells were thoroughly washed and fixed in 600 µL 4% (v/v) 
PFA/FACS buffer, transferred to a 5 mL polypropylene tube, and kept on ice and protected from 
light until analysis. 
Saturation binding studies were performed with intact A549 cells.  Sixteen (16) tubes 
were prepared, each containing 50 µL FITC-labeled CD44 mAb and 50 µL of 2x107 A549 
cells/mL, and incubated in FACS buffer at 4°C for 1 hr.  After the hour, cells were spun to a 
pellet, washed three times with FACS buffer, and fixed in 600 µL of 4% PFA/FACS buffer.  For 
competition studies, a saturating concentration of FITC-labeled CD44 mAb was mixed with 
increasing concentrations of native CD44 mAb to a final volume of 50 µL and incubated with 50 
µL of 2x107 cells/mL for 4 h at 4°C protected from light.  Cells were pelleted, washed three 
times, and fixed in 600 µL 4% PFA/FACS buffer.   
The rate of internalization of CD44 mAb was determined by measuring surface-bound 
CD44 mAb after various incubation periods at 37°C.  CD44 mAb at 2 µg/mL in FACS buffer 
were incubated with 50 µL of 2x107 A549 cells for 1 h on ice at 4°C. After three washes, cells 
were suspended in 200 µL FACS buffer and placed at 37°C.  At time points between 15 and 120 
min, cells were removed from 37°C and immediately quenched with 1 mL ice cold FACS buffer, 
spun to a pellet, and resuspended in 2 µg/mL Alexa-488 anti-mouse IgG secondary antibody for 
30 min on ice at 4°C.  Cells were washed three times, fixed in 4% PFA/FACS buffer and stored 
at 4°C until all samples were collected.  Internalization was plotted as percent fluorescence of a 
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control sample held for equal time at 4°C.  FACS analysis was performed on a Beckman Coulter 
CyAn the same day as sample preparation for all samples. 
 
Generation and characterization of 125I-labeled CD44 mAb 
CD44 mAb B, C, G, J and X were radiolabeled with iodine-125.  Briefly, 4 µL of 125I 
(126 µCi/µL) was added to 100 µg of each mAb in 25 mM Tris, 0.4 M NaCl (approximately 500 
µCi/100 µg mAb) in Pierce pre-coated iodination tubes.  The reaction mixture was stirred gently 
for 15 min at room temperature.  Radioiodinated mAb was purified using a PD-10 column 
(gravity protocol) pre-equilibrated and eluted with ice cold PBS, and fractions were stored at 4°C 
until further use.  Confirmation of retained binding and cell uptake characteristics of 
radioiodinated CD44 mAb were determined using A549 cells in vitro.  Briefly, A549 cells plates 
at 5x105 per well on a 24-well tissue culture treated plate were incubated at 37°C, 5% CO2 
overnight.  The following morning cells were washed with 37°C pre-warmed media and 
incubated with a saturating concentration of 125I-CD44 mAb prepared in serum-free RPMI 1640.  
At 1, 8, and 24 h, the supernatant was collected and counted by gamma counter to determine the 
125I-CD44 mAb unbound fraction.  Cells were thoroughly washed and incubated with pH 2.2 
glycine-HCl buffer at room temperature for 5 min to collect the 125I-CD44 mAb cell-surface 
bound fraction.  After another wash, cells were incubated with equal parts trypsin-EDTA (Gibco 
25300-054) and RIPA lysis buffer (Thermo 89901) for 10 min at room temperature to collect the 
125I-CD44 mAb internalized fraction.  All fractions were collected separately and counted by 
gamma counter.  Data were plotted as a fraction of total CPM using a reference sample. 
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Biodistribution 
A549 cells (5x106) were injected subcutaneously in the rear flank of 6-8 week old 
athymic (nu/nu) mice.  To minimize tumor uptake differences due to tumor pathophysiology and 
the enhanced permeability and retention (EPR) effect, the biodistribution study was designed and 
executed as five discrete studies each with mice displaying tumors 200 ± 50 mm3.  When 16 
mice reached the target tumor size, they were randomized into four groups of four and injected 
i.v. with 125I-labeled mAb by tail vein.  Blood, tumor, liver, kidneys, spleen, stomach, intestine, 
heart, lungs, thyroid, muscle, brain, tail, and carcass were collected, weighed, and measured by 
gamma counter.  All mice were pretreated with 0.5% (v/v) Lugol’s solution (ENG Scientific 
6850), added directly to the drinking water at least 48 h prior to injection, and this treatment was 
continued until time of sacrifice.  Blood collected at each time point during the study was 
subjected to trichloroacetic acid (TCA) precipitation to measure percent free 125I content by 
standard procedures. 
 
Blocking study 
Twelve (12) athymic (nu/nu) mice were implanted with 5x106 A549 cells and monitored 
as described above.  Mice were randomized and grouped into four groups of three, each 
separately injected i.v. by tail vein with 20 µg native CD44 mAb B, C, G and J.  Twenty-four 
(24) h later mice were injected with 2 µg 125I-labeled CD44 mAb.  Seventy-two (72) h later (or 
96 h post cold dose) blood and tumor were harvested, weighed, and counted by gamma counter. 
 
Tumor histology 
Ten (10) athymic (nu/nu) mice were implanted with 5x106 A549 cells as described.  Once 
tumors reached the target size, mice were randomized into two groups of five mice.  Four mice 
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per group were injected i.v. by tail vein with 20 µg CD44 mAb B, C, G or J.  The fifth mouse 
served as a tumor-only control.  Mice were sacrificed after 24 h or 72 h and tumors were excised, 
fixed in formalin for 72 h, washed thoroughly with ultrapure water, and stored in 70% (v/v) 
ethanol.  Tumors were embedded in paraffin, sectioned, mounted for immunohistochemistry, and 
stained (H&E and DAB) for mouse anti-human CD44 mAb. 
 
Statistical analysis 
All data were analyzed using GraphPad PRISM 6.  
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Results 
CD44 expression in human cancer cells lines A549, MDA-MB-231, and mouse 4T1 cancer cells 
CD44 expression was evaluated in two immortalized human cancer cells lines derived 
from primary tumors, A549 human non-small cell lung carcinoma cells and MDA-MB-231 
human triple negative breast/mammary gland cells, as well as 4T1 murine stage IV human breast 
cancer cell line.  Cell-surface density was assessed qualitatively by western blot (WB), 
fluorescence-activated cell sorting (FACS), and enzyme-linked immunosorbent assay (ELISA) 
(Figure 3-1 A-C).  CD44 is broadly expressed at the cell surface of CD44+ A549 cells, especially 
within the cell pseudopodia and sites of cell-cell interactions (Figure 3-1 D). 
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Figure 3-1. CD44 expression by 4T1, MDA-MB-231 and A549 cells confirmed by western blot 
(A) and FACS analysis (B).  CD44 mAb saturation binding to 4T1, MDA-MB-231 and A549 
cells by whole-cell ELISA (C).  CD44 cell-surface expression on A549 cells by confocal 
microscopy (D).  Nuclei were stained blue with DAPI and CD44 stained green with mouse anti-
human CD44 mAb followed by Alexa488-labeled goat anti-mouse IgG secondary antibody. 
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CD44 mAb cell-surface binding screen to A549 NSCLC cells 
Ten (10) CD44 mAbs were screened for cell-surface binding to A549 human NSCLC 
cells (Table 3-1). 
Table 3-1. CD44 mAbs* screened for A549 NSCLC tumor targeting 
mAb Clone Isotype Immunogen Specificity Species Reactivity 
mAb A MA54 IgG1 
Exon v6 on the variant 
portion of CD44 of 
human origin 
CD44v6, variant of 
human CD44 Human 
mAb B MEM-85 IgG2b 
Leucocytes of patient 
suffering from LGL-
type leukemia 
Extracellular domain 
of CD44v10, variant 
of human CD44 
Human 
mAb C MEM-263 IgG1 COS-7 cells 
Extracellular domain 
of CD44v10, variant 
of human CD44 
Human 
mAb D FW11-10-3 IgG2a 
Fusion protein 
corresponding to variant 
region of human CD44 
(3v to 10v) 
CD44v4, variant of 
human CD44 Human 
mAb E FW11-24-17-36 IgG1 
Fusion protein 
corresponding to variant 
region of human CD44 
(3v to 10v) 
CD44v9, variant of 
human CD44 Human 
mAb G F10-44-2 IgG2a 
CD44-positive cell 
preparation of human 
origin 
CD44 of human 
origin Human 
mAb J P2A1 IgG2a 
Ocular melanoma cell 
line V+B2 of human 
origin 
CD44 of human 
origin Human 
mAb K VFF-7 IgG1 
Exon v6 on the variant 
portion of CD44 of 
human origin 
CD44v6, variant of 
human CD44 Human 
mAb L DF1485 IgG1 
Purified CD44 antigen 
from lymphocyte 
membrane 
CD44 of mouse and 
human origin 
Human 
Mouse 
mAb M F-4 IgG1 
Amino acids 21-320 of 
CD44 of human origin 
CD44 of mouse and 
human origin 
Human 
Mouse 
* Only murine mAbs generated using a primary human cancer cell immunogen or purified 
immunogenic protein antigen and previously validated for immunofluorescence, 
immunohistochemistry, flow cytometry, and immunoprecipitation were included in the study. 
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A549 NSCLC cells were used as the model CD44+ cell line in all studies included in this 
work.  CD44 mAb were screened for cell-surface binding to A549 cells by incubating cells with 
2 µg/mL native CD44 mAb until equilibrium binding was reached.  Unbound CD44 was 
separated by centrifugation and cells were thoroughly washed to remove non-specific, surface-
associated mAb.  CD44-bound CD44 mAb was detected using goat anti-mouse IgG-Alexa 488 
conjugate and analyzed by FACS (Figure 3-2). 
 
 
Figure 3-2. FACS histograms of A549 cell-surface binding of CD44 mAb and assay controls.  
X-axis records the log of fluorescence captured in the FITC channel detector and the y-axis 
measures counts, or cells, gated for whole cells using the Front Scatter-Side Scatter histogram 
and single cells using the Side Scatter linear-Side Scatter area histogram. 
 
Five of the ten CD44 mAbs exhibited greater cell-surface binding to A549 cells than a 
non-specific mouse mAb control (Figure 3-3 A).  MAb B, C, G and J rapidly bound the cell 
surface of A549 cells, exhibiting a surface-bound fraction greater than 47.3% after 5 min, 83.0% 
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after 10 min, and 97% after 30 min.  Contrarily, mAb L exhibited only 6.7% fraction surface-
bound at 5 min, 9.9% at 10 min, and 40.3% after 30 min (Figure 3-3 B).  MAb B, C, G and J 
were selected for further screening on the basis of statistically significant higher fraction cell-
surface bound fractions than isotype control after 5 min incubation with CD44-expressing A549 
cells. 
 
 
Figure 3-3. A549 cell-surface CD44 mAb binding screen.  Ten (10) CD44-specific mAbs were 
screened for equilibrium binding to A549 NSCLC cells by FACS (A).  Data analyzed by one-
way ANOVA (p<0.001) using Dunnett’s multiple comparison post-test identified mAb J, G, B, 
C and L for binding greater than mouse anti-human control mAb.  Data analyzed by one-way 
ANOVA and Dunnett’s multiple comparison post-test showed the significance of time on A549 
cell-surface binding (p<0.001) and demonstrated mAb B, C, G and J, but not mAb L, rapidly 
bound to A549 cells, exhibiting differences as early as 5 min after incubation (B).  Significance 
for mAb L displayed only.  ns – not significant, *** p<0.001 
 
Affinity and specificity of CD44 mAb to A549 NSCLC cells 
CD44 mAb exhibiting rapid cell-surface binding to CD44+ A549 cells were 
characterized for their binding affinity and specificity.  Binding affinity was first studied by 
saturation in a whole-cell enzyme linked immunosorbent assay format (ELISA) (Figure 3-4).  
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Significant differences between the binding affinity (noted by the slope) and the saturating 
concentration (noted by the plateau) were observed between CD44 mAb J, G, B and C. 
 
 
Figure 3-4. Saturation binding of CD44 mAb B, C, G and J to CD44+ A549 cells by whole-cell 
ELISA.  Data analyzed by non-linear regression one-site binding model in GraphPad PRISM 6. 
 
While ELISA enables rapid assessment of cell binding, it cannot be easily modified to 
assess receptor specificity by competition.  Contrarily, established methods in cell flow 
cytometry [265, 266] enable rapid and versatile saturation binding and competition experiments 
to determine both affinity and specificity of mAb to specific cell-surface receptors.  Thus, 
binding of CD44 mAb to CD44-overexpressing A549 cells was characterized by fluorescence-
activated cell sorting (FACS) following established protocols.  Saturation binding was 
determined by incubating an increasing concentration of FITC-labeled mAb B, C, G and J with 
A549 cells until median fluorescent intensity plateaued (Figure 3-5 A).  Specificity of native 
CD44 mAb was observed by incubating increasing concentrations of native mAb with the 
respective FITC-labeled CD44 mAb at saturating conditions, and native CD44 mAb affinity was 
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determined by competitive equilibrium binding at the same conditions (Figure 3-5 B).  MAb G 
and mAb J exhibited similar high affinity binding to CD44 expressed on A549 cells with an 
apparent Kd of 12.14 nM and 24.47 nM, respectively.  MAb B and mAb C exhibited intermediate 
and low affinity CD44 binding with an apparent Kd of 49.21 nM and 209.8 nM, respectively.  
Interestingly, MAb G was unable to competitively inhibit binding of mAb J to A549 cells, 
indicating the two high affinity clones bind unique epitopes of the CD44 receptor (Figure 3-5 C). 
 
 
Figure 3-5. Saturation and competitive equilibrium binding of CD44 mAb to A549 NSCLC 
cells.  Saturation binding of CD44 mAb B, C, G and J to A549 cells was monitored by FACS 
(A).  Apparent equilibrium dissociation constants (Kd) for FITC-labeled mAb B, C, G and J were 
determined using a non-linear regression one-site saturation binding model in GraphPad PRISM 
6.  Affinity and specificity of native CD44 mAb B, C, G and J, performed by co-incubating 
FITC-labeled CD44 mAb at each Kd with increasing concentrations of native CD44 mAb, was 
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determined by competitive equilibrium binding (B).  High-affinity mAb G and low affinity mAb 
L were used to assess epitope-specificity in a competitive binding assay with FITC-labeled mAb 
J (C).  Non-competitive binding suggests high affinity mAb G and low affinity mAb L do not 
compete with the same CD44 epitope as high affinity mAb J. 
 
CD44 mAb cell uptake by A549 NSCLC cells 
High affinity surface-bound CD44 mAb internalized more rapidly than intermediate or 
low affinity mAb by A549 cells in vitro.  Longer incubations of A549 cells with CD44 mAb 
resulted in more cell uptake (p<0.01), and differences were observed between mAb G and mAb 
B (p<0.05) and mAb G and mAb C (p<0.01) but not between the two high affinity clones mAb 
G and mAb J.  One-way ANOVA using Dunnett’s multiple comparison post-test showed 
significant cell uptake of mAb B at 120 min (Figure 3-6 A, p<0.01), mAb G at 45 min (Figure 3-
6 C, p<0.01), and mAb J at 60 min (Figure 3-6 D, p<0.001).  Conversely, 120 min incubation of 
mAb C with A549 cells at 37°C failed to result in significant cell uptake (Figure 3-6 B, 
p=0.1385).  Differences among the mean internalized fraction of CD44 mAbs were first 
observed at 45 min, when mAb G showed significantly higher fraction internalized than mAb B, 
C and J (p=0.0476) (Figure 3-6 E). 
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Figure 3-6. CD44 mAb internalization by A549 cells.  Percent internalized CD44 mAb plotted 
as mean fluorescence intensity of CD44 mAb incubated with A549 cells at 37°C compared to 
CD44 mAb incubated with A549 cells at 4°C for equivalent time.  One-way ANOVA for each 
CD44 mAb confirmed significant A549 cell uptake of mAb B at 120 min (p<0.01); mAb G at 45 
min (p<0.01), 90 min (p<0.01) and 120 min (p<0.01); and mAb J at 60 min (p<0.001), 90 min 
(p<0.05) and 120 min (p<0.05) (A, C, D).  CD44 mAb C failed to demonstrate significant cell 
uptake by A549 cells after 120 min 37°C incubation (p = 0.1385) (B).  Differences among the 
internalized fraction of CD44 mAb were first observed at 45 minutes and confirmed by one-way 
ordinary ANOVA (p=0.0476) (E).  * p<0.05, ** p<0.01, *** p<0.001 
 
CD44 mAb exhibit differential uptake and spatiotemporal trafficking in CD44+ A549 cells 
CD44 mAb display unique uptake and intracellular trafficking behavior in CD44+ A549 
cells.  Uptake, trafficking, and co-localization of CD44 mAb were monitored by confocal 
microscopy using the endosomal marker EEA1 (early endosome-associated protein 1) and 
lysosome marker LAMP-1 (lysosome-associated membrane protein 1) (an example is shown for 
mAb G with EEA1, Figure 3-7).  Spatiotemporal trafficking to the endosome (Figure 3-8) and 
lysosome (Figure 3-9) were collected during independent experiments for each CD44 mAb and 
quantified by co-localization index.  The co-localization index (CI) was determined by 
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quantifying the % fluorescence associated with CD44 (detected in the green channel) that co-
localized with fluorescence associated with reporter fluorescent marker EEA1 or LAMP-1 
(detected in the red channel), divided by the total CD44-associated green fluorescence.  High 
affinity CD44 mAb G and mAb J internalized more rapidly and to a much greater extent 
compared to intermediate mAb B and low affinity mAb C.  MAb C, mAb B and mAb G readily 
accumulated in the endosome within the first 2 h of incubation.  After these early time points, 
endosomal accumulation of mAb G and mAb C decreased while the lysosomal accumulation 
increased, whereas mAb B endosome accumulation remained constant out to 48 h.  Contrary to 
the behavior of mAb G, C, and B, mAb J accumulated in the endosome slowly and steadily over 
the course of 24 h.  Co-localization of mAb J increased in the lysosome from 24 to 48 h, at the 
same time as co-localization decreased in the endosome. 
 
  
Figure 3-7. Cell uptake, accumulation and retention of mAb G within the endosome of CD44+ A549 cells by confocal microscopy.  
Data collected between 0 and 48 h in the blue channel, green channel, and red channel allowed simultaneous visualization and 
quantification of endosome accumulation by calculating the colocalization index of mAb G with the endosome marker EEA1.  
121 
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Figure 3-8. CD44 mAb B, C, G and J cell uptake and 48 h-spatiotemporal endosome tracking in 
CD44+ A549 NSCLC cells.  Nuclei were stained blue with DAPI, CD44 mAb stained green with 
anti-mouse-Alexa488, and EEA-1 endosome biomarker stained red with anti-rat-Texas Red. 
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Figure 3-9. CD44 mAb B, C, G and J cell uptake and 48 h-spatiotemporal lysosome tracking by 
CD44+ A549 NSCLC cells.  Nuclei were stained blue with DAPI, CD44 mAb stained green with 
anti-mouse-Alexa488, and LAMP-1 lysosome biomarker stained red with anti-rat-Texas Red. 
 
Confocal microscopy directly confirmed CD44 mAb uptake by A549 cells similar to the 
results of the indirect FACS-based assay (Figure 3-6), which quantified cell uptake by decreases 
in surface-bound CD44 mAb.  While high affinity mAb G showed the highest fractions co-
localized with endosome and lysosome at each time point of the 48 h assay, the most striking 
data were observed with mAb B.  Unlike other CD44 mAbs, mAb B rapidly co-localized with 
the lysosome, demonstrating the highest lysosome CI of all CD44 mAb tested after just 120 
minutes.  In fact, mAb B endosome accumulation was nearly undetectable until 120 min due to 
rapid lysosomal trafficking. 
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Figure 3-10. Accumulation and retention of CD44 mAb B (A), mAb C (B), mAb G (C) and 
mAb J (D) within the endosome and lysosome of CD44+ A549 NSLCL cells.  Data were 
collected by confocal microscopy and analyzed for colocalization with EEA1 (endosome 
marker) and LAMP-1 (lysosome marker) in independent continuous exposure experiments 
ranging from 0 to 48 h. 
 
Preparation and characterization of radioiodinated CD44 mAb 
MAb B, C, G, J and X (non-specific normal mouse IgG) were labeled with iodine-125.  
Briefly, CD44 mAb (100 µg prepared in 25 mM Tris, 0.4 M NaCl) was reacted with 
approximately 500 µCi 125I at room temperature for 15 min.  Radioiodinated CD44 mAb were 
labeled with 82-91% radiochemical yield to a specific activity between 3.69 and 4.36 µCi/µg 
(Table 3-2). 
 
 125 
Table 3-2. Radiochemical yield and specific activity of radioiodinated CD44 mAb  
MAb J C G B X 
Activity 125I added to reaction 
(µCi) 390 398 400 396 378 
Activity in empty Eppendorf 
(µCi) 7.3 2.8 2.5 1.7 15.01 
Activity in empty PD-10 
(µCi) 12.8 12.1 17.1 10.9 22.3 
Radiochemical Yield  
(%) 91 91 90 91 82 
Specific Activity  
(µCi / µg) 4.22 4.36 4.32 4.33 3.69 
 
The mixture was purified by PD-10 gravity protocol pre-equilibrated with 10 mM PBS 
pH 7.2.  Fractions were collected and counted for activity.  Volume fractions of 0.5 mL at the 5, 
5.5, 6, and 6.5 mL mark were pooled and stored at 4ºC until further use. 
 
 
Figure 3-11. PD-10 column purification of 125I-CD44 mAb B, C, G, J and X prepared for in vivo 
biodistribution and tumor uptake studies in A549 tumor-bearing mice. 
 
To probe the impact of radiolabeling of CD44 mAb binding affinity and specificity, 125I-
labeled CD44 mAb were assayed for cell-surface binding and cell uptake by CD44+ A549 cells.  
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Cells exposed with a saturating concentration of 125I-CD44 mAb were allowed to reach binding 
equilibrium.  Unbound 125I-CD44 mAb was aspirated and cells were thoroughly washed to 
remove residual non-specific 125I-CD44 mAb from the assay plate.  Cells with surface-bound 
125I-CD44 mAb were incubated for 1, 8, and 24 h at 37ºC and 5% CO2 and fractions of 125I-
CD44 mAb unbound, surface-bound, and internalized were collected and counted by gamma 
counter (Figure 3-12).  Low affinity 125I-CD44 mAb C rapidly dissociated from the A549 cell 
surface, which limited the internalized fraction to a maximum of 8% at 1 h.  Contrarily, high 
affinity 125I-labeled CD44 mAb G and J remained highly surface-bound through the course of the 
study, ranging from 55% to 40% for mAb G and 50% to 25% for mAb J.  High affinity 125I-
CD44 mAb G and mAb J reached a maximum internalized fraction of 22% at 1 h.  Intermediate 
affinity 125I-CD44 mAb demonstrated the highest fraction internalized of all CD44 mAb studied.  
The internalized fraction peaked to nearly 50% at 1 h, fell to 35% at 8 h, and increased to 40% at 
24 h 125I-mAb B internalized fraction remained higher than the surface-bound fraction through 
the course of the 24 h study, a unique finding among 125I-CD44 mAb studied. 
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Figure 3-12. In vitro cell-surface binding and internalization of 125I-labeled CD44 mAb B (A), 
mAb C (B), mAb G (C), and mAb J (D) by CD44+ A549 cells.  Unbound, surface-bound, and 
internalized fractions were collected at 1, 8, and 24 h and counted by gamma counter.  Data were 
plotted as percent of total activity incubated with the A549 cells during 24 h continuous 
exposure. 
 
Biodistribution and tumor uptake study design in A549 tumor-bearing mice 
A 72 h scouting experiment was performed to gain experience with iodine-125 
radiolabeling, the A549-tumor bearing animal model and the in vivo behavior of the 125I-labeled 
CD44 mAbs.  Mice were implanted with 5 x 106 A549 cells and later injected with 3-6 µCi 125I-
CD44 mAb B, 125I-CD44 mAb C, 125I-CD44 mAb G, or 125I-CD44 mAb J prepared with a 
specific activity of approximately 1.5 µCi/µg.  Organs including blood and tumor were 
harvested, weighed, and counted for activity 72 h after injection (Figure 3-13). 
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Figure 3-13. 72-hr biodistribution and tumor uptake of 125I-CD44 mAb in A549 tumor-bearing 
mice.  Data presented as normalized for tissue mass (%ID/g, A) and absolute value (%ID, B). 
 
Intermediate affinity mAb B demonstrated the greatest tumor uptake of all CD44 mAb.  
Interestingly, differences in tumor uptake were observed between 125I-labeled CD44 mAb B and 
mAb G (p<0.05) and well as mAb B and mAb C (p<0.05) (Figure 3-14 A), yet no differences 
among CD44 mAb tumor uptake were observed when data were not normalized by tumor mass 
(Figure 3-14 B). 
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Figure 3-14. Tumor accumulation of 125I-CD44 mAb 72 h post i.v. injection to A549 tumor-
bearing mice.  Data presented as normalized per mass of tumor tissue (%ID/g, A) and absolute 
value (%ID, B).  * p<0.05 
 
Significant variance was observed among groups of mice injected with the same 125I-
CD44 mAb, especially mAb B (Figure 3-14 B).  Thus, it was hypothesized that tumor size might 
impact CD44 mAb uptake, since mAb tumor uptake requires sufficient tumor vascularization 
and extravasation of the mAb into the solid tumor mass.  Analysis demonstrated that tumor size 
significantly altered CD44 mAb tumor uptake, and this observation held for all four CD44 mAbs 
studied (Figure 3-15 A).  Significant thyroid uptake of radioactive iodine was also observed in 
A549 tumor-bearing mice (Figure 3-15 B).  This likely occurs due to the endogenous function of 
the thyroid, which is to sequester iodine from the blood for incorporation into essential 
hormones.  Addition of Lugol’s solution to the drinking water of mice 48 h prior to 125I-mAb 
administration largely suppressed thyroid uptake of radioactive iodine in a subsequent 
biodistribution study (Figure 3-15 B). 
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Figure 3-15. Tumor size significantly impacts tumor uptake of 125I-CD44 mAb in A549 tumor 
bearing mice (A).  The addition of 0.5% v/v Lugol’s solution to mouse drinking water (B, 
blocking) significantly reduced thyroid uptake of radioactive iodine compared to no pretreatment 
(B, non-blocking) in A549 tumor-bearing mice dosed with 125I-CD44 mAb. 
 
The scouting study data were used to plan and execute future biodistribution and tumor 
uptake studies.  All subsequent in vivo studies were initiated only when all mice of a group 
reached tumor sizes between 150 mm3 and 250 mm3.  Furthermore, mice in future studies using 
radioactive iodine-labeled CD44 mAb were pre-treated with 0.5% v/v Lugol’s solution 48 h prior 
to 125I-CD44 mAb to mitigate thyroid uptake of radioactive iodine. 
 
CD44 mAb biodistribution and tumor uptake in A549 tumor-bearing mice 
Athymic (nu/nu) mice bearing a 200 ± 50 mm3 A549 subcutaneous tumor xenograft were 
injected i.v. by tail vein with 6-10 µCi 125I-CD44 mAb.  Organs were collected, weighed and 
measured by gamma counter at 2, 24, 48, 72, and 120 h post injection (Figure 3-16). 
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Figure 3-16. Biodistribution of 125I-CD44 mAb following i.v. tail injection in A549 
subcutaneous xenograft tumor-bearing mice.  Non-CD44 specific 125I-mAb X was collected only 
at 72 h.  Organs collected at 2 h (A), 24 h (B), 48 h (C), 72 h (D), and 120 h (E) were 
immediately weighed and counted for activity by gamma counter.  All data were normalized to 
tissue mass and reported as %ID/g. 
 
Total tumor exposure of each CD44 mAb was extracted from the biodistribution data and 
plotted as function of time (Figure 3-17).  MAb C and mAb J showed consistent tumor 
concentrations up to 48 h, after which time their tumor uptake began to decline.   MAb G tumor 
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exposure decreased between 2 h and 24 h, after which time it showed a bell shaped curve with a 
maximum tumor concentration at 72 h.  MAb B tumor accumulation steadily increased up to 48 
h and then slowly decreased, a typical uptake-clearance profile for tumor-specific mAb 
administered i.v. to tumor-bearing mice.  Total tumor exposure was determined by calculating 
the area under the curve and found to be 569.3, 356.1, 235.3, and 152.6 %ID*hr/g for 125I-mAb 
B, mAb C, mAb G and mAb J, respectively. 
 
 
Figure 3-17. Kinetic profile of tumor exposure of 125I-CD44 mAb following i.v. tail vein 
injection in mice bearing a 200 ± 50 mm3 A549 subcutaneous xenograft tumor.  Data plotted as 
%ID normalized to tumor mass at 2, 24, 48, 72, and 120 h. 
 
Differences in tumor uptake between 125I-labeled CD44 mAbs were observed at 24 h 
(Figure 3-18A, p<0.05), 48 h (Figure 3-18B, p<0.05), 72 h (Figure 3-18C, p<0.001), and 120 h 
(Figure 3-18D, p<0.01).  Tumor uptake of mAb B was greater than mAb G at 24, 72, and 120 h; 
tumor uptake of mAb B was greater than mAb J at 48, 72, and 120 h; and tumor uptake of mAb 
C was greater than mAb J at 72 h. 
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Figure 3-18. Tumor uptake of 125I-CD44 mAb in A549 tumor-bearing mice.  Tumors excised 
from A549 tumor-bearing mice injected with 125I-labeled CD44 mAb B, C, G or J and counted by 
gamma counter showed mAb-specific differences in tumor uptake at 24 h (A), 48 h (B), 72 h 
(C), and 120 h (D).  One-way ANOVA using Tukey’s multiple comparison post-test 
demonstrated statistically greater tumor uptake of mAb B than mAb G at 24 h (p<0.05), 72 h 
(p<0.05), and 120 h (p<0.05); greater tumor uptake of mAb B than mAb J at 48 h (p<0.05), 72 h 
(p<0.001), and 120 h (p<0.01); and greater tumor uptake of mAb C than mAb J at 72 h (p<0.01).  
* p<0.05, ** p<0.01, *** p<0.001 
 
Tumor uptake data following i.v. injection of 125I-CD44 mAb (Figure 3-17, Figure 3-18) 
was corroborated by immunohistochemistry (IHC) of excised tumors 24 h and 72 h following i.v. 
tail vein injection of native CD44 mAb (Figure 3-19).  Tumor sections were stained H&E (blue, 
nucleus, and red, membrane) to show tissue architecture and DAB (brown) for CD44 mAb.  
Tumor staining of both high affinity mAb G and mAb J was strong at 24 h dramatically reduced 
by 72 h.  Tumor uptake of low affinity mAb C was modest at 24 h but increased significantly at 
72 h, consistent with tumor uptake data of 125I-CD44 mAb C.  Intermediate affinity mAb B 
readily accumulated at concentrated areas within the tumor at 24 h yet also demonstrated broad 
and diffuse tumor staining at 72 h.  Moreover, significant fraction of mAb B localized within the 
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cell and frequently co-localized with the nucleus of A549 cells at 72 h.  Cellular uptake and 
nuclear colocalization of mAb B was unique among the CD44 mAb screened. 
 
 
Figure 3-19. Tumor uptake of CD44 mAb in A549 tumor-bearing mice.  Tumors were excised 
from mice 24 h or 72 h following i.v. administration of CD44 mAb B, C, G or J.  Excised tumors 
were stained for CD44 mAb by immunohistochemistry (DAB substrate, brown) as well as H&E 
for tumor tissue architecture. 
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CD44 mediates tumor targeting in A549 tumor-bearing mice 
The mechanism of CD44 mAb tumor uptake was investigated by comparing tumor 
accumulation of CD44 mAb to a non-CD44 specific monoclonal antibody over time.  Tumor-to-
non tumor tissue ratios, calculated by dividing the %ID/g in the tumor by the %ID/g in the non-
tumor tissue, were calculated for each CD44 mAb at 2, 24, 48, 72, and 120 h, as well as for non- 
specific mAb X at 72 h (Table 3-3). 
 
 Table 3-3. Tumor-to-non-tumor tissue ratios calculated from the biodistribution of 125I-labeled CD44 mAb and non-specific mAb X 2, 
24, 48, 72, and 120 h after i.v. tail vein administration to A549 subcutaneous xenograft tumor-bearing mice 
mAb Blood Tumor Lung Heart Stomach Spleen Kidney Liver Intestine Brain Muscle 
2 h 
mAb B 0.10 1.00 0.34 0.29 0.97 0.96 0.55 1.04 3.24 3.68 3.47 
mAb C 0.16 1.00 0.69 0.47 1.18 1.34 1.22 1.18 3.60 6.66 7.63 
mAb G 0.14 1.00 1.44 0.37 1.00 1.16 1.03 0.58 2.84 5.89 12.17 
mAb J 0.25 1.00 1.05 0.74 0.16 0.21 0.68 1.03 1.76 8.08 16.83 
24 h 
mAb B 0.44 1.00 1.33 1.36 1.33 1.63 2.47 2.52 5.22 13.94 11.07 
mAb C 0.38 1.00 1.46 1.51 1.06 2.70 3.46 2.05 4.48 12.59 11.96 
mAb G 0.25 1.00 0.87 0.72 0.56 0.52 2.33 0.85 2.25 7.98 15.22 
mAb J 0.49 1.00 2.47 1.61 1.19 2.05 2.16 1.11 6.68 16.51 46.34 
48 h 
mAb B 0.74 1.00 1.94 2.03 5.05 3.50 3.87 3.95 13.83 22.57 25.95 
mAb C 0.54 1.00 3.24 1.82 2.89 4.88 4.36 8.76 15.77 17.46 11.93 
mAb G 0.73 1.00 3.37 2.17 3.59 1.00 2.98 3.93 9.33 24.77 12.09 
mAb J 0.52 1.00 2.51 1.60 2.14 2.68 1.76 3.50 8.20 21.60 35.77 
72 h 
mAb B 1.02 1.00 3.36 2.84 7.58 4.22 8.56 10.68 20.05 34.92 34.30 
mAb C 0.83 1.00 2.47 2.81 6.29 5.79 5.67 5.00 21.09 26.13 13.99 
mAb G 0.76 1.00 3.65 2.45 4.59 2.96 5.62 6.54 13.72 27.86 9.78 
mAb J 0.40 1.00 1.83 1.33 1.98 2.38 1.41 2.00 6.42 12.34 16.45 
mAb X 0.54 1.00 1.37 1.56 2.14 0.95 1.34 1.47 5.53 14.99 5.55 
120 h 
mAb B 0.87 1.00 3.30 2.66 4.29 4.49 4.07 7.07 15.49 34.59 66.24 
mAb C 0.79 1.00 2.81 2.07 4.24 5.26 7.49 6.42 17.09 25.12 34.05 
mAb G 0.63 1.00 3.32 1.45 2.86 2.19 3.12 3.39 12.84 21.53 30.66 
mAb J 0.66 1.00 12.69 2.73 3.06 3.85 1.82 1.74 13.03 22.29 37.77 
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Tumor-to-blood (Figure 3-20 A) and tumor-to-muscle (Figure 3-20 B) data were 
extracted and plotted as a function of time.  Increases in tumor-to-blood ratios indicate 
preferential extravasation and retention of mAb at the tumor.  At the same time, increases in 
tumor-to-non-tumor tissue ratios confirm specificity of tumor homing mAb to antigen expressing 
tissues.  Tumor-to-blood tissue ratios increased for all CD44 mAb, with mAb B being the only 
mAb to surpass 1.0 at 72 h.  MAb B, C, and G each had a higher tumor-to-blood ratio than mAb 
X, indicating the role of CD44 expression on tumor uptake for these CD44 mAb.  All four CD44 
mAbs exhibited higher tumor-to-muscle ratios compared to non-specific CD44 mAb X at 72 hr.  
High affinity mAb J demonstrated the highest tumor-to-muscle ratio at 24 h, but intermediate 
affinity mAb B increased dramatically at 48 h and maintained a tumor-to-muscle ratio above 60 
between 48 and 120 h. 
 
 
Figure 3-20. Preferential accumulation of 125I-CD44 mAb at the tumor compared to blood (A) 
and tumor compared to muscle (B) following i.v. tail vein injection in A549 tumor-bearing mice. 
 
Tumor uptake of 125I-labeled non-CD44-specific mAb X showed significantly less tumor 
accumulation (1.39 %ID/g) compared to the tumor accumulation of 125I-mAb B (5.83 %ID/g, 
p<0.001) and 125I-mAb C (4.56 %ID/g, p<0.01) at 72 h (Figure 3-5A).  A blocking study was 
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performed by pre-dosing 10-fold molar excess of native CD44 mAb i.v. 24 h prior to the 
standard dose of the respective 125I-CD44 mAb.  At the modest 10-fold blocking dose, mAb B 
demonstrated a lower tumor-to-blood ratio than mAb C, G or J (Figure 3-21 B).  MAb B also 
exhibited statistically greater tumor-to-blood uptake (1.05 ± 0.133) compared to mAb J (0.41 ± 
0.09, p<0.01) and mAb X (0.56 ± 0.06, p<0.05) at 72 h (Figure 3-21 C).  Moreover, CD44 mAb 
B preferentially accumulated in the tumor compared to non-target muscle (63.0 ± 24.6) more 
than mAb X (5.52 ± 0.34) at 72 h (Figure 3-21 D). 
 
 
Figure 3-21. CD44 mediates tumor uptake in A549-tumor bearing mice.  Data analyzed by one-
way ANOVA using Tukey’s multiple comparison post-test showed 125I-labeled non-CD44 mAb 
X poorly accumulated in the tumor of A549 tumor-bearing mice compared to 125I-CD44 mAb B 
and 125I-CD44 mAb C (A).  A 10-fold molar excess i.v. pre-dose of native CD44 mAb 24 h 
before i.v. dose of 125I-CD44 mAb lowered tumor uptake for mAb B (p=0.0317) but failed to 
reduce tumor uptake for mAb C, G or J (B).  The 72 h tumor-to-blood ratio (C, p<0.01) and 
tumor-to-muscle ratio (D, p<0.05) confirmed superior CD44-mediated tumor uptake of mAb B 
compared to non-CD44 specific mAb X in A549 tumor-bearing mice by one-way ANOVA using 
Tukey’s multiple comparison post-test.  * p<0.05, ** p<0.01, *** p<0.001. 
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Pharmacokinetic profiles and distribution differ among CD44 mAb in CD44-overexpressing 
A549 tumor-bearing mice 
Blood collected from A549 tumor-bearing mice was weighed and counted by gamma 
counter 2, 24, 48, 72, and 120 h after administration of 125I-CD44 mAb.  All samples were 
assayed for percent free 125I by TCA precipitation (Figure 3-22).  With the exception of mAb J at 
2 h, more than 90% of the %ID of radioactive iodine remained associated with the mAb for all 
four CD44 mAbs through the 120 h study.  TCA precipitation assay confirmed the integrity of 
iodine-125 radiolabeling on CD44 mAb, the stability of the 125I-labeled mAb in the blood stream, 
and the accuracy of tumor uptake and biodistribution data observed with 125I-labeled mAbs. 
 
 
Figure 3-22. TCA precipitation and quantification of percent free radioactive iodine following 
i.v. tail vein injection of 125I-labeled CD44 mAb to A549 tumor-bearing mice. 
 
Significant differences in the total systemic exposure and circulating half-life of 125I-
CD44 mAb in A549 tumor-bearing mice were observed (Figure 3-23 A).  For example, the 
systemic exposure (AUCblood) of 125I-CD44 mAb B determined by the area under the %ID/g 
blood versus time curve was found to be 964.2 %ID*hr/g, whereas the systemic exposure of 125I-
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labeled mAb C, G and J were 744.3, 655.9, and 353.0 %ID*hr/g, respectively.  Key differences 
in distribution of 125I-CD44 mAb were also observed 2 hr following i.v. tail vein injection.  125I-
mAb J rapidly accumulated in the spleen (Figure 3-23 B) and stomach (Figure 3-23 C), and had 
significantly higher percent free 125I in the blood than mAb B, C or G (Figure 3-23 D). 
 
 
Figure 3-23. Pharmacokinetics and selected tissue uptake (2 h) of 125I-labeled CD44 mAb in 
A549 tumor-bearing mice.  Blood of A549 tumor-bearing mice was collected at 2, 24, 48, 72, 
and 120 h after 125I-CD44 mAb i.v. tail vein injection and counted for activity (A).  
Pharmacokinetic parameters, using a two-phase exponential decay, were determined by 
GraphPad PRISM 6.  Non-target tissue uptake analyzed by one-way ANOVA using Tukey’s 
multiple comparison post-test demonstrated higher uptake of 125I-mAb J compared to 125I-labeled 
mAb B, C or G in the spleen (B) and stomach (C) 2 hr post injection.  Free iodine-125 was 
significantly higher for mAb J compared to 125I-labeled mAb B, C or G 2 h post injection in 
A549 tumor-bearing mice (D).  * p<0.05, ** p<0.01, *** p<0.001 
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Discussion 
Effective tumor targeting relies on the dynamic and complex interplay between the 
location, density, and turnover rate of the target antigen, the characteristics of the antibody, like 
antigen affinity, internalization kinetics, in vivo stability, distribution, and clearance, and the 
tumor microenvironment.  Because tumor-associated antigens (TAAs) rarely show sufficiently 
dense, selective expression at the tumor, mAb tumor targeting critically requires identifying 
specific characteristics of the antibody that result in preferential tumor accumulation.  This study 
systematically and carefully isolated the antibody characteristics that enable A549 solid tumor 
targeting and retention from a panel of monoclonal antibody (mAb) specific to the cancer-
associated cell-surface receptor CD44 (Table 3-4). 
 
Table 3-4. Total tumor exposure of CD44 mAb B, C, G and J and associations with 
experimentally determined antigen affinity, internalization rate, and systemic exposure in A549 
tumor-bearing mice 
 Kd 
(nM) 
kint 
(ng/min) 
AUCblood 
(%ID*hr/g) 
Cmax,tumor 
(%ID/g) 
AUCtumor 
(%ID*hr/g) 
mAb B 49.21 0.321 964.2 6.72 569.3 
mAb C 209.8 0.231 744.3 4.56 356.1 
mAb G 12.14 0.556 655.9 3.00 265.1 
mAb J 24.47 0.493 353.9 1.83 152.6 
R2 with AUCtumor 
(p-value) 
0.046 
(0.786) 
0.394 
(0.373) 
0.930 
(0.036) 
0.991 
(0.005) 
 
 
CD44 mAb antigen affinity, as measured by the apparent equilibrium dissociation 
constant, showed no relationship with cumulative tumor exposure (Table 2-2, Figure 2-24, R2 = 
0.046).  Addressed in the discussion to follow, this surprising finding suggests one of three 
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possibilities: (1) CD44 density on the A549 cell surface was sufficiently low to favor the CD44 
mAb-CD44 receptor unbound state; (2) the mAb equilibrium dissociation constant (Kd) was 
sufficiently high (low affinity) to favor the CD44 mAb-CD44 receptor unbound state; or, (3) the 
concentration of CD44 mAb was too low to appreciably accumulate at CD44-expressing tumor 
tissue due to non-target tissue distribution, rapid blood clearance, or cell internalization, 
catabolism, and efflux. 
We selected A549 cells to investigate CD44-positive mAb tumor targeting following 
literature precedent [267-270].  A549 moderately but consistently overexpress CD44 at the cell 
surface, especially within cell pseudopodia and at cell-cell interfaces.  Compared to high CD44-
overexpressing MDA-MB-231 or negligible CD44-expressing 4T1 cells, moderate CD44-
overexpressing A549 cells represent the median clinical phenotype and therefore more fairly and 
accurately reflect the tumor accumulation and tissue distribution of CD44-targeted mAbs in vivo.  
Interestingly, we noted equivalent saturation binding of CD44 mAb between the moderate 
CD44-overexpressing A549 cells and high CD44-overexpressing MDA-MB-231 cells.  We 
limited our investigation to A549 cells to delineate the mAb properties that impact tumor 
targeting, uptake and retention separate from the TAA, cell line, or cancer subtype under 
investigation. 
CD44 mAb included in this study ranged in affinity from 10 – 200 nM to CD44 
expressed on A549 cells.  Recent studies have shown that intermediate affinity mAb (1 – 100 
nM) can result in greater tumor uptake, improved tumor penetration, and enhanced target 
engagement than high (<1 nM) or low (>100 nM) affinity mAbs binding to identical epitopes on 
the same target cell [66-68].  In one tumor uptake study, scFv variants ranging between 0.01 and 
100 nM showed that tumor uptake did not to improve significantly with affinity enhancements 
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beyond 1 nM, and the lowest affinity molecules exhibited diffuse tumor staining while high 
affinity clones were primarily restricted to the perivascular regions of the tumor [66].  A 
comparative study of 125I-radiolabeled mAb demonstrated that low affinity mAb penetrated a 
tumor spheroid much more deeply and evenly than high affinity mAb that binds the same antigen 
[85].  High antigen affinity also limited the transcytosis of a bispecific mAb, which was later re-
engineered with lower affinity to cross the blood-brain barrier [65].  Moreover, intermediate 
affinity EGFR-targeted nimotuzumab administered to EGFR-overexpressing A431 tumor-
bearing mice results in greater tumor uptake and less liver uptake than high affinity EGFR-
specific cetuximab or panitumumab (Chapter 4).  Taken together, these studies suggest CD44 
mAb in the panel, with antigen affinity between 10 and 200 nM, were within a reasonable range 
to exhibit CD44-mediated tumor targeting and deep A549 tumor penetration. 
Previous studies tactfully demonstrated that both expression level and turnover rate of the 
antigen impact the uptake [71] and penetration [72] of mAb by a tumor.  CD44 expressed on 
A549 cells has shown to mediate uptake of HA-derivatized particles [267-270], particularly 
those of high-molecular weight and high grafting density [271], and localize within endosomes 
and lysosomes [267, 271].  Similar to particles with high density, high molecular weight HA, 
CD44 mAb with high CD44 antigen affinity associated with faster internalization rates, likely 
due to a greater number of receptors bound for high affinity CD44 mAb compared to 
intermediate or low affinity CD44 mAb (Table 2-2, Figure 2-24, R2 = 0.79).  However, 
internalization of CD44 mAb by A549 cells poorly correlated with tumor uptake (Table 2-2, 
Figure 2-24, R2 = 0.39).  In landmark cancer cell uptake, metabolism and retention studies with 
125I-labeled mAb, it was observed that antibody labeled with 125I (by the Peirce iodination 
method) proteolytically degraded in the lysosome following endocytosis and rapidly released 
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radioiodinated tyrosine into the cell supernatant [96, 97].  These studies established that high 
affinity, rapidly internalizing mAb displayed inferior retention of radioactivity in the tumor 
compared to antibody-antigen systems exhibiting slow rates of endocytosis.  High affinity CD44 
mAb J and G internalized faster and accumulated more quickly in the endosome and lysosome 
than intermediate and low affinity CD44 mAb B and C, yet showed a lower fraction internalized 
than intermediate affinity 125I-labeled mAb B in vitro.  In fact, histology confirmed rapid tumor 
uptake of mAb G, mAb J, and mAb B at 24 hr, yet only mAb B displayed broad tumor staining, 
intracellular accumulation and nuclear localization at 72 hr.  The discrepancy in cell uptake 
between native and 125I-labeled CD44 mAb is likely due to the unique intracellular processing 
and fate of the 125I-labeled CD44 mAbs.  Rapid A549 cellular catabolism and release of 
radioiodinated tyrosine from mAb J and mAb G may, in part, explain the poor tumor retention of 
the high affinity CD44 mAbs in A549 tumor-bearing mice compared to intermediate affinity 
CD44 mAb B. 
Epitope specificity can also lead to differential cell uptake and trafficking of tumor 
targeting mAb, as observed with higher lysosomal accumulation of the HER2 antibody 73JIgG 
compared to trastuzumab [272].  Fluctuations in surface-bound fraction of high affinity CD44 
mAb over time suggest modest time-dependent recycling by CD44-expressing A549 cells, 
whereas low affinity mAb dissociate from the receptor at the cell surface or within the 
endosome.  Similar behavior was demonstrated using cells with intermediate levels of HER2 
expression, which exhibit both antibody recycling and clearance from the cell surface [273].  The 
lower plateau median fluorescent intensity observed with CD44 mAb G compared to mAb B, C 
and J suggests mAb G binds to a different, less prominent CD44 epitope.  A competition 
equilibrium binding experiment between high affinity mAb G and mAb J confirmed that mAb G 
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was unable to inhibit mAb J binding to A549 cells in vitro.  Though both standard and variant 
isoform epitopes of CD44 have been targeted for therapy, studies evaluating epitope-specific 
tumor targeting, cell uptake, and intracellular trafficking remain unexplored for the CD44 
receptor. 
Unlike antigen affinity and cell internalization kinetics, systemic exposure of CD44 mAb 
showed a strong association with tumor uptake and retention by CD44-expressing A549 tumors 
(Table 2-2, Figure 2-24, R2 = 0.93).  In vivo studies in tumor-bearing mice were carefully 
designed and carried out to minimize effects of the tumor microenvironment on CD44 mAb 
tumor uptake.  Sufficient host vascularization of a xenograft tumor occurs only after tumors 
reach 150 mm3, and tumors must be sufficiently vascularized in order for molecules in the blood 
to extravasate and infiltrate the solid cell mass [274].  Tumors that grow too large, however, can 
become necrotic and exhibit high interstitial fluid pressure, increased tumor convection, spatial 
variations in extravasation, and altered receptor expression, all of which impact mAb tumor 
uptake and retention [275-277].  A preliminary 72 hr scouting study demonstrated significant 
differences in tumor uptake of CD44 mAb in mice bearing different size tumors and significant 
accumulation of 125I in the thyroid.  Effect of tumor size on CD44 mAb uptake was mitigated by 
initiating all in vivo studies with mice bearing tumors 200 ± 50 mm3, and Lugol’s solution was 
added to drinking water 48 hr before injection of 125I-labeled mAb to minimize thyroid uptake of 
free 125I. 
Although differences in the distribution of CD44 mAb were observed at early time points 
of the study, the full time-course biodistribution data of 125I-labeled CD44 mAb revealed no 
significant role of TMDD, or off-target tissue uptake and catabolism, on tumor targeting of 
CD44 mAb.  Previous studies of mouse tissues identified CD44 expression in the spleen, liver, 
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eye, and intestines [278], and a biodistribution study of 89Zr-labeled RG7356, a humanized 
antibody targeting the constant region of CD44, in MDA-MB-231 tumor-bearing mice resulted 
in modest liver, spleen, and kidney uptake [279].  The same molecule studied in cynomolgus 
monkey showed uptake in spleen, salivary glands, and bone marrow, likely related to low levels 
of tissue CD44 expression.  Modest non-specific tissue uptake of CD44 mAb was observed 
within liver, kidneys, and intestine but did not appreciably accumulate.  However, within the first 
two hours a significant percent injected dose of 125I-mAb J accumulated in stomach and spleen, 
typical of mAb aggregates [280, 281], and released a large fraction of 125I in the blood compared 
to radioiodinated mAb B, C and G.  This behavior resulted in significantly decreased systemic 
exposure of 125I-mAb J compared to 125I-mAb B, C and G in A549 tumor-bearing mice. 
Intermediate affinity CD44 mAb B did not demonstrate higher tumor uptake than low affinity 
mAb C at any time point in the study.  However, tumor accumulation of mAb B was mediated by 
antigen affinity, whereas tumor accumulation of mAb C was not.  Blocking CD44 mAb uptake 
in the tumor with a modest 10-fold higher dose of native mAb B administered 24 hr before 125I-
mAb B significantly decreased the radioactivity measured in the tumor (Figure 5B).  This 
difference was not observed with 125I-mAb C, G or J likely due to poor target engagement of 
mAb C and rapid cell uptake and processing of mAb G and J.  Particularly for high affinity mAb 
G and mAb J, blocking could be improved with a blocking dose 100-1000-fold above the hot 
dose co-administered simultaneously, rather than 24 hours in advance as was performed in this 
study.  This would significantly increase the circulating concentration of the cold mAb at the 
time of injection, which based on the pharmacokinetic data was nearly equimolar at the time of 
the hot dose administration in our study design.  Compared to non-specific mAb X, mAb B also 
demonstrated higher tumor-to-blood and tumor-to-muscle ratios and was the only mAb to 
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surpass a tumor-to-blood ratio of 1.0 through the course of study, a well-established indicator of 
antigen-specific tumor uptake. 
MAbs offer an unparalleled platform to target tumors with radionuclides and drugs that 
enable robust diagnosis and treatment of cancer.  However, predicting the in vivo behavior of 
tumor targeting mAb against a diversity of biological targets, all while incorporating highly 
variable biological data like inter-patient variability and the expression level and turnover rate of 
the target receptor in non-target tissues, remains a significant challenge in the field.  Tumor 
targeting models in quantitative pharmacology probe the underlying mechanisms that limit mAb 
tumor uptake and predict distribution, circulating half-life, and target cell uptake [102-105].  
These models also contribute to a greater appreciation to the complex interplay between antigen 
and antibody and can accelerate screening and selection campaigns of tumor targeting mAb with 
specific localization and exposure requirements.  Herein we subjected a simple tumor targeting 
framework, in which mAb antigen affinity, internalization rate, and pharmacokinetics impact 
total tumor uptake in tumor bearing mice, to experimental validation using a panel of CD44 
mAbs against A549 human NSCLC cells.  While differences between in vitro and in vivo 
behavior of the CD44 mAb were anticipated, we were surprised how poorly high affinity, rapidly 
internalizing CD44 mAb G and mAb J performed in vivo compared to intermediate affinity mAb 
B and low affinity mAb C.  A549 tumor uptake of CD44 mAb used in this study was largely 
governed by the pharmacokinetics of the mAb, rather than the antigen affinity or internalization 
rate, and in vitro characterization alone would have failed to identify mAb B as the superior 
CD44-specific A549 tumor targeting agent.  With an increasingly diverse array of TAAs to 
target for cancer therapy, identifying the ideal properties of tumor targeting mAb remains a 
critical area of research in drug delivery. 
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CHAPTER 4: ON TUMOR TARGETING AND DEVELOPMENT OF A BROAD 
ACTING PRECLINICAL IMMUNOPET IMAGING AGENT FOR EGFR-
OVEREXPRESSING SOLID TUMORS 
 
Introduction 
Detailed studies demonstrate the complexity and cooperativity of the ErbB family of 
receptor tyrosine kinases, whose interactions with each other and extracellular ligands are 
necessary for cell transformation, survival, and proliferation [282].  The ErbB family has long 
been shown to play a critical role in the proliferation and survival of carcinoma cells in humans 
[283].  Epidermal growth factor receptor (EGFR, ErbB1, HER1), in particular, plays a central 
role in the pathogenesis and progression of different carcinomas, including lung, breast, stomach, 
colorectal, head and neck, and pancreatic carcinomas and glioblastoma [284].  Due to its broad 
overexpression across different carcinoma tissues and central role in cancer progression, 
developing an EGFR-specific radiotracer would enable early detection, accurate diagnosis, and 
real-time monitoring of tumor growth or regression during and after a treatment campaign [285]. 
Due to the nature of their high-affinity and specific binding, monoclonal antibodies 
(mAbs) are the leading clinical candidates to carry radionuclides for both therapy or imaging.  
Cetuximab and panitumumab are clinical grade FDA-approved therapeutic mAbs that bind with 
high affinity and specificity to the extracellular domain of EGFR [286].  Both have been labeled 
with zirconium-89 and evaluated as an immunoPET imaging agent in preclinical studies in mice 
[287-291] and patients with metastatic colorectal cancer [292-294].  Nimotuzumab is a third 
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clinical grade mAb approved for squamous cell head and neck carcinoma, glioma, and 
nasopharyngeal cancer in Cuba, India, China, Argentina and others [295], but only has achieved 
orphan status for glioma in the US and pancreatic cancer in the EU.  Like cetuximab and 
panitumumab, nimotuzumab binds human EGFR with high specificity [296], but at 1-2 orders of 
magnitude lower affinity [297], and has also been studied as an EGFR-specific radiotracer in 
preclinical and clinical settings [298, 299]. 
In the first half of the presented work, native and 89Zr-labeled cetuximab, panitumumab, 
and nimotuzumab were characterized in vitro for differences in EGFR specificity, affinity and 
internalization.  MAbs against the same cell surface antigen often demonstrate unique 
mechanisms of action and different in vitro and in vivo characteristics [255].  Antigen affinity is 
the primary and often singular parameter used to screen and select mAb for use in tumor 
targeting and drug delivery.  Increasing mAb binding affinity and valence improves tumor 
uptake [78-80].  However, critically, high affinity mAb selected during standard screening and 
selection campaigns can exhibit poor tumor penetration, poor tumor retention, off-target tissue 
uptake, rapid catabolism and clearance [66-68, 85, 86].  These observations are attributed to two 
phenomena.  The first phenomenon is coined the binding site barrier (BSB), which predicts the 
diffusion of high-affinity mAb into tumors is limited by the low local concentration of diffusible, 
free antibody due to slow rates of antibody-antigen dissociation [87-89].  The second 
phenomenon limiting tumor uptake of high-affinity mAb is coined target-mediated drug 
disposition (TMDD).  TMDD accelerates clearance of high-affinity mAb due to rapid target cell 
uptake, catabolism and efflux of high-affinity mAb, as well as decreases target engagement due 
to antigen-specific nontarget tissue uptake [75, 92]. For these reason, a head-to-head-to-head 
study was performed to evaluate the tumor targeting performance of 89Zr-labeled nimotuzumab, 
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cetuximab, and panitumumab.  Past studies have elegantly shown that intermediate mAb can 
exhibit superior tumor targeting features [300], and nimotuzumab in particular displays unique 
clinical features due to its intermediate affinity [301, 302].  Due to the high specificity but lower 
affinity of nimotuzumab compared to cetuximab and panitumumab, it was hypothesized that 
89Zr-nimotuzumab could exhibit better tumor targeting features, in particular a higher tumor-to-
blood ratio and lower nontarget tissue uptake, than 89Zr-labeled cetuximab or panitumumab in 
mice bearing highly EGFR-overexpressing A431 tumors. 
In the second half the presented work, fragments of panitumumab and cetuximab were 
produced, characterized in vitro, and studied as immunoPET radiotracer agents in tumor-bearing 
mice.  Prolonged circulation and delayed tumor uptake are major limitations toward the use of 
intact mAbs as molecular imaging agents [303-305]; however enzymatically produced and 
engineered antibody fragments display rapid tumor uptake and significantly faster clearance rates 
[306-310].  Compared to intact mAb, fragments typically demonstrate lower antigen affinity and 
significantly reduced or abated target cell uptake [311].  Furthermore, their smaller size and 
decreased antigen affinity improve penetration and distribution within a solid tumor compared to 
intact mAb [83, 312-315].  It was hypothesized that 64Cu-labeled Fab and Fab’ fragments of 
cetuximab and panitumumab, respectively, would accumulate rapidly in the EGFR-expressing 
tumor, providing excellent tumor-to-noise ratios at early time points, and also clear rapidly from 
the blood, lowering the overall radioactive exposure to healthy tissues.  
The studies herein set out to characterize the role of antigen affinity on EGFR-positive 
tumor uptake of intact nimotuzumab, cetuximab, and panitumumab.  It was hypothesized that 
intermediate affinity nimotuzumab would display better tumor targeting features and lower 
nontarget tissue uptake than high-affinity cetuximab and panitumumab in mice bearing a highly 
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EGFR-overexpressing A431 tumor.  Size and specificity were also examined using 
enzymatically prepared fragments of panitumumab and cetuximab in an expanded panel of 
EGFR human cancer lines and xenograft models.   Together, these studies aimed to define 
critical molecular attributes of tumor targeting mAb and develop an immunoPET imaging agent 
for use in detection, diagnosis, treatment monitoring, and imaging of EGFR-overexpressing 
tumors.  
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Materials and methods 
Cell culture 
A431 human epidermoid carcinoma, U87MG human malignant glioblastoma, HT-29 
human colorectal adenocarcinoma, and MDA-MB-468 human mammary gland/breast metastatic 
cells were purchased from the American Type Culture Collection (ATCC) and cultured in 37 ˚C 
5% CO2 as described.  A431 and U87MG cells were cultured in high glucose DMEM (Gibco 
11995-065) supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma F2442) and 100 
U/mL penicillin-streptomycin (PS, Gibco 15140-122).  HT-29 cells were cultured in McCoy’s 
5A modified medium (Gibco 16600-0882) complete with 10% (v/v) FBS and 100 U/mL PS.  
MD-MB-468 cells were cultured in RPMI 1640 (Gibco 11875-093) also complete with 10% 
(v/v) FBS and 100 U/mL PS.  All experiments were performed with cells between passage 5 and 
20. 
 
Materials and mAbs 
Cetuximab (Erbitux®, Eli Lilly) and Panitumumab (Vectibix®, Amgen) were purchased 
from the University of North Carolina Pharmacy and used as received.  Nimotuzumab was 
generously provided as a gift from Oncoscience AG (Wedel, Germany) and used as received.  
Pierce Fab Preparation Kit (44985) and Pierce F(ab’)2 Preparation Kit (44988) were used as 
received though following significantly modified protocols.  Radioactive copper-64 and 
zirconium-89 were purchased from Perkin Elmer or the Washington University in St. Louis, MO.  
Radioactivity of non-biological samples was measured in a CRC-55tW dose calibrator-well 
counter (Capintec, NJ, USA), and radioactivity of biological samples was measured using an 
automatic γ-counter (2470, Wizard2, Perkin Elmer, Waltham, MA). 
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Preparation of 89Zr-labeled EGFR mAb, 64Cu-labeled cetuximab Fab, and 64Cu-labeled 
panitumumab Fab’ 
 Intact cetuximab, panitumumab, and nimotuzumab were labeled with zirconium-89 
following covalent conjugation to solvent accessible lysine on the antibody with the NHS-
activated chelator DFO.  Fragments of cetuximab and panitumumab were prepared by enzymatic 
degradation with papain and pepsin, respectively.  The fragments were isolated by affinity 
column purification and concentrated by centrifugal filtration.  Cetuximab Fab was labeled with 
copper-64 following covalent conjugation between solvent accessible lysine on the fragment and 
the NHS-activated chelator NOTA.  Panitumumab F(ab’)2 was further modified by reduction in 
2-mercaptoethylamine (2-MEA) to produce monovalent F(ab’), and the monovalent fragment 
was labeled with copper-64 following covalent modification to the free hinge thiol on the 
fragment with the maleimide-activated chelator NOTA.  Size and structure of the mAbs, 
fragments, and chelator-conjugates were assessed by SDS-PAGE, MALDI-TOF, and SE-HPLC 
(280 nm).  Radiolabeled mAbs and fragments were further characterized by SE-HPLC (CPM).  
Preparation and characterization of radioimmunoconjugates are described in detail elsewhere 
[316-318]. 
 
Saturation binding of native, conjugated, and radiolabeled EGFR mAb and fragments 
Binding affinity and specificity of mAb, fragments, mAb-chelator conjugates, and 
radioimmunoconjugates were investigated using a whole cell enzyme-linked immunosorbent 
assay (ELISA).  Briefly, cells were harvested from tissue culture flaks and prepared at 1 x 105 
cells/mL in complete media.  To each well of the high-binding tissue 96-well plate (Costar 
3903), 100 µL (10,000 cells) of cell stock was added and incubated at 37˚C and 5% CO2 
overnight.  The following morning, cells were blocked by adding 200 µL/well 5% (w/v) milk 
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diluted in PBS (blocking buffer) and incubated for 1 h at 4˚C.  After blocking, cells were washed 
thoroughly with 0.05% (v/v) Tween-20 diluted in PBS (PBS-T) and incubated for 1 h at 4˚C with 
increasing concentrations of mAb, fragment, or conjugate (50 µL/well prepared in 1% (w/v) milk 
diluted in PBS) (ELISA buffer).  Cells were again washed thoroughly with PBS-T and incubated 
for 30 min at 4˚C with the appropriate HRP-conjugated secondary antibody (50 µL/well prepared 
at 1:20,000 volume dilution in ELISA buffer).  Cells were thoroughly washed with PBS-T, 
incubated with Ultra-TMB substrate (100 µL/well) for 20 min at room temperature (RT), 
quenched with 2N H2SO4(100 µL/well), and measured for absorbance at 450 nm.  Absorbance 
data at 450 nm were blank corrected and normalized by cell number.  Saturation binding of 
radiolabeled mAb and fragments was performed by incubating cells with increasing 
concentrations of radioactive material, washing cells thoroughly, collecting detached cells 
following trypsin digest, and measuring the surface-bound fraction by gamma counter.  Activity 
(measured in both counts and CPM) was also blank corrected.  The equilibrium dissociation 
constant (Kd) for mAb, fragments, conjugates, and radioimmunoconjugates was calculated using 
a nonlinear regression one-site specific binding model in GraphPad PRISM 6. 
 
Competitive equilibrium binding of 89Zr-EGFR mAbs and 64Cu-EGFR mAb fragments 
 Retained EGFR specificity of mAb and fragments after chelator conjugation and/or 
radiolabeling was confirmed by competitive equilibrium binding with native mAb.  Cells were 
harvested and prepared at 2.5 x 104 cells/mL in complete media.  To each well of a 24-well plate, 
3 mL (75,000 cells) of cell stock was added and incubated at 37 ˚C and 5% CO2 overnight.  The 
following morning, cells were blocked for 1 h at 4˚C with ice cold 5 % (v/v/) FBS diluted in PBS 
solution.  After the cells were washed, a saturating concentration of 89Zr-labeled mAb or 64Cu-
labeled mAb fragment was mixed with increasing concentrations of the corresponding native 
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EGFR mAb (500 µL/well final volume prepared in 1% (v/v) FBS diluted in PBS) and incubated 
for 4 h at 4˚C with cells.  Cells were thoroughly washed, treated with trypsin-EDTA, collected 
and counted by gamma counter.  Data were plotted with activity measured as a function of the 
log concentration of native (inhibitory) mAb and analyzed using the one-site log(IC50) fit model 
in GraphPad PRISM 6. 
 
In vitro cell uptake of 89Zr-EGFR mAb  
Binding and cell uptake of 89Zr-labeled EGFR mAb were examined after 8 h incubation 
with EGFR-overexpressing A431 cells.  Cells were prepared as described in the 24-well 
competitive equilibrium binding assay (above).  After overnight incubation, cells were washed 
with ice cold serum free media and incubated for 1 h at 4˚C with 89Zr-labeled EGFR mAb 
prepared in serum free media.  Unbound 89Zr-labeleed EGFR mAb was collected, stored at 4˚C, 
and counted for activity.  Cells were thoroughly washed with serum-free media and incubated for 
8 h at 37˚C 5% CO2 in complete media.  The 89Zr-EGFR mAb unbound fraction was collected by 
recovering the supernatant of each well plus one wash (500 µL/well) with ice cold PBS.  The 
surface-bound fraction was collected by incubating cells with glycine-HCl pH 2.2 (500 µL/well) 
for 5 min at RT followed by one thorough PBS wash.  The internalized fraction was collected by 
incubating cells with equal parts trypsin-EDTA (500 µL/well) for 5 min followed by RIPA lysis 
buffer (500 µL/well, 1 mL total volume) for an additional 5 min at RT.  Each collection fraction 
was placed in a 5 mL scintillation vial and its activity measured by gamma counter.  Data for 
each fraction was plotted as a percent of the total amount of activity incubated with cells. 
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Statistical Analysis 
All data were analyzed using GraphPad PRISM 6.  Equilibrium dissociation constants 
(Kd) were calculated using a nonlinear regression one-site specific binding model.  Inhibitory 
concentration (IC50) values were determined by competition studies and analyzed using the 
nonlinear regression log(inhibitor) vs. response model in GraphPad PRISM 6. 
  
  157 
Results 
Saturation binding of native, DFO-conjugated, and 89Zr-labeled nimotuzumab, cetuximab, and 
panitumumab to EGFR-overexpressing gA431 cells 
 
EGFR mAbs nimotuzumab, cetuximab, and panitumumab were conjugated with DFO 
and as described [316].  Attachment of the DFO chelator had minimal effect on the mAb-EGFR 
binding interaction based on a head-to-head comparison of native mAb versus DFO-mAb 
conjugates (Figure 3-1).  Increasing concentrations of EGFR mAbs nimotuzumab, cetuximab, 
and panitumumab were incubated with EGFR-overexpressing A431 cells until saturating binding 
was reached.  Nimotuzumab and nimotuzumab-DFO exhibited intermediate binding affinity to 
EGFR, whereas cetuximab, panitumumab and their respective DFO-conjugates exhibited high 
binding affinity to EGFR.  Equilibrium dissociation constants (Kd) were determined to be 1.85, 
0.537, and 0.538 nM (nimotuzumab, cetuximab, and panitumumab) and 2.31, 0.616, and 0.574 
nM for the respective DFO-conjugate. 
 
 
Figure 4-1. Saturation binding of EGFR mAbs nimotuzumab (N), cetuximab (C), and 
panitumumab (P) and their respective DFO-conjugate (N-DFO, C-DFO, and P-DFO) to EGFR-
overexpressing A431 cells by whole cell enzyme-linked immunosorbent assay (ELISA).  DFO-
attachment to nimotuzumab (A), cetuximab (B), or panitumumab (C) had a minimal effect on 
binding affinity. 
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 Saturation binding was also performed after chelation of the 89Zr radionuclide to the 
DFO-conjugate of each nimotuzumab, cetuximab, and panitumumab (Figure 3-2).  After 
labeling, the equilibrium binding constant (Kd) increased, to 51.0, 8.51, 4.12, and nM for 
nimotuzumab, cetuximab, and panitumumab, respectively, resulting in an 8-30-fold decrease in 
binding affinity compared to native, unmodified mAb. 
 
 
Figure 4-2. Saturation binding of 89Zr-labeled EGFR mAbs nimotuzumab (89Zr-DFO-N), 
cetuximab (89Zr-DFO-C), and panitumumab (89Zr-DFO-P) to EGFR-overexpressing A431 cells. 
 
Specificity of 89Zr-labeled EGFR mAbs by equilibrium competition binding to A431 cells 
To confirm specific, high-affinity binding of the new 89Zr-labeled mAb to the EGF 
receptor, we conducted a binding competition study by co-incubating A431 cells with an 
increasing concentration of native mAb and a saturating concentration of 89Zr-labeled mAb.  As 
the concentration of the native mAb increased, the radioactivity or counts per minute (CPM) of 
the 89Zr-labeled mAb associated with the cell decreased (Figure 3-3).  Thus, native mAb 
successfully displaces the radioactive 89Zr-labeled mAb from the EGF-receptor and directly 
confirms EGFR specificity of each mAb after DFO-conjugation and 89Zr labeling.  The half 
maximal inhibitory concentration (IC50) for 89Zr-labeled nimotuzumab, cetuximab, 
and panitumumab were found to be 6.62, 5.62, and 6.64 nM, respectively. 
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Figure 4-3. Competitive equilibrium binding of 89Zr-labeled nimotuzumab (89Zr-DFO-N), 
cetuximab (89Zr-DFO-C), and panitumumab (89Zr-DFO-P) with native nimotuzumab, cetuximab, 
and panitumumab, respectively, confirmed EGFR specific binding of 89Zr-DFO-N, 89Zr-DFO-C, 
and 89Zr-DFO-P to EGFR-overexpressing A431 cells.  Increasing the concentration of native N, 
C, or P successfully inhibited binding of the 89Zr-labeled conjugate. 
 
Cell uptake of intermediate affinity 89Zr-labeled nimotuzumab and high affinity 89Zr-labeled 
cetuximab and panitumumab 
 
Cell uptake of 89Zr-DFO-N, 89Zr-DFO-C, and 89Zr-DFO-P was assayed by exposing 
A431 cells to a saturating concentration of 89Zr-labeled mAb for 8 h at 37 °C.  The unbound 
fraction of 89Zr-labeled mAb was collected in the supernatant; the surface-bound fraction was 
collected after 5 min exposure to glycine-HCl pH 2.2; and the internalized fraction was collected 
after 5-minute trypsin digest followed by 5-minute cell membrane lysis with RIPA lysis buffer.  
Fractions were counted for activity and normalized to total CPM incubated with the A431 cells 
(Table 3-1). 
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Table 4-1. Fraction unbound, surface-bound, and internalized of 89Zr-labeled nimotuzumab, 
cetuximab and panitumumab incubated with EGFR-overexpressing A431 (8 h, 37 ˚C, 5% CO2) 
 Unbound (%) Surface-bound (%) Internalized (%) 
89Zr-DFO-N 70.83 18.47 10.70 
89Zr-DFO-C 30.13 45.97 23.87 
89Zr-DFO-P 32.77 45.87 21.37 
 
High affinity 89Zr-labeled cetuximab and panitumumab demonstrated significantly higher 
surface-bound and internalized fractions compared to intermediate affinity 89Zr-labeled 
nimotuzumab.  Likewise, intermediate affinity 89Zr-labeled nimotuzumab had a significantly 
higher fraction unbound compared to high affinity 89Zr-labeled cetuximab or panitumumab 
(Figure 3-4). 
 
 
Figure 4-4. Fraction unbound, surface-bound, and internalized of 89Zr-labeled nimotuzumab 
(89Zr-DFO-N), cetuximab (89Zr-DFO-C) and panitumumab (89Zr-DFO-P) following 8 h exposure 
to EGFR-overexpressing A431 cells.  Data were analyzed by ordinary ANOVA using Tukey’s 
multiple comparison post-test.  **** p < 0.0001 
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89Zr-DFO-N binding, competition, and cell uptake in low-EGFR expressing U87MG, moderate-
EGFR expressing MDA-MB-468, and high-EGFR expressing A431 cells 
 
89Zr-DFO-N was selected for further in vitro characterization in a panel of cell lines 
known to express different levels of EGFR.  Low-EGFR expressing U87MG, moderate-EGFR 
expressing MDA-MB-468, and high-EGFR expressing A431 cells were exposed to 89Zr-labeled 
nimotuzumab and characterized for binding affinity, specificity, and cell uptake by saturation 
binding, competition, and internalization assays respectively. 
Binding affinity of 89Zr-DFO-N was determined by saturation binding separately for each 
EGFR expressing cell line.  The equilibrium dissociation constant (Kd) was determined to be 
90.39 and 63.21 nM for A431 cell and MDA-MB-468 cells, respectively.  The equilibrium 
dissociation constant for U87MG could not be determined. 
 
 
Figure 4-5. Saturation binding of 89Zr-DFO-N on low- (U87MG), moderate- (MDA-MB-468), 
and high- (A431) EGFR expressing human cancer cells. 
 
Cell-surface association of 89Zr-DFO-N was confirmed to be EGFR specific by 
competitive equilibrium binding.  Mixtures of 89Zr-DFO-N and native nimotuzumab were 
prepared with increasing concentrations of native nimotuzumab and a constant concentration of 
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89Zr-DFO-N.  The mixtures were co-incubated with EGFR-expressing cells until equilibrium was 
achieved.  As the concentration of native nimotuzumab increased, the radioactivity or counts 
per minute (CPM) of the 89Zr-DFO-N associated with EGFR-expressing cells decreased (Figure 
3-6).  Competition signals specificity and affinity of the 89Zr-DFO-N conjugate to the EGF 
receptor expressed on each cell line.  The half maximal inhibitory concentration (IC50) for 89Zr-
DFO-N was found to be 36.55 and 25.86 nM for A431 and MDA-MB-468 cells, respectively.  
The IC50 for 89Zr-DFO-N with U87MG cells was determined to be 3641 nM, suggesting the cell-
associated fraction of 89Zr-DFO-N was predominantly non-specific. 
 
 
Figure 4-6. Competitive equilibrium binding of 89Zr-DFO-N with native nimotuzumab to EGFR-
expressing A431, MDA-MB-468, and U87MG cells.  Increasing the concentration of native 
nimotuzumab successfully inhibited binding of 89Zr-DFO-N, particularly in the high- and 
moderate-EGFR expressing human cancer cell lines (A).  Data were also normalized to cells 
treated with a saturating concentration of 89Zr-DFO-N without inhibitory nimotuzumab (B) to 
visualize differences in the half maximal inhibitory concentration (IC50) and EGFR specificity. 
 
Cell uptake behavior of 89Zr-DFO-N was assayed after 4 h and 24 h incubation and data 
were plotted as a percent of total CPM to determine differences in the fraction unbound, fraction 
surface-bound, and fraction internalized among the various EGFR-expressing cell lines over 
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time.  Data were analyzed for differences between the fraction across various cell lines, 
differences between the cell lines across various fractions, and also differences between the 4 h 
and 24 h data for a specific fraction in a specific cell line.  High- and moderate-EGFR expressing 
A431 and MDA-MB-468 cells both demonstrated significant differences between fraction 
surface-bound and internalized, but low-EGFR expressing U87MG only demonstrated a 
difference after 24 h incubation.  For all cell lines between 4 h and 24 h, the fraction unbound 
decreased and the fraction surface-bound increased.  However, the fraction internalized only 
increased for the high- and moderate-EGFR expressing A431 and MDA-MB-468 cells, 
respectively.  Fraction unbound, surface-bound, and internalized were significantly different 
between the cell lines at both 4 h and 24 h (data not shown). 
 
 
Figure 4-7. Cell uptake behavior of 89Zr-DFO-N in EGFR-expressing human cancer lines.  89Zr-
DFO-N fraction unbound, surface-bound, and internalized was measured at 4 h (A) and 24 h (B) 
 
Figure 3-7. Cell uptake behavior of 89Zr-DFO-N in EGFR-expressing human cancer lines.  89Zr-
DFO-N fraction unbound, surface-bound, and internalized was measured at 4 h (A) and 24 h (B) 
and plotted as % total CPM.  Significant differences (p<0.001) were observed among the the cell 
lines for each fraction (data not shown) and between the fraction unbound, surface-bound, and 
internalized within each cell line.  Time (p<0.0001) influenced the 89Zr-DFO-N fraction unbound 
(C), fraction surface-bound (D), and fraction internalized (E) for each cell line.  Individual 
differences between the 4 h data and 24 h data were observed for fractions of all cells, except the 
internalized fraction of U87MG, which did not change between 4 h and 24 h. 
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and plotted as % total CPM.  Significant differences (p<0.001) were observed among the cell 
lines for each fraction (data not shown) and between the fraction unbound, surface-bound, and 
internalized within each cell line.  Time (p<0.0001) influenced the 89Zr-DFO-N fraction unbound 
(C), fraction surface-bound (D), and fraction internalized (E) for each cell line.  Individual 
differences between the 4 h data and 24 h data were observed for fractions of all cells, except the 
internalized fraction of U87MG, which did not change between 4 h and 24 h. 
 
Binding affinity and specificity of 64Cu-NOTA-cetuximAb Fab to EGFR-expressing cancer cells 
Saturation binding of the cetuximab Fab was performed on a panel of human cancer cell 
lines expressing various levels of the surface EGF receptor.  Equilibrium dissociation constants 
(Kd) were determined to be 0.858, 0.790, 0.178, and 5.756 for cetuximab Fab to A431, MDA-
MB-468, HT-29, and U87MG cells, respectively, compared to 0.274, 0.192, 0.062, and 0.057 
nM for full length, bivalent cetuximab mAb.  Therefore, the binding affinity of cetuximab Fab to 
EGFR-expressing human cancer cell lines decreases on average 4-fold compared to intact, 
bivalent cetuximab mAb.  Loss of binding affinity increases with lower EGFR-expressing cell 
lines. 
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Figure 4-8. Saturation binding of cetuximab Fab with high-EGFR expressing A431 (A), 
moderate-EGFR expressing MDA-MB-468 (B), and low-EGFR expressing HT-29 (C) and 
U87MG (D).  Monovalent cetuximab Fab demonstrated on average 4-fold lower binding affinity 
to EGFR than its bivalent cetuximab mAb parent compound. 
 
 EGFR binding of 64Cu-labeled cetuximab Fab was assessed in A431 EGFR-high 
expressing cells and HT-29 EGFR-low expressing cells.  As with the binding assay with full 
length 89Zr-labeled cetuximab (89Zr-DFO-C), increasing concentrations of 64Cu-NOTA-C Fab 
were incubated with EGFR-overexpressing A431 cells until saturating binding was reached 
(Figure 3-5).  The assay was performed up to 500 nM to ensure saturation was reached.  The 
equilibrium dissociation constant (Kd) of 64Cu-NOTA-C Fab was determined to be 7.86 nM with 
A431 cells, nearly equivalent to 89Zr-DFO-C (8.51 nM, Figure 3-2).  Differences in the absolute 
Binding affinity and specificity of 64Cu-NOTA-cetuximab Fab to EGFR-expressing cancer cells 
Saturation binding of the cetuximab Fab was performed on a panel of human cancer cell 
lines expressing various levels of the surface EGF receptor.  Equilibrium dissociation constants 
(Kd) were determined to be 0.858, 0.790, 0.178, and 5.756 for cetuximab Fab to A431, MDA-MB-
468, HT-29, and U87MG cells, respectively, compared to 0.274, 0.192, 0.062, and 0.057 nM for 
full length, bivalent cetuximab mAb.  Therefore, the binding affinity of cetuximab Fab to EGFR-
expressing human cancer cell lines decreases on average 4-fold compared to intact, bivalent 
cetuximab mAb.  Loss of binding affinity increases with lower EGFR-expressing cell lines. 
 
 
Figure 3-8. Saturation binding of cetuximab Fab with high-EGFR expressing A431 (A), 
moderate-EGFR expressing MDA-MB-468 (B), and low-EGFR expressing HT-29 (C) and 
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value 64Cu CPM reached in the assay correspond to the various levels of EGFR expression 
among the cell lines studied. 
 
 
Figure 4-9. Saturation binding of 64Cu-NOTA-C Fab to high EGFR-overexpressing A431 cells 
(A) and low EGFR-expressing and HT-29 cells (B).  Compiling the saturation binding data 
visually confirmed relative levels of EGFR expression across the cell lines (C). 
 
Specificity and affinity of 64Cu-NOTA-C Fab was confirmed by competitive equilibrium 
binding with cetuximab.  Increasing concentrations of full-length, intact cetuximab were mixed 
with a saturating concentration of 64Cu-NOTA-C Fab (60 nM, Figure 3-5) and incubated with 
EGFR-high expressing A431 cells and EGFR-low expressing HT-29 cells.  As the concentration 
of native cetuximab increased, the radioactivity or counts per minute (CPM) of the 64Cu-NOTA-
C Fab associated with the cell decreased (Figure 3-6).  Thus, cetuximab successfully displaced 
the radioactive 64Cu-NOTA-C Fab from the EGF-receptor and directly confirms EGFR 
specificity of cetuximab Fab after NOTA conjugation and 64Cu labeling.  The half maximal 
inhibitory concentration (IC50) for 64Cu-NOTA-C Fab was found to be 3.12 nM and 0.706 nM 
for A431 and HT-29 cells, respectively. 
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Figure 4-10. Competitive equilibrium binding of 64Cu-NOTA-C Fab with native cetuximab.  
Increasing the concentration of native cetuximab successfully inhibited binding of 64Cu-NOTA-C 
Fab to EGFR-expressing cancer cells, confirming the specificity of 64Cu-NOTA-C Fab to EGFR.  
Competitive equilibrium binding was performed in high EGFR-overexpressing A431 cells and 
low EGFR-expressing HT-29 cells (A).  Data were also normalized to cells treated with a 
saturating concentration of 64Cu-NOTA-C Fab without inhibitory cetuximab (B) to visualize 
differences in the half maximal inhibitory concentration (IC50) and EGFR specificity. 
 
Binding affinity and specificity of 64Cu-NOTA-panitumumAb Fab’ to EGFR-expressing cancer 
cells 
 
Saturation binding of the panitumumab Fab’ was also performed on panel of human 
cancer cell lines expressing various levels of the surface EGF receptor.  Equilibrium dissociation 
constants (Kd) were determined to be 0.550, 0.405, and 0.086 for panitumumab Fab’ to A431, 
MDA-MB-468, and HT-29 cells, respectively, compared to 0.324, 0.338, and 0.089 nM for full 
length, bivalent panitumumab.  Binding affinity for U87MG could not be determined due to the 
low level of cell association observed.  On average, the binding affinity of panitumumab Fab’ 
decreased 1-2-fold compared to intact, bivalent panitumumab. 
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Figure 4-11. Saturation binding of panitumumab Fab’ with high-EGFR expressing A431 (A), 
moderate-EGFR expressing MDA-MB-468 (B), and low-EGFR expressing HT-29 (C) and 
U87MG (D).  Enzymatic degradation and reduction of panitumumab to its Fab’ fragment did not 
appreciably alter its binding affinity to EGFR expressed on human cancer cells. 
 
 EGFR binding of 64Cu-labeled panitumumab Fab’ was assessed in a panel of EGFR 
expressing cells lines, including high EGFR-expressing A431 cells, moderate EGFR-expressing 
MDA-MB-468 cells, and low-EGFR expressing U87MG and HT-29 cells.  As with the binding 
assay with full length 89Zr-labeled panitumumab (89Zr-DFO-P), increasing concentrations of 
64Cu-NOTA-P Fab’ were incubated with EGFR-overexpressing A431 cells until saturating 
binding was reached (Figure 3-7).  The assay was performed up to 200 nM to ensure saturation 
was reached.  The equilibrium dissociation constant (Kd) of 64Cu-NOTA-P Fab’ was determined 
 
Figure 3-11. Saturation binding of panitumumab Fab’ with high-EGFR expressing A431 (A), 
moderate-EGFR expressing MDA-MB-468 (B), and low-EGFR expressing HT-29 (C) and 
U87MG (D).  Enzymatic degradation and reduction of panitumumab to its Fab’ fragment did not 
appreciably alter its binding affinity to EGFR expressed on human cancer cells. 
 
 EGFR binding of 64Cu-labeled panitumumab Fab’ was assessed in a panel of EGFR 
expressing cells lines, including high EGFR-expressing A431 cells, moderate EGFR-expressing 
MDA-MB-468 cells, and low-EGFR expressing U87MG and HT-29 cells.  As with the binding 
assay with full length 89Zr-labeled panitumumab (89Zr-DFO-P), increasing concentrations of 64Cu-
NOTA-P Fab’ were incubated with EGFR-overexpressing A431 cells until saturating binding was 
reached (Figure 3-7).  The assay was performed up to 200 nM to ensure saturation was reached.  
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to be 4.65 nM with A431 cells, nearly equivalent to 89Zr-DFO-P (4.12 nM, Figure 3-2).  
Differences in the absolutely value 64Cu CPM reached in the assay correspond to the various 
levels of EGFR expression among the cell lines studied. 
 
 
Figure 4-12. Saturation binding of 64Cu-NOTA-P Fab’ to high EGFR-overexpressing A431 cells 
(A), moderate EGFR-expressing MDA-MB-468 cells (B), and low EGFR-expressing U87MG 
cells (C) and HT-29 cells (D).  Compiling the saturation binding data visually confirmed relative 
levels of EGFR expression across the cell lines (E). 
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Specificity and affinity of 64Cu-NOTA-P Fab’ was confirmed by competitive equilibrium 
binding with panitumumab.  Increasing concentrations of full-length, intact panitumumab were 
mixed with a saturating concentration of 64Cu-NOTA-P Fab’ (60 nM, Figure 3-6) and incubated 
with EGFR-high expressing A431 cells, moderate EGFR-expressing MDA-MB-468 cells, and 
low EGFR- expressing U87MG and HT-29 cells.  As the concentration of native panitumumab 
increased, the radioactivity or counts per minute (CPM) of the 64Cu-NOTA-P Fab’ associated 
with the cell decreased (Figure 3-8).  Thus, panitumumab successfully displaced the 
radioactive 64Cu-NOTA-P Fab’ from the EGF-receptor and directly confirms EGFR specificity 
of panitumumab Fab’ following NOTA conjugation and 64Cu labeling.  The half maximal 
inhibitory concentration (IC50) for 64Cu-NOTA-P Fab’ was found to be 4.44, 3.12, 8.04, and 4.68 
nM for A431, MDA-MB-468, U87MG, and HT-29 cells, respectively. 
 
 
Figure 4-13. Competitive equilibrium binding of 64Cu-NOTA-P Fab’ with native panitumumab.  
Increasing the concentration of native panitumumab successfully inhibited binding of 64Cu-
NOTA-P Fab’ to EGFR expressing cancer cells, confirming the specificity of 64Cu-NOTA-P 
Fab’ to EGFR.  Competitive equilibrium binding was performed in high EGFR-overexpressing 
A431 cells, moderate EGFR-expressing MDA-MB-468 cells, and low EGFR-expressing 
U87MG cells and HT-29 cells (A).  Data were also normalized to cells treated with a saturating 
concentration of 64Cu-NOTA-P Fab’ without inhibitory panitumumab (B) to visualize differences 
in the half maximal inhibitory concentration (IC50) and EGFR specificity. 
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Discussion 
Studies presented herein were performed to support the preclinical development of a 
novel EGFR-targeted immunoPET imaging agent.  In many cases, a prior study evaluated the 
tumor uptake of one or another EGFR radioimmunoconjugates described.  However, no prior 
studies were found in literature that evaluate anti-EGFR mAbs and fragments collectively for the 
ideal properties of an immunoPET imaging agent.  Coupled with robust in vitro data in low-, 
moderate-, and high-EGFR expressing human cancer cell lines, this head-to-head approach 
highlighted the effects of chelation and radioisotopic complexation on affinity and specificity of 
a panel of anti-EGFR mAbs and fragments, as well as the interconnected roles of EGFR 
expression and EGFR affinity on the cell surface binding of anti-EGFR mAb and fragments to 
cancer cells. 
Native nimotuzumab (N), cetuximab (C), and panitumumab (P) bind with high affinity 
(1.85, 0.537, and 0.538 nM Kd, respectively) and specificity to EGFR-overexpressing A431 
human epidermoid carcinoma cells.  These values approximately reflect reported Kd values 
against native human EGFR antigen and relative affinities to EGFR-overexpressing A431 cells 
[255, 302]. 
Chelate conjugation and zirconium-89 complexation decreased the antigen affinity of 
anti-EGFR mAbs N, C, and P.  Intact mAbs were radiolabeled with zirconium-89 using the 
bifunctional chelator p –isothiocyanatobenzyldesferrioxamine (DFO), a facile chelator that 
enables stable complexation of ziroconim-89 to mAb [319].  Covalent conjugation of DFO to 
mAb occurs at native lysine residues to form a stable thiourea bond [320].  Following 
conjugation, the EGFR antigen affinity of N decreased 1.25-fold (2.31 nM), compared to 1.15-
  172 
fold (0.616 nM) for C and 1.07-fold (0.574 nM) for P, confirming that antigen affinity was 
largely maintained with conjugates prepared with 2-3 DFO chelates per mAb [316]. 
However, affinity losses became more pronounced following zirconium-89 
complexation.  89Zr-DFO-N displayed 25-50-fold lower affinity than native N, 89Zr-DFO-C was 
15.8-fold lower affinity native C, and 89Zr-DFO-P was 7.66-fold lower affinity than native P.  
The effect of radiolabeling on antigen binding affinity can be attributed to differences in primary, 
secondary, or tertiary structure between N, C, and P, or particular susceptibility to biochemical 
changes following DFO conjugation and zirconium-89 labeling.  The isothiocyanate-lysine 
chemistry used to attach DFO to N, C, and P is non-specific, resulting in a heterogeneous 
mixture of DFO-mAb conjugates with a distribution in number and location of DFO chelates 
covalently attached to the mAb.  Lysine found within the antigen-binding region or along the 
CDR loops tend to be solvent exposed and thus more susceptible to chemical modification.  
Chemical modification to lysine in this region can result in lower antigen affinity.  While a 
negligible difference was observed in binding affinity between the DFO-conjugates and native 
N, C, or P, a modest reduction in affinity to EGFR was observed with 89Zr-DFO-C (8.51 nM) 
and 89Zr-DFO-P (4.12 nM), and moderate reduction in affinity for 89Zr-DFO-N (90.4 nM), when 
exposed to A431 cells.  Moreover, reduced A431 affinity was specific to EGFR, as each of the 
89Zr-DFO-mAbs was potently and completely displaced from the A431 cell surface by 
competitive equilibrium binding with its native counterpart. 
Fragmentation of cetuximab and panitumumab to monovalent Fab and F(ab’) fragments 
resulted in modest and negligible reductions in EGFR binding affinity, respectively.  Cetuximab 
treated with papain generated the monovalent Fab fragment, which reduced EGFR binding 
affinity 1.6-fold (0.858 nM) compared to native cetuximab.  Panitumumab treated with pepsin 
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resulted in the bivalent dimeric F(ab’)2 fragment, which when subjected to high concentration 2-
mercaptoethylamine fragmented to yield two monovalent F(ab’) fragments.  Interestingly, both 
the bivalent F(ab’)2 (data not shown) and monovalent (Fab’) fragment maintained near identical 
EGFR binding affinity (0.550 nM) as intact panitumumab. 
 
Table 4-2. Affinity and specificity of intact panitumumab, DFO-panitumumab, and 89Zr-labeled 
panitumumab, panitumumab F(ab’), and 64Cu-labeled panitumumab F(ab’) determined by 
saturation binding (Kd) and competition (IC50) with highly EGFR-overexpressing A431 human 
epidermoid carcinoma cells 
 Kd (nM) IC50 (nM) Kd / Kd,N 
N 1.85   
DFO-N 2.31  1.25 
89Zr-DFO-N 90.4 36.6 48.9 
 
C 0.537   
DFO-C 0.616  1.15 
89Zr-DFO-C 8.51 5.62 15.8 
C Fab 0.858  1.60 
64Cu-NOTA-C Fab 7.86 3.12 14.6 
 
P 0.538   
DFO-P 0.574  1.07 
89Zr-DFO-P 4.12 6.64 7.66 
P Fab’ 0.550  1.02 
64Cu-NOTA-P Fab’ 4.65 4.44 8.64 
 
Chelate conjugation and copper-64 complexation to the Fab fragment of cetuximab and 
F(ab’) fragment of panitumumab modestly decreased the antigen binding affinity to EGFR-
overexpressing A431 cells.  Cetuximab Fab was covalently conjugated with isothiocyanate-
activated 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA-SCN), a facile, highly stable, 
and proven chelator for copper-64 labeling to mAbs [321].  Like DFO, NOTA-SCN reacts with 
surface-exposed lysine in a non-specific manner, resulting in a heterogeneous distribution in 
number and location of NOTA chelates covalently attached to the Fab.  The EGFR binding 
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affinity of 64Cu-labeled cetuximab Fab decreased 14.6-fold (7.86 nM) compared to native C and 
9.16-fold compared to cetuximab Fab.  Panitumumab F(ab’) was covalently conjugated with 
maleimide-activated NOTA (NOTA-MAL).  In the presence of the panitumumab F(ab’), NOTA-
MAL forms a stable, site-specific thioether bond with the free thiol generated on panitumumab 
F(ab’) following reduction from the F(ab’)2 fragment.  The site-specific nature of the linkage 
dictates the location and number of modifications, potentially leading to a near-homogenous 
radioimmunoconjugate with retained binding features.  The EGFR binding affinity of 64Cu-
labeled panitumumab F(ab’) decreased 8.64-fold (4.65 nM) compared to native P and 8.45-fold 
compared to panitumumab F(ab’).  Both 64Cu-labeled cetuximab Fab and panitumumab F(ab’) 
were displaced by competitive equilibrium binding with intact cetuximab and panitumumab, 
respectively.  Taken together, the EGFR binding affinity of 64Cu-labeled cetuximab Fab and 
64Cu-labeled panitumumab F(ab’) nearly mimicked the binding affinity of 89Zr-DFO C and 89Zr-
DFO-P, respectively, and simultaneously maintained selectivity to EGFR expressed on A431 
cells. 
EGFR binding affinity and specificity was studied across a panel of human cancer cell 
lines to better understand the interconnected roles of EGFR expression and antigen affinity on 
the tumor targeting of radiolabeled mAb and fragments.  Studies were carried out in EGFR high-
expressing A431 human epidermoid carcinoma cells (EGFR+++), moderate-expressing MDA-
MB-468 human triple-negative breast/mammary adenocarcinoma cells (EGFR++), and low-
expressing HT-29 human colorectal adenocarcinoma and U87MG human glioblastoma cells 
(EGFR+). 
Cell-surface binding studies followed demonstrating the total surface bound fractions of 
anti-EGFR mAbs and fragments matched the expression level (cell surface density) of EGFR on 
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the cancer cell.  89Zr-DFO-N exhibited intermediate-affinity binding to EGFR+++ A431 (Kd = 
90.4 nM) and EGFR++ MDA-MB-468 (Kd =63.2 nM).  In the same saturation binding assay, 
increasing the incubating concentration of 89Zr-DFO-N with EGFR+ U87MG resulted in a linear 
increase in the fraction of radioactivity associated with U8MG cells, characteristic of a non-
specific interaction.  Moreover, competitive equilibrium binding with native nimotuzumab failed 
to competitively displace the 89Zr-DFO-N at a reasonable inhibitor concentration (IC50 = 3641 
nM), whereas nimotuzumab potently and completely displaced 89Zr-DFO-N incubated with 
EGFR++ MDA-MB-468 (IC50 = 25.9 nM) and EGFR+++ A431 (IC50 = 36.6 nM). 
 
Table 4-3. Affinity of anti-EGFR mAbs, fragments, and radioimmunoconjugates determined by 
saturation binding with high- (A431), moderate- (MDA-MB-468), and low- (HT-29 and 
U87MG) EGFR expressing cell lines. All data reported as Kd in nM. 
 A431 EGFR+++ 
MDA-MB-468 
EGFR++ 
HT-29 
EGFR+ 
U87MG 
EGFR+ 
89Zr-DFO-N 90.4 63.2 * ND 
 
C 0.274 0.192 0.062 0.057 
C Fab 0.858 0.790 0.178 5.76 
64Cu-NOTA-C Fab 7.86 * 980 * 
 
P 0.324 0.338 0.089 ND 
P F(ab’) 0.550 0.405 0.086 ND 
64Cu-NOTA-P F(ab’) 4.65 1.38 0.193 0.176 
ND = GraphPad PRISM was unable to determine Kd with the experimental data 
* = data not collected  
 
Native and 64Cu-labeled fragments of cetuximab and panitumumab were subjected to 
similar pan-cancer cell line affinity and specificity studies with similar results.  In each assay the 
fragments were compared head-to-head with intact cetuximab or panitumumab as controls.  
64Cu-labeled cetuximab Fab and panitumumab F(ab’) immunoconstructs exhibited comparable, 
high-affinity binding to the high- and moderate-EGFR expressing lines.  Binding to A431 and 
MDA-MB-468 was EGFR specific, as noted by the potent and complete displacement of the 
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radioactivity from the cell surface when co-incubated with native cetuximab or panitumumab in 
the competitive equilibrium binding experiments.  Contrarily, with the exception of 64Cu-NOTA-
C Fab on HT-29 cells, binding to low-EGFR expressing HT-29 and U87MG cell lines was 
predominantly nonspecific, and the reported equilibrium dissociation constant in these cell lines 
is artificial.  Even at extraordinarily high molar concentrations of high-affinity competitor, no 
more than 75% binding inhibition (usually 60-70%) was observed when 64Cu-NOTA-C Fab and 
64Cu-NOTA P F(ab’) was mixed with cetuximab or panitumumab, respectively, and co-
incubated with HT-29 or U87MG.  To summarize, binding of EGFR mAbs and fragments to HT-
29 and U87MG cells is largely driven by non-specific interactions. 
Many mAbs can induce receptor-mediated endocytosis following specific binding to the 
target antigen expressed constitutively on the cell surface.  In an attempt to further characterize 
the interconnected roles of antigen affinity and EGFR expression at the cellular level, retention 
and cell uptake of 89Zr-labeled N, C, and P were studied in EGFR+++ A431 cells.  High-affinity 
89Zr-DFO-C and 89Zr-DFO-P demonstrated significantly higher surface-bound and internalized 
fractions than intermediate-affinity 89Zr-DFO-N.  By mass balance, the unbound fraction of 89Zr-
DFO-N was significantly higher than either 89Zr-DFO-P or 89Zr-DFO-C. 
 
Table 4-4. Cellular retention and uptake of intermediate-affinity anti-EGFR 89Zr-DFO-N by 
human cancer cells lines with low-, moderate-, and high-levels of EGFR cell surface expression 
 Unbound (%) Surface-bound (%) Internalized (%) 4 h 24 h 4 h 24 h 4 h 24 h 
A431 
EGFR+++ 95.0 91.3 3.34 3.78 1.68 4.95 
MDA-MB-468 
EGFR++ 95.7 92.8 2.03 3.10 2.32 4.10 
U87MG 
EGFR+ 99.3 98.4 0.293 1.03 0.433 0.54 
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Cellular retention and uptake behavior of 89Zr-DFO-N was also studied over time in low-, 
moderate-, and high-EGFR expressing U87MG, MDA-MB-468, and A431 cells.  In these 
studies, only a fraction (0.5-10%) of radiolabeled mAb binds or internalizes within the cancer 
cell, influenced jointly by EGFR affinity of the mAb and EGFR antigen expression on the cancer 
cell.  EGFR+++ A431 cells exhibited the greatest surface-bound and internalized fractions after 24 
h, EGFR++ MDA-MB-468 cells exhibited the greatest internalized fraction of 89Zr-DFO-N at the 
early 4 h time point.  89Zr-DFO-N unbound fraction significantly decreased and surface-bound 
fraction significantly increased between 4 and 24 h for all cell lines.  Internalized fraction of 
89Zr-DFO-N increased between 4 h and 24 h for A431 and MDA-MB-468, but not U87MG.  
During 4 h, only 5% of the saturating dose of 89Zr-DFO-N is surface-bound or internalized by 
A431 cells, compared to 4% and less than 1 % for MDA-MB-468 and U87MG cells, 
respectively.  After 24 h, the combined surface-bound and internalized fraction increases to 9% 
for A431, compared to 7% and 1.5% for MDA-MB-468 and U87MG cells, respectively.  Taken 
together, both EGFR expression level and time influenced the cell surface binding and uptake 
kinetics of 89Zr-DFO-N. 
These in vitro data sets aim to support the preclinical development of a novel 
immunoPET imaging agent capable of early detection, diagnosis, and real-time monitoring of 
EGFR-overexpressing cancers.  An ideal immunoPET imaging agent exhibits rapid and specific 
tumor uptake, high signal-to-noise, and rapid clearance following an appropriate window of 
imaging time.  Based on the literature precedent with high-affinity therapeutic mAbs [300] and 
the unique safety profile observed clinically with nimotuzumab [295, 296, 301, 302, 322], it was 
hypothesized that intermediate affinity 89Zr-DFO-N would display more tumor uptake and less 
nontarget tissue uptake than high affinity 89Zr -DFO-C and 89Zr -DFO-P.  It was also 
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hypothesized fragmentation and subsequent radiolabeling of high-affinity panitumumab and 
cetuximab would yield immunoPET imaging agents with significantly improved immunoPET 
properties compared to their fully intact precursors, including deep tumor penetration and rapid 
systemic clearance.   Additionally, we set out to identify the interconnected roles of EGFR 
antigen affinity and cell-surface expression on target engagement, tumor uptake, and tumor 
specificity.  Among the radioimmunoconjugates studied, 64Cu-NOTA-P F(ab’) demonstrates the 
highest affinity and specificity to EGFR expressing cancers.  Its small size and site-specific 
covalent attachment improve its appeal as an effective imaging agent.  For these reasons, 64Cu-
NOTA-P F(ab’) should be evaluated as a broad-acting immunoPET imaging agent for cancers 
with moderate to high EGFR expression in preclinical testing.  
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CHAPTER 5: SYNTHESIS AND CHARACTERIZATION OF DISULFIDE-LINKED 
ANTIBODY-DOCETAXEL CONJUGTAES THAT IMPROVE SELECTIVITY AND 
ACTIVITY OF DOCETAXEL TO EGFR-OVEREXPRESSING CANCERS 
 
Introduction 
 Of the 60 currently FDA-approved mAbs, 10 are indicated for treatment of cancer and 
only one, ipilimumab (Yervoy®), is indicated as a stand-alone agent for solid tumor therapy 
[15].  EGFR and HER2, both members of the ErbB family of receptor tyrosine kinases, remain 
the only two clinically validated cancer cell targets for mAb used in solid tumor therapy, yet 
anti-EGFR and anti-HER2 mAbs show limited antitumor activity as stand-alone agents [28].  
Genentech partnered with ImmunoGen to repurpose the anti-HER2 mAb Herceptin®, indicated 
for metastatic breast cancer (MBC), with a series of potent antimitotic maytansinoid-linker 
configurations and observed significant efficacy and safety profiles in vitro and in vivo [136].  
The resulting molecule, ado-trastuzumab emtansine or T-DM1, demonstrated improved safety 
and efficacy in a randomized phase 2 study against an active regimen for first-line treatment of 
HER2-positive MBC, trastuzumab plus docetaxel [323].  Kadcyla® was the first ADC to receive 
full FDA approval [168] and unambiguously outperforms its parent molecule Herceptin® as a 
stand-alone agent for MBC [324]. 
Detailed studies demonstrate the complexity and cooperativity of the ErbB family of 
receptor tyrosine kinases, whose interactions with each other and extracellular ligands are 
necessary for cell transformation, survival, and proliferation [282].  The ErbB family has long 
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been shown to play a critical role in the proliferation and survival of carcinoma cells in humans 
[283].  Epidermal growth factor receptor (EGFR, ErbB1, HER1), in particular, plays a central 
role in the pathogenesis and progression of different carcinomas, including lung, breast, stomach, 
colorectal, head and neck, and pancreatic carcinomas and glioblastoma [284]. 
Despite basal-level EGFR expression on many healthy tissues, anti-EGFR mAbs have 
proven effective at extending survival of certain cancer patients, particularly for the treatment of 
EGFR-positive head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal 
cancers (CRC) when administered in combination with chemotherapy or additional targeted 
therapy [325-327].  Panitumumab (Vectibix®, Amgen) is an FDA-approved human IgG2 mAb 
that binds human EGFR with high affinity (Kd ~ 50 pM) [328].  Cetuximab (Erbitux®, Eli Lilly) 
is an FDA-approved mouse-human chimeric IgG1 mAb that also binds EGFR with high affinity 
(Kd ~ 200 pM) [329].  Both panitumumab and cetuximab exhibit activity by binding the 
ectodomain III of EGFR, blocking epidermal growth factor receptor (EGFR)-ligand interaction 
and receptor dimerization [330, 331], as well as inhibiting a variety of downstream proliferation 
and survival pathways [332, 333].  Collectively, these activities have shown to inhibit cell 
survival, induce cell arrest, induce apoptosis, reduce angiogenesis, and reduce metastasis [334-
338], as well as sensitize cancers to additional chemotherapy [339] or radiation [340].  
Cetuximab, and to a lesser extent panitumumab [341], also activates antibody-dependent cellular 
cytotoxicity to elicit a potent immune response to EGFR-overexpressing solid tumors [342, 343].  
Drug resistance can occur with cetuximab [344, 345] or panitumumab [346] as soon as 3 months 
from the start of therapy [347].  In addition to improving activity, combination regimens of 
cetuximab or panitumumab plus a chemotherapy can delay onset of drug resistance [283, 348]. 
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Based on the exciting results with Kadcyla®, we set out to perform proof-of-concept 
studies evaluating the safety and efficacy of anti-EGFR panitumumab- and cetuximab-docetaxel 
conjugates on EGFR-expressing carcinomas in vitro and in vivo.  It was hypothesized that an 
anti-EGFR mAb covalently conjugated with docetaxel would specific antigen-dependent activity 
in vitro and antitumor activity in vivo. Head-to-head, we expected the cetuximab ADC to 
outperform the panitumumab ADC due to the robust anticancer biological activity of cetuximab 
compared to panitumumab.  However, due to the high innate biological activity of each mAb, 
low potency of docetaxel, and modest drug loading, neither ADC was expected to outperform the 
mixed dose of anti-EGFR mAb plus docetaxel control arm in vivo. 
In addition to studying safety against low EGFR-expressing cells in vitro and efficacy 
compared to combination docetaxel plus anti-EGFR mAb in vivo, careful studies were 
undertaken to examine the reaction conditions needed to covalently conjugate docetaxel to the 
unique disulfide structures of IgG1 isotype cetuximab and IgG2 isotype panitumumab.  To our 
knowledge, this study is the first to produce thiol-linked panitumumab- and cetuximab-docetaxel 
conjugates via a similar reduction-alkylation synthetic scheme used in the production of the 
auristatin-loaded CD30-targeted ADC brentuximab vedotin (Adcetris®) [192].  Moreover, while 
other groups have extensively studied disulfide linked antibody-drug conjugates, particularly the 
role of disulfide steric hindrance on stability and drug release [120, 136], none to our knowledge 
have developed an ADC with the newly formed disulfide bond at the cysteine residue of the 
reduced IgG disulfide.  
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Materials and methods 
Cell lines and cell culture 
A431 human epidermoid carcinoma, U87MG human malignant glioblastoma, and MDA-
MB-468 human mammary gland/breast metastatic cells were purchased from the American Type 
Culture Collection (ATCC) and cultured as described.  A431 and U87MG cells were cultured in 
high glucose DMEM (Gibco 11995-065) supplemented with 10% (v/v) fetal bovine serum (FBS, 
Sigma F2442) and 100 U/mL penicillin-streptomycin (PS, Gibco 15140-122).  MD-MB-468 
cells were cultured in RPMI 1640 (Gibco 11875-093) also complete with 10% (v/v) FBS and 
100 U/mL PS.  Cells were maintained in a humidified incubator of 5% CO2 at 37 °C and 
passaged at 80-85% confluency.  All experiments were performed with cells between passage 5 
and 20. 
 
Antibodies, chemotherapeutic drugs, and chemicals 
Cetuximab (Erbitux®, Eli Lilly), Panitumumab (Vectibix®, Amgen), and Taxotere® 
(Sanofi NDC 0955-1020-01) were purchased from the University of North Carolina Pharmacy 
and used as received.  Docetaxel (TSZ CHEM RS019) was prepared as a 10mM stock in DMSO 
fresh for each assay.  All other chemicals were purchased as the highest grade from Fischer 
Scientific. 
 
Long chain-docetaxel prodrug (LC-DX) synthesis 
A flame-dried round-bottom flask was charged with docetaxel (DX) (80 mg, 9.9 × 10-5 
mol, 1.0 equiv) a catalytic amount of 4-dimethylaminopyridine (DMAP) (12 mg, 9.9 × 10-5 mol, 
1 equiv) in dry CH2Cl2 (20 mL) under argon, and the solution was stirred for 10 min at room 
temperature.  LC-SPDP (Thermo 21651, 42 mg, 9.9 × 10-5 mol, 1 equiv) was added and the 
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reaction mixture stirred at room temperature overnight.  The reaction was monitored by TLC 
(CH2Cl2: MeOH 95:5 v/v) for completion.  The solution was evaporated under vaccuo, and the 
crude product was purified by preparative TLC in CHCl3:MOH (95:5) (Rf = 0.39).  The silica gel 
was removed by filtration through a fine fritted funnel and the filtrate was evaporated under 
vaccuo to give the desired product as a white powder (LC-DX) (72 mg, 65%).  1H NMR (400 
MHz, CDCl3): δ (ppm) = 0.06 (s, 3H, –C15CH3), 1.1 (s, 3H, –CH19), 1.2 (s, 9H, –H7’-9’), 1.27 (s, 
3H, –H19), 1.74 (s, 3H, –H18), 1.93 (m, 2H, –C7HCH2), 2.4 (s, 3H, –C21OCH3), 2.59 (t, 2H, –
CH2C1”), 3.06 (t, 2H, –CH2NHCO), 4.19 (d, 1H, –H5), 4.3 (d, 1H, –H7), 4.85 (d, 1H, –H2), 5.25 
(s, 1H, –OH), 5.4 (d, 1H, –H10), 5.55 (t, 2H, –H13), 5.64 (d, 2H, –H20), 6.2 (d, 1H, –H2’), 6.6 (d, 
1H, –H3’), 7.22-7.53 (m, 8H, –Ar-H26-28 and Ar-H30-35), 8.05 (d, 2H, –Ar-H25,29), 8.4 (d, 1H, –Ar-
NCH). 13C NMR (100 MHz, CD3OD): δ (ppm) = 9.9 (–C19), 14.3 (–C18), 20.8 (–C22), 22.6 (–
C16,17), 25.9 (–C1”OCH2CH2), 26.4 (C1”OCH2CH2CH2), 28.1 (–C7’-9’), 29.6 (–(CH2)14C1”), 31.9 (–
C6,14), 43.1 (–C15), 44.5 (–C3), 45 (–CHBr), 46.4 (–C3’),  57.5 (–C8), 71.8 (–C13), 72.1 (–C7), 74.4 
(–C2), 75 (–C10), 75.3 (–C20),  78.9 (–C6’), 79.9 (–C1), 80.9 (–C4), 84.2 (–C5), 126.3 (–C31,33,35), 
128.9 (–C32,34), 129.2 (–C26,28), 130.2 (–C24,25,29), 133.6 (–C27), 135.5 (–C11), 138.9 (–C12), 154.2 
(–C5’), 167 (–C23), 168.3 (–C21), 169.6 (–C1), 170.8 (–C1”), 172.6 (–CONH), 211.5  (–C9). 
 
Short chain-docetaxel prodrug (SC-DX) synthesis 
A flame-dried round-bottom flask was charged with docetaxel (DX) (129.3 mg, 1.6 × 10-4 
mol, 1.0 equiv) a catalytic amount of 4-dimethylaminopyridine (DMAP) (20 mg, 1.6 × 10-4 mol, 
1 equiv) in dry CH2Cl2 (30 mL) under argon.  The solution was stirred for 10 min at room 
temperature.  SPDP (Thermo 21857, 50 mg, 1.6 × 10-4 mol, 1 equiv) was added and the reaction 
mixture was stirred at room temperature overnight.  The reaction was monitored by TLC 
(CH2Cl2: MeOH 95:5 v/v) for completion.  The white precipitate of dicyclohexyl urea byproduct 
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was filtered through a fritted funnel, and the filtrate was evaporated under vaccuo.  The crude 
product was purified by preparative TLC in CHCl3:MOH (95:5) (Rf = 0.26).  The silica gel was 
removed by filtration through a fine fritted funnel and the filtrate was evaporated under vaccuo 
to give the desired product as a white powder (118 mg, 73%).  1H NMR (400 MHz, CDCl3): δ 
(ppm) = 0.07 (s, 3H, –C15CH3), 1.1 (s, 3H, –CH19), 1.2 (s, 9H, –H7’-9’), 1.25 (s, 3H, –H19), 1.33 
(m, 28H, –(CH2)14CH3), 1.75 (s, 3H, –H18), 1.83 (m, 2H, –C7HCH2), 2.4 (s, 3H, –C21OCH3), 
2.84 (t, 2H, –CH2C1”), 2.97 (t, 2H, –CH2NHCO), 4.19 (d, 1H, –H5), 4.3 (d, 1H, –H7), 4.85 (d, 
1H, –H2), 5.16 (s, 1H, –OH), 5.4 (d, 1H, –H10), 5.47 (t, 2H, –H13), 5.62 (d, 2H, –H20), 6.2 (d, 1H, 
–H2’), 7.22-7.53 (m, 8H, –Ar-H26-28 and Ar-H30-35), 8.05 (d, 2H, –Ar-H25,29), 8.4 (d, 1H, –Ar-
NCH). 13C NMR (100 MHz, CD3OD): δ (ppm) = 9.9 (–C19), 14.2 (–C18), 20.8 (–C22), 22.6 (–
C16,17), 26.4 (C1”OCH2CH2CH2), 28.2 (–C7’-9’), 32.9 (–(CH2)C1”), 33.5 ((–(CH2CH2)C1”),  35.5 (–
C6,14), 43.1 (–C15), 46.5 (–C3), 57.6 (–C3’,8), 71.8 (–C13), 74.5 (–C2), 75 (–C10), 76.5 (–C20),  78.8 
(–C6’), 79.9 (–C1), 81 (–C4), 84.3 (–C5), 119.9 (Ar-SPDP), 121.5 (Ar-SPDP), 126.3 (–C31,33,35), 
128.9 (–C32,34), 129.2 (–C26,28), 130.2 (–C24,25,29), 133.6 (–C27), 135.5 (–C11), 138.9 (–C12), 149.3 
(Ar-SPDP),  155.1 (–C5’), 159.6 (Ar-SPDP), 167 (–C23), 167.9 (–C21), 169.7 (–C1), 170.6 (–C1”), 
211.5  (–C9). 
 
Antibody-docetaxel conjugate preparation 
Panitumumab (PAN or P) and Cetuximab (CET or C) were prepared at 10 mg/mL in 25 
mM sodium borate pH 8.1, 25 mM NaCl, 5 mM EDTA and treated with dithiothreitol (DTT), 2-
mercaptoethylamine (2-MEA), tris(2-carboxyethyl)phosphine (TCEP), or 2-mercaptoethanol (2-
ME).  Reduction of antibody disulfides to free thiols was monitored as a function of time and 
reducing agent concentration.  All DX-ADCs in the study were prepared by reduction of mAb 
disulfides followed by alkylation with the DX prodrug.  Drug loading was controlled by 
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monitoring the number of free thiols generated by reduction.  As an example, Panitumumab 
prepared at 10 mg/mL in 25 mM sodium borate pH 8.1, 25 mM NaCl, 5 mM EDTA (borate 
buffer) was treated with 10 mM TCEP also prepared in borate buffer at 3.5 mole TCEP/mole 
PAN (low DAR) or 8 mole TCEP/mole PAN (high DAR) for 1-2 h at 37 ˚C under gentle 
agitation.  Reduced PAN was purified from the reducing agent and buffer exchanged into ice 
cold 40/60 (%v/v) DMSO/0.1 M Tris-HCl pH 8.1 with 1 mM EDTA (Tris/DMSO buffer) by 
PD-10 column filtration.  Antibody fractions were pooled, concentrated by ultrafiltration over a 
30 kDa MWCO Amicon filter, and assayed for free thiol content.  SC-DX or LC-DX prepared at 
10 mM in DMSO was added dropwise (10 mole DX-prodrug/mole PAN for low DAR or 40 
mole DX prodrug/mole PAN for high DAR) to reduced PAN at room temperature under gentle 
agitation.  This reaction proceeded for 30 min at 37 ˚C and continued overnight at 4 ˚C.  Excess 
N-acetyl cysteine (NAC) prepared in Tris/DMSO buffer was added to quench unreacted DX-
prodrug.  PAN-DX conjugates were filtered by centrifugation through a 0.1 µm filter, assayed 
for free thiol content, and treated with excess N-ethyl maleimide (NEM) to quench unreacted 
free thiols.  Pure ADC was prepared by PD-10 column filtration pre-equilibrated with 10 mM 
PBS pH 7.4 150 mM NaCl, concentrated to at least 5 mg/mL by ultrafiltration over a 30 kDa 
MWCO Amicon filter, assayed for free thiol content, and stored at 4 ˚C in 10 mM PBS pH 7.4 
150 mM NaCl until further use.  The concentration of PAN, CET, P-DX and C-DX ADCs was 
measured by absorbance at 280 nm.  The concentration of mAb-cysteine thiols was determined 
by Ellman assay following standard methods using a cysteine standard.  CET-DX conjugates 
were prepared as described except the reducing conditions were 1.25 mole TCEP/mole CET for 
low DAR and 2.75 mole TCEP/mole CET for high DAR.  Given the very poor aqueous 
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solubility of the DX-prodrugs, alkylation buffer and conditions were studied extensively to 
optimize for consistent and predictable drug loading. 
 
Bioanalytical characterization of ADCs 
DX-ADCs were subjected to a variety of assays to characterize drug-loading, retained 
macromolecular structure, and EGFR binding affinity.  The number of free thiols was quantified 
using the Ellman assay and L-cysteine-HCl-H2O as a standard.  When incubated with thiolate 
anion, the disulfide bond of DTNB cleaves to release 2-nitro-5-thiobenzoate (TNB).  The 
reaction is rapid and stoichiometric, with one mole of thiol releasing one mole of TNB.  TNB is 
yellow and with a peak absorbance at 412 nm.  Free thiol content was monitored throughout 
bioconjugation and assayed prior to each in vivo study.  MALDI-TOF was used to study 
increases in mass/charge (m/z) peaks of the DX-ADCs compared to native PAN or CET 
following bioconjugation of the DX-prodrug.  Mass spectra were also analyzed prior to each in 
vivo study to confirm retained drug-loading.  Drug-loading of DX-ADCs was quantified using 
RP-HPLC by measuring the generation of DX-prodrug after 30 min treatment with 10 mM DTT 
at 37 ˚C.  Intact DX ADC was confirmed after reduction and DX prodrug alkylation by native 
SDS-PAGE on a 4-12% bis-tris gel (NuPAGE Novex NP0322BOX) with MOPS running buffer 
(NuPAGE NP0001).  Aggregates generated following bioconjugation were monitored by SE-
HPLC.  Retained binding affinity to the EGFR receptor was confirmed by whole-cell enzyme 
linked immunosorbent assay (ELISA) to EGFR-overexpressing A431 cells.  Briefly, freshly 
harvested cells were prepared at 2 x 105 cells/mL in complete media, seeded at 2 x 104 cells per 
well in Costar 3903 96-well plates, and cultured for 24 h at 37 ˚C and 5% CO2.  The following 
morning, cells were blocked (200 µL/well) with 5% (w/v) non-fat dry milk (LabScientific 
M0841) in PBS (Gibco D-PBS 1X 14190-144) at 4 °C for 1 h.  After aspirating the blocking 
  187 
buffer, serially diluted treatments (50 µL/well) in 1% (w/v) milk in PBS (ELISA buffer) were 
added and incubated with cells at 4 °C for 1 h.  Cells were washed with 3 sequential flushes (200 
µL/well) of with 0.05% Tween-20 (Fischer 9005-64-5) in PBS buffer (PBS-T).  To each well, 50 
µL of HRP-conjugated anti-human Fab-specific secondary antibody (Sigma A0293) prepared at 
1:10000 in ELISA buffer was incubated at 4 °C for 30 min.  Cells were washed, incubated with 
Ultra-TMB blotting solution (Thermo Scientific 37574, 100 µL/well) for 10 min at RT while 
shielded from light, quenched with 2N H2SO4 (100 µL/well), and absorbance read at 450 nm.  
All data are reported as blank corrected and normalized per cell. 
 
EGFR expression modulates cytotoxic activity in vitro 
In vitro cytotoxicity of DX-ADCs was performed on high EGFR expressing A431 
(EGFR+++), moderate EGFR expressing MDA-MB-468 (EGFR++), and low EGFR expressing 
U87MG (EGFR+) cell lines.  Briefly, cells were seeded at 5000 cells per well in 100 µL complete 
DMEM and incubated for 48 h at 37˚C and 5% CO2.  Media was aspirated and cells were treated 
with 50 µL of serially diluted DX-ADC prepared in complete DMEM and incubated at 37 °C.  In 
the pulse exposure assay, cells were exposed to treatment for 4 hours, aspirated and thoroughly 
washed, and incubated with complete DMEM for an additional 68 h.  Separately, cells were 
exposed to treatment continuously for 72 h.  Pulse-chase experiments were performed by 
incubating cells for 30 min with anti-EGFR mAb followed by 72 h incubation with the 
respective DX-ADC.  Cell viability was measured using the Promega CellTiter-Glo Luminescent 
Cell Viability Assay (G7571) following the supplied protocol.  Data were analyzed using the 
log(inhibitor) vs. response model and plotted using the log(inhibitor) vs. normalized response 
model in GraphPad PRISM 6. 
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In vivo stability and intracellular drug release studies 
The mechanism, rate, and extent of drug release from the DX-ADC was monitored at 
assay conditions that mimic various intracellular compartments encountered following receptor-
mediated endocytosis by the target cell.  DX-ADC (0.3 mL of 10 mg/mL stock) was incubated in 
10 mM glutathione (GSH) in 50 mM sodium acetate 1mM EDTA pH 5 buffer (acetate/EDTA 
buffer), acetate/EDTA buffer alone, and mouse plasma (168 h) to a final volume of 1 mL.  All 
mixtures were incubated at 37 °C and compared to stock DX-ADC in PBS pH 7.4.  Periodically, 
50 µL were removed and diluted with ice cold methanol (100 µL) to precipitate the protein.  The 
samples were centrifuged and supernatants were injected on the HPLC monitor at 265 nm for the 
formation of free DX and DX-prodrug over time.  Half-lives were calculated by calibration with 
DX peak areas from a standard curve of known DX concentrations.  Briefly, 20 µL of sample 
was injected and run at 1 mL/min on a gradient starting with 0.1% (v/v) TFA in ddH2O (solvent 
A) and 0.1% (v/v) TFA in ACN (solvent B) at a 95/5 ratio and ending at 0/100 solvent A/solvent 
B after 20 min.  Solvent B is held at 100% for 2 min to flush the column, at which time the 
column re-equilibrates at the stating 95/5 solvent A for 3 min before the next injection (total run 
time 25 min). 
 
Pharmacokinetics in healthy and tumor-bearing mice 
Athymic (nu/nu) mice 6-8 weeks old were randomized into 8 groups of 3 (24 mice total) 
and injected iv by tail vein with DX-ADC prepared at 2 mg/mL in PBS and dosed at 10 mg/kg 
mouse (approximately 200 µg/mouse, initial in vivo concentration estimated between 500 nM 
and 1 µM).  Separately, athymic (nu/nu) mice 6-8 weeks old were implanted with 1 x 106 A431 
cells (100 µL/mouse prepared at 1 x 107 cells/mL in D-PBS) in the rear flank by subcutaneous 
xenograft.  Tumors grew to approximately 150 mm3, at which time mice were randomized into 4 
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groups of 3-4 mice and administered 10 mg/kg PAN, CET, P-DX, or C-DX.  Approximately 10-
20 µL of blood was collected by tail nick in a 500 µL Eppendorf pre-treated with 2 µL 0.5 M 
EDTA.  The concentration or anti-EGFR mAb and ADCs was determined by ELISA (previously 
described) using a calibration curve with fresh PAN, CET, P-DX, and C-DX. 
 
Singe-dose efficacy in tumor-bearing mice 
Athymic (nu/nu) mice 6-8 weeks old were implanted with 1 x 106 A431 cells (100 
µL/mouse prepared at 1 x 107 cells/mL in D-PBS) in the rear flank by subcutaneous xenograft.  
Tumors grew to approximately 150 mm3, at which time mice were randomized into four groups 
of 3-4 mice and treated with 10 mg/kg DX-ADC or 10 mg/kg anti-EGFR mAb iv by tail vein 
injection.  Tumors were monitored for size (mm3) and mice were monitored for body weight (g).  
Mice were sacrificed when tumors exceeded 1 cm in any direction. 
 
Multi-dose efficacy study in tumor-bearing mice 
Athymic (nu/nu) mice 6-8 weeks old were implanted with 1 x 106 A431 cells (100 
µL/mouse prepared at 1 x 107 cells/mL in D-PBS) in the rear flank by subcutaneous xenograft.  
Tumors grew for three weeks, at which time mice were randomized into 9 groups of 6 mice and 
treated with DX-ADC administered iv by tail vein injection at 20 mg/kg (high dose, 
approximately 400 µg/mouse) or 5 mg/kg (low dose, approximately 100 µg/mouse) weekly for 
four weeks.  Tumors were monitored for size (mm3) and mice were monitored for body weight 
(g).  Mice were sacrificed when tumors exceeded 1 cm in any direction or body weight decreased 
by more than 20% or the initial weight.  
  190 
Results 
LC-DX prodrug synthesis and characterization 
 LC-DX was prepared to a yield of 65% by mass and characterized by NMR and RP-
HPLC. 
 
Figure 5-1. Synthesis of LC-DX prodrug from the LC-SPDP heterobifunctional linker 
 
 NMR spectra confirmed esterification of the 2’ hydroxyl of docetaxel with the LC-SPDP 
heterobifunctional linker.  LC-DX prepared at 250 µg/mL in acetonitrile (ACN) was assessed for 
purity by reverse-phase high-performance liquid chromatography (RP-HPLC).  Separately, 
samples of LC-DX were spiked with DX or LC-SPDP and run under the same conditions.  LC-
DX elutes at 15.9 min, whereas DX elutes at 14.4 min and the LC-SPDP linker elutes at 10.2 
min. Spiked samples of the LC-DX conjugate with free DX (Figure 4-XD) and free LC-SPDP 
(Figure 4-XE) confirmed peak identification and purity of the LC-DX prodrug (Figure 4-X). 
 
  191 
 
Figure 5-2. Chromatograms of DX (A), LC-SPDP linker (B), and LC-DX conjugate (C) by RP-
HPLC.  LC-DX (dashed line) was spiked with DX (solid line, D) or the LC-SPDP linker (dotted 
line, E) and analyzed by the same method.  All samples prepared at 250 µg/mL in ACN. 
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Cell viability following 72 h incubation of LC-DX was studied EGFR+++ A431 cells.  
Cytotoxicity was determined by measuring the concentration of LC-DX, compared to free DX 
and the LC-SPDP linker, that resulted in 50% cell viability (IC50).  The IC50 value of LC-DX was 
1083 nM, compared to 107.9 nM for DX and 40,000 nM for LC-SPDP. 
 
 
Figure 5-3. Cytotoxicity of the LC-DX prodrug (square, dashed line) compared to free DX 
(circle, solid line) and the LC-SPDP linker (triangle, dotted line) studied with A431 cells. 
 
The LC-DX prodrug is designed to remain stable during circulation at pH 7.4, yet rapidly 
cleave to release free DX once internalized by a cell and subjected to the low pH, high reducing 
environment characteristic of the late endosome and lysosome.  To further confirm formation of 
the esterified DX prodrug and evaluate its pH-sensitive liberation, LC-DX was prepared in 
buffers ranging from pH 4 to pH 7.4 and the % decrease of LC-DX in each buffer was quantified 
by RP-HPLC (Figure 4-X).  LC-DX demonstrates adequate stability at pH 7.4, showing less 
ell viability following 72 h incubation of LC-DX was studied EGFR+++ A431 cells.  
ytotoxicity as deter ined by easuring the concentration of L - , co pared to free DX and 
the LC-SPDP linker, that resulted in 50% cell viability (IC50).  The IC50 value of LC-DX was 1083 
nM, compared to 107.9 nM for DX and 40,000 nM for LC-SPDP. 
 
 
Figure 4-X. Cytotoxicity of the LC-DX prodrug (square, dashed line) compared to free DX (circle, 
solid line) and the LC-SPDP linker (triangle, dotted line) studied with A431 cells. 
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than 10% prodrug loss after 6 h and less than 25% after 24 h.  Contrarily, 24 h incubation at pH 
6, pH 5, and pH4 results in 65%, 50%, and 35% loss of the LC-DX prodrug, respectively. 
 
 
 
Figure 5-4. pH-sensitive hydrolysis of LC-DX.   
 
 The LC-DX hydrolysis study failed to produce a peak corresponding to free, liberated 
docetaxel, which was expected to elute at 14.4 min based on prepared standards.  We therefore 
studied whether the DX prodrugs were cleaving at the intended ester, to reproduce free docetaxel 
and free linker, or whether the decrease in LC-DX was attributed to other undesired degradation 
of the DX prodrugs or starting materials.  All starting materials were prepared in pure ACN or a 
50/50% (v/v) mixture of ACN/ddH2O to study the formation degradants over time.  DX prodrugs 
and starting materials were also subjected to treatment with 10 mM DTT for 30 min at 37 °C and 
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studied by RP-HPLC.  Compared to DX prodrug and linker prepared in the pure ACN, 
significant degradation was observed for the DX prodrugs and starting materials incubated in a 
50% ddH2O mixture, DX included.  The short chain SPDP linker and SC-DX prodrug, in 
particular, resulted in the formation of prominent non-DX peaks when studied by RP-HPLC.  
Treatment with high concentration DTT did not significantly accelerate degradation, but it did 
yield the formation of the pyridinesulfide (RT 3.25 min).  Fraction remaining of DX, SC-DX, 
SPDP, LC-DX, and LC-SPDP after 38 h treatment in 50% ddH2O with 10 mM DTT was 60%, 
30%, 65%, 55%, and 90%, respectively. 
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Figure 5-5. Degradation of DX-prodrugs.  DX (A), SPDP (B) and LC-SPDP (C), and DX 
prodrugs SC-DX (D) and LC-DX (E) were prepared in 50/50 (v/v) ACN/ddH2O and incubated at 
37 °C in the presence of 10 mM DTT for 38 h.  Degradation was monitored by RP-HPLC by 
determining the area under the curve for each peak greater than 50,000 mAU at 265 nm. 
 
SC-DX prodrug synthesis and characterization 
 SC-DX was prepared to a yield of 73% by mass and characterized by NMR and RP-
HPLC. 
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Figure 5-6. Synthesis of SC-DX prodrug from the SPDP heterobifunctional linker 
 
 NMR spectra confirmed esterification of the 2’ hydroxyl of docetaxel with the SPDP 
heterobifunctional linker.  SC-DX prepared at 250 µg/mL in acetonitrile (ACN) was assessed for 
purity by RP-HPLC.  Separately, SC-DX spiked with DX and SPDP were run under the same 
conditions.  SC-DX elutes at 16.8 min, whereas DX elutes at 14.4 min and the SPDP linker 
elutes at 10.8 min.  Spiked samples of SC-DX conjugate were spiked with free DX and free 
SPDP confirmed the peak identifications and purity of the SC-DX prodrug (data not shown). 
 
Thiolation of anti-EGFR panitumumab and cetuximab  
 Two different reaction schemes were evaluated to thiolate anti-EGFR mAbs.  An 
available free thiol on the mAb is essential for subsequent bioconjugation to the docetaxel 
prodrugs. 
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Figure 5-7. Reaction schemes covalently modify anti-EGFR mAbs PAN and CET with a 
dipyridyl disulfide containing docetaxel prodrug.  Scheme 1 relies on a thiolation step converting 
select lysine residues to free thiols with a heterobifunctional PEG linker, whereas Scheme 2 
relies on directly reducing mAb disulfides to free thiols.  The alkylation step is the same in both 
schemes. 
 
In the first approach (Scheme 1), anti-EGFR mAbs cetuximab and panitumumab were 
treated 3, 6, or 12 molar equivalents of NHS-PEG2000-SH per mole mAb for 1h at 4 °C, and 
molecular weight of the resulting conjugates was monitored by SDS-PAGE under native and 
reduced conditions.  Higher molecular weight species were not observed at the conditions 
studied.  High temperature treatment prior to electrophoresis caused complete fragmentation of 
both native and treated samples. 
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Figure 5-8. Time- and concentration-dependent modification of panitumumab with NHS-
PEG2000-SH at 4 °C.  PAN-SH (A and B) and CET-SH (C and D) conjugates were monitored by 
SDS-PAGE in reducing (A and C) and non-reducing (B and D) conditions. 
 
 Incubating 10, 50, and 200 molar equivalents of NHS-PEG2000-SH:mAb for 1 h at 37 °C 
successfully modified anti-EGFR mAb cetuximab at the 200 molar ratio conditions, albeit the 
fraction of higher molecular weight species was low compared to unmodified starting material.  
Panitumumab incubated with NHS-PEG2000-SH resulted in negligible changes in molecular 
weight (data not shown).  Samples were incubated at 40 °C or 60 °C prior to electrophoresis.  
High temperature treatment prior to electrophoresis appeared to fragment cetuximab. 
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Figure 5-9. Modification of cetuximab with NHS-PEG2000-SH monitored by SDS-PAGE under 
reducing (left) and non-reducing (right) conditions.  Molar ratio of NHS:mAb was studied for 
reactions carried at 37 °C. 
 
 Scheme 1 resulted in limited modification of the anti-EGFR mAbs panitumumab and 
cetuximab at all conditions studied.  Thus, a secondary approach to generate mAb free thiols was 
pursued (Scheme 2).  Anti-EGFR mAbs cetuximab and panitumumab were treated with a 
reducing agent and monitored for their thiol concentration using the Ellman assay. 
 
 
Figure 5-10. Common agents used to reduce mAb disulfide bonds: dithiothreitol (DTT), tris(2-
carboxyethyl)phosphine (TCEP), 2-mercaptoethylamine (2-MEA), and 2-mercaptoethanol (2-
ME), listed in order of reducing power. 
 
Panitumumab and cetuximab were treated with reducing agent for 1h at 37 °C.  DTT 
displayed the most reducing power of the agents studied.  CET was equally susceptible to 
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reduction with TCEP as DTT, but PAN resisted TCEP reduction.  Very high concentrations of 2-
MEA were needed to observe disulfide reduction in either PAN or CET.  2-ME did not reduce 
PAN or CET at the studied concentrations. 
 
 
Figure 5-11. Quantification of the number of free thiols on panitumumab (A) and cetuximab (B) 
following 1 h 37 °C incubation with DTT, TCEP, 2-MEA, or 2-ME.  Concentration of free thiols 
was determined by Ellman assay using a L-cysteine standard curve, and then converted to 
number. 
 
The production of free thiols on PAN and CET was most controlled and consistent – 
defined by modest changes in free thiol concentration over a broad molar ratio of reducing agent-
to-mAb – with the reducing agent TCEP.  For this reason, TCEP was selected as the preferred 
reducing agent for all subsequent reduction-alkylation reactions.  The impact of TCEP 
incubation time was studied by Ellman assay.  Higher ratios of TCEP:mAb produced more free 
thiols; however, longer incubation with TCEP did not increase free thiol concentration of either 
PAN or CET. 
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Figure 5-12. Time- and concentration-dependence on the disulfide reduction of cetuximab (A) 
and panitumumab (B) following incubation with the reducing agent TCEP.  Aliquots from three 
separate stocks were removed and free thiol concentration determined by Ellman assay. 
 
 Alkylation to available thiols on the mAb was initially studied using maleimide-activated 
PEG2000 and a non-specific mAb.  Non-specific mAb was reduced by TCEP at various 
TCEP:mAb molar ratios and immediately alkylated with maleimide-PEG2000.  Alkylation was 
performed by incubating reduced mAb with a constant 40:1 molar ratio of maleimide:mAb 
overnight at 4 °C in 100 mM PBS pH 7.2 buffer.  Maleimide reacts mAb thiols at pH 6.5-7.5 to 
form a stable thioether bond. 
 
 
Figure 5-13. PEGylation of mAb via reduction-alkylation.  MAb reduced with different molar 
ratios of TCEP was incubated for 2 h at 37 °C with 40:1 molar ratio maleimide-activated 
PEG:mAb and reacted overnight at 4 °C to form mAb-PEG conjugates. 
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Increasing the TCEP:mAb molar ratio and length of reducing time led to the generation 
of more and higher molecular weight mAb-PEG conjugates, as determined by the increasing 
molecular weight bands on the SDS-PAGE.  Reduction-alkylation results in a heterogeneous 
distribution of mAb-PEG conjugates. 
 
 
Figure 5-14. PEGylated mAb generated by reduction-alkylation of the mAb disulfides with 
maleimide-PEG2000.  Increasing time and TCEP:mAb molar ratio led to greater average MW of 
the mAb-PEG conjugates.  MW ladder in the non-labeled lanes. Lane B and P are native mAb; 
C, D, E and F were incubated with 3 molar equiv TCEP for 1.5, 3, 6, or 8 h, respectively; G, H, 
J, and K were incubated with 6 molar equiv TCEP for 1.5, 3, 6, or 8 h, respectively; L, N, Q and 
R were incubated with 12 molar equiv TCEP for 1.5, 3, 6, or 8 h, respectively; S, T, U and V 
were incubated with 24 molar equiv TCEP for 1.5, 3, 6, or 8 h, respectively; and W, X, Y, and Z 
were incubated with 48 molar equiv TCEP for 1.5, 3, 6, or 8 h, respectively. 
 
Alkylation of reduced disulfides was next extended to the anti-EGFR mAbs 
panitumumab and cetuximab.  PAN and CET treated with increasing concentrations of TCEP for 
1 h at 37 °C were alkylated with maleimide-PEG2000.  Increases in molecular weight following 
reduction-alkylation with PEG were monitored by SDS-PAGE.  Moreover, the free thiol content 
of mAbs were monitored using the Ellman assay.  Reduced samples without alkylating agent and 
samples treated with the facile thiol alkylating agent N-ethyl maleimide (NEM) were used as 
controls.  TCEP:CET molar ratios greater than 2 resulted in fragmentation of CET compared to 
PAN, which remained intact when treated with up to 8 molar equiv of TCEP.  CET-PEG 
conjugates were formed in high yield when CET is reduced with 2, 4, 6, or 8 molar equiv TCEP 
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and alkylated with 40 molar equiv mal-PEG.  Contrarily, significant unmodified fractions of 
PAN were observed after treatment with 6 or 8 molar equiv TCEP. 
 
 
Figure 5-15. PEGylation of cetuximab and panitumumab.  MAb was treated with 2, 4, 6, or 8 
molar equiv TCEP, reacted overnight with 40 molar equiv maleimide-PEG, and analyzed for 
increased molecular weight by SDS-PAGE. 
 
Figure 5-16. PEGylation of cetuximab and panitumumab.  MAb was treated with 2, 4, 6, or 8 
molar equiv TCEP, reacted overnight with 40 molar equiv maleimide-PEG, and analyzed for free 
thiol content by Ellman assay. 
 
Optimizing the antibody-docetaxel bioconjugation 
 Preparation of antibody-docetaxel conjugates (DX-ADCs) was investigated with the 
panel of reducing agents.  Following treatment with DTT, TCEP, or 2-MEA, select samples of 
reduced CET and PAN were alkylated with the 40 molar equivalents of LC-DX prodrug per 
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mole mAb for 48h at 4 °C (denoted with a *).  Non-alkylated samples served as a control to 
monitor the extent of disulfide reformation at the alkylating conditions. 
 
 
Figure 5-17. Number of free thiols formed after reduction (black bars) of CET (A, C, E) and 
PAN (B, D, F) incubated with DTT (A and B), TCEP (C and D), or 2-MEA (E and F).  Select 
samples were alkylated with LC-DX prodrug (denoted by a *).  The number of free thiols 
remaining after 48 h 4 °C incubation in alkylation buffer or with 40:1 molar ratio LC-DX 
prodrug to mAb (white bars).  Number of free thiols was determined by Ellman assay using a L-
cysteine standard curve. 
 
 Select samples alkylated with LC-DX prodrug were further characterized by SDS-PAGE 
and MALDI-TOF mass spectrometry.  No change in molecular weight was observed following 
LC-DX alkylation to reduced CET.  Contrarily, PAN molecular weight increased modestly 
following LC-DX alkylation.  PAN monomer (m/z = 1) increased from 147,797.797 Da to 
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148,265.234 Da following alkylation.  The m/z = 2 peak also increased from 74,001.555 Da to 
74,351.031 Da.  Moreover, a new peak was observed at 24,395.490 Da, a 1010 Da peak shift 
from the 23,385.522 peak observed with native PAN.  The molecular weight of LC-DX is 1118 
Da.  Thus, LC-DX was added to PAN with an average DAR of 0.8. 
 
 
Figure 5-18. Characterization of LC-DX alkylation to reduced CET and PAN by MALDI-TOF 
and SDS-PAGE.  Following alkylation, the observed molecular weight of the m/z =1 and m/z =2 
peaks for PAN increased.  No increase was observed for CET.  Non-reducing SDS-PAGE of 
partially reduced CET (C-J) and LC-DX alkylated CET (M) confirmed no appreciable changes 
from stock native CET (B), fully reduced CET (K) and CET fully reduced and alkylated (L).  
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Non-reducing SDS-PAGE of partially reduced PAN (P-V) and LC-DX alkylated CET (Y) 
confirmed no appreciable changes from stock native PAN (O), fully reduced CET (W) and CET 
fully reduced and alkylated (X). 
 
 Addition of the docetaxel prodrug to reduced CET or PAN caused rapid precipitation.  
Given the high solubility of docetaxel in DMSO, the solubility of LC-DX and SC-DX (data not 
shown) was investigated in a PBS using a DMSO co-solvent.  Once crossing a 40% (v/v) 
threshold, the solubility of a 1 mg/mL preparation of LC-DX increased rapidly with continued 
addition of DMSO to the PBS/DMSO co-solvent system.  Addition of polysorbate 80 (PS80), a 
widely-used solubilizing agent and component of the clinical docetaxel formulation Taxotere®, 
was also studied.   PS80 enhanced the solubility of LC-DX formulated with 0, 20, or 40% (v/v) 
DMSO but decreased the solubility of LC-DX formulated with 60 or 100 % (v/v) DMSO. 
 
 
Figure 5-19. Enhancing the solubility of DX prodrug in aqueous-organic co-solvent systems.  
LC-DX rapidly precipitated when exposed to aqueous solvent (A).  Addition of DMSO as a co-
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solvent enhanced solubility LC-DX (B).  PS80 increased solubility of LC-DX in formulations 
with less than 60% (v/v) DMSO (C). 
 
 Denaturation of mAbs can occur when exposed to high concentrations of organic solvent.  
To study the impact of DMSO exposure, cetuximab and panitumumab were incubated with 
increasing concentrations of DMSO at 37 °C.  After 1 h incubation, an aliquot was removed and 
assayed for retained affinity and specificity to EGFR by ELISA.  Exposure to 90% or 72% 
categorically eliminated binding of CET or PAN to EGFR overexpressing A431 cells.  CET 
exposed to 54%, 36%, or 18% (v/v) DMSO retained specificity and affinity, with an apparent Kd 
of 0.664, 0.537, and 0.529 nM, respectively, compared to 0.542 nM for CET in PBS.  PAN 
exposed to 54%, 36%, or 18% (v/v) DMSO retained specificity and affinity, with an apparent Kd 
of 0.727, 0.819, and 0.726 nM, respectively, compared to 0.893 nM for PAN in PBS.  PAN 
appeared more sensitive to DMSO, as EGFR binding at very low concentrations (< 100 pM) was 
decreased compared to control. 
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Figure 5-20. Binding affinity of anti-EGFR mAbs following DMSO exposure.  ELISA of PAN 
(A) and CET (B) incubated with 90, 72, 54, 36, 18, and 0% (v/v) DMSO in PBS for 1 h at 37 °C.  
Data were normalized to control to highlight concentration-dependent sensitivity of PAN (B) and 
CET (D) to DMSO exposure. 
 
 Both PS80 and DMSO were shown to increase the solubility of LC-DX and SC-DX in 
aqueous buffer.  Following disulfide reduction, panitumumab-docetaxel (P-DX) and cetuximab-
docetaxel (C-DX) conjugates were prepared either using a 1% PS80 buffer (Case 1) or 40% 
DMSO buffer (Case 2).  The resulting DX-ADCs were assessed for free thiol concentration, 
molecular weight, and retained binding to EGFR-overexpressing A431 cells. 
 
Preparation and characterization of DX-ADCs 
Eight unique anti-EGFR antibody-docetaxel conjugates (DX-ADCs) were prepared in 
three separate batches, each batch from fresh starting materials.  The resulting DX-ADCs were 
characterized for structural integrity, drug loading, and retained binding to EGFR-expressing 
0.819, and 0.726 nM, respectively, compared to 0.893 nM for PAN in PBS.  PAN appeared more 
sensitive to DMSO, as EGFR binding at very low concentrations (< 100 pM) was decreased 
compared to control. 
 
 
Figure 4-X. Binding affinity of anti-EGFR mAbs following DMSO exposure.  ELISA of PAN 
(A) and CET (B) incubated with 90, 72, 54, 36, 18, and 0% (v/v) DMSO in PBS for 1 h at 37 °C.  
Data were normalized to control to highlight concentration-dependent sensitivity of PAN (B) and 
CET (D) to DMSO exposure. 
 
 Both PS80 and DMSO were shown to increase the solubility of LC-DX and SC-DX in 
aqueous buffer.  Following disulfide reduction, panitumumab-docetaxel (P-DX) and cetuximab-
docetaxel (C-DX) conjugates were prepared either using a 1% PS80 buffer (Case 1) or 40% 
DMSO buffer (Case 2).  The resulting DX-ADCs were assessed for free thiol concentration, 
molecular weight, and retained binding to EGFR-overexpressing A431 cells (APPENDIX). 
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cells.  Reaction yield was determined by calculating the percent mass of anti-EGFR mAb 
recovered as the newly formed DX-ADC conjugate.  Significant differences in the reaction yield 
of DX-ADCs were not observed. 
 
Table 5-1. Reaction yield of-anti-EGFR ADCs 
DX-ADC components (TCEP:mAb ratio) Abbreviation Yield (% by mass) Avg ± St Dev 
Cetuximab 
LC-DX 
Low DAR (1.5) C-LC-DXlow 52.8 ± 16.6 
High DAR (2.75) C-LC-DXhigh 39.2 ± 13.7 
SC-DX 
Low DAR (1.5) C-DXlow 48.4 ± 7.94 
High DAR (2.75) C-DXhigh 40.1 ± 9.23 
Panitumumab 
LC-DX 
Low DAR (8) P-LC-DXlow 49.5 ± 13.1 
High DAR (24) P-LC-DXhigh 41.8 ± 12.3 
SC-DX Low DAR (8) P-DXlow 54.5 ± 12.6 
High DAR (24) P-LC-DXhigh 46.3 ± 9.71 
 
 At various steps during antibody-docetaxel bioconjugation, aliquots were assayed for free 
thiol concentration using the Ellman assay and changes in size by SDS-PAGE using a molecular 
weight ladder.  PAN was consistently more resistant to TCEP treatment than CET.  In fact, 
treatment of CET with more than 2 molar equiv TCEP resulted notable formation of low 
molecular weight species.  Subsequent alkylation of modestly reduced CET led to the 
reappearance of the molecular weight band corresponding to intact CET.  Alkylation of DX 
prodrugs does not lead to observable molecular weight changes by SDS-PAGE.  These data were 
consistent among the three separate batches; therefore, one batch is presented as a representative 
data set  
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Figure 5-21. Preparation and characterization of anti-EGFR ADCs.  Aliquots of PAN (A and C) 
and CET (B and D) were collected during the bioconjugation and studied for changes in 
molecular weight (A and B) and free thiol concentration (C and D).   
 
Due to the low level sensitivity of SDS-PAGE to small molecular weight changes on very 
large molecules such as mAb, MALDI-TOF mass spectrometry was employed to study 
molecular weight changes, and by extension, DX prodrug alkylation to DX ADCs.  DX ADCs 
were prepared in pure water and crystals formed by dilution into saturated sapienic acid.  DAR 
of DX-ADCs were determined by studying shifts in the three characteristic peaks of the MALDI-
TOF spectra of PAN and CET: m/z =1 species (~ 150 kDa), a m/z – 2 species (~ 75 kDa), and 
the m/z = 6 species (~ 25 kDa).  Under identical bioconjugation conditions, CET reduced with 
high TCEP (2.75 molar equiv) resulted in greater molecular weight gains than CET reduced with 
low TCEP (1.5 molar equiv).  At low and high reducing conditions, respectively, C-DX was 
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prepared to an average DAR of 1.92 and 2.88, and C-LC-DX was prepared to an average DAR 
1.97 and 2.54.  
 
 
Figure 5-22. MALDI-TOF of CET and anti-EGFR ADC C-DX reduced with either low or high 
concentration TCEP and alkylated with the SC-DX prodrug. 
 
 
Figure 5-23. MALDI-TOF of CET and anti-EGFR ADC C-LC-DX reduced with either low or 
high concentration TCEP and alkylated with the LC-DX prodrug. 
 
 On the other hand, under identical bioconjugation conditions, PAN reduced with high 
TCEP (24 molar equiv) was indistinguishable from PAN reduced with low TCEP (8 molar 
equiv).  P-DX was prepared to an average DAR 3.07 or 3.06 with low and high reducing 
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conditions, respectively.  Likewise, at low and high reducing conditions P-LC-DX was prepared 
to an average DAR of 2.98 or 2.92 respectively. 
 
 
Figure 5-24. MALDI-TOF of PAN and anti-EGFR ADC P-DX reduced with either low or high 
concentration TCEP and alkylated with the SC-DX prodrug. 
 
 
Figure 5-25. MALDI-TOF of PAN and anti-EGFR ADC P-LC-DX reduced with either low or 
high concentration TCEP and alkylated with the LC-DX prodrug. 
 
 Following synthesis of the conjugates, DX ADCs were characterized for retained binding 
affinity and specificity by whole-cell ELISA to a panel of EGFR-expressing human cancer cell 
lines. 
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Figure 5-26. Saturation binding of cetuximab DX-ADCs (A, B, and C) and panitumumab DX-
ADCs (D, E, and F) with EGFR+++ A431 (A and D), EGFR++ MDA-MB-468 (B and E), and 
EGFR+ U87MG cells (C and F).  Data were used to determine the equilibrium dissociation 
constant (Kd) using the one-site specific binding model in GraphPad PRISM 6. 
 
 Modest changes (no more than 2.3-fold) to the equilibrium dissociation constant (Kd) 
were observed when DX ADCs were incubated with EGFR+++ A431 cells.  P-DX and P-LC-
DX showed slightly larger decreases in binding affinity than C-DX and C-LC-DX, perhaps due 
to drug loading, but differences were not observed between the low and high DAR species. 
 
 
 
 
 
 
Figure 4-X. MALDI-TOF of PAN and anti-EGFR ADC P-LC-DX reduced with either low or high 
concentration TCEP and alkylated with the LC-DX prodrug. 
 
 Following synthesis of the conjugates, DX ADCs were characterized for retained binding 
affinity and specificity by whole-cell ELISA to a panel of EGFR-expressing human cancer cell 
lines. 
 
Figure 4-X. Saturation binding of cetuximab DX-ADCs (A, B, and C) and pantitumumab DX-
ADCs (D, E, and F) with EGFR+++ A431 (A and D), EGFR++ MDA-MB-468 (B and E), and 
EGFR+ U87MG cells (C and F).  Data were used to determine the equilibrium dissociation 
constant (Kd) using the one-site specific binding model in GraphPad PRISM 6. 
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Table 5-2. Equilibrium dissociation constant (Kd) of DX-ADCs determined by saturation 
binding to EGFR+++ A431 cells using whole-cell ELISA 
ADC DAR Kd (nM) 
Fold-increase 
(Kd,mAb / Kd,DX-ADC) 
CET 0 2.07  
C-DXlow 1.92 2.13 1.03 
C-DXhigh 2.88 2.13 1.03 
C-LC-DXlow 1.97 1.78 0.86 
C-LC-DXhigh 2.54 1.44 0.70 
 
PAN 0 0.883  
P-DXlow 3.07 1.76 1.99 
P-DXhigh 3.05 1.79 2.03 
P-LC-DXlow 2.98 2.02 2.29 
P-LC-DXhigh 2.92 1.94 2.20 
 
Cytotoxicity of DX-ADCs was assessed on a panel of cell lines exhibiting various levels 
of EGFR expression after 4 h exposure (pulse) or 72 h exposure (continuous).  First, EGFR+++ 
A431 cells were exposed to panitumumab (PAN), docetaxel conjugates of panitumumab (P-DX 
and P-LC-DX), cetuximab (CET), docetaxel conjugates of cetuximab (C-DX and C-LC-DX) for 
4 h and then assayed for cell viability 68 h later.  Differences in cell viability were observed 
between treatments and controls for panitumumab-docetaxel conjugates (p<0.030) and 
cetuximab-docetaxel conjugates (p<0.003).  The short-chain docetaxel conjugates P-DXlow (p < 
0.035) and P-DXhigh (p<0.038) were found to exhibit greater toxicity to A431 cells than PAN, 
but differences were not observed between the long-chain derived P-LC-DX and PAN.  
However, C-DXlow (p < 0.006), C-DXhigh (p<0.005), C-LC-DXlow (p <0.018), and C-LC-DXhigh 
(p<0.008) each exhibited greater activity than CET alone on A431 cells.  Drug loading did not 
increase cytotoxicity of the short chain P-DX conjugates (p=0.543) or the long chain P-LC-DX 
conjugates (p=0.864).  The same was observed for the long chain C-LC-DX conjugates 
(p=0.065), but a difference was observed between the high and low DAR short chain C-DX 
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conjugate (p=0.044).  Differences between cytotoxicity of conjugates loaded with either the SC-
DX prodrug or the LC-DX prodrug were observed high DAR panitumumab-docetaxel 
conjugates (p=0.0437), low DAR panitumumab-docetaxel conjugates (p=0.0492), and high DAR 
cetuximab-docetaxel conjugates (p=0.045), but not between the low DAR cetuximab-docetaxel 
conjugates (p=0.0581).  Cytotoxicity of each mAb and DX-ADC was determined by measuring 
the concentration of mAb and mAb-DX that resulted in 50% cell viability (IC50). 
 
 
Figure 5-27. Cytotoxicity of anti-EGFR antibody-docetaxel conjugates.  Panitumumab (PAN) or 
cetuximab (CET), short-chain DX-ADCs (P-DX or C-DX), or long-chain DX-ADCs (P-LC-DX 
or C-LC-DX) were exposed to EGFR+++ A431 cells for 4 h and assayed at 72 h for cell viability.  
Cytotoxicity was plotted as % cell viability and normalized to an untreated control. 
 
Table 5-3. IC50 values (nM) of anti-EGFR antibody-docetaxel conjugates following 4 h 
treatment with EGFR+++ A431 cells 
Panitumumab 
native 4682 ± 3428 
-DX low DAR 202.8 ± 106.7 high DAR 265.9 ± 125.8 
-LC-DX low DAR 1053 ± 444.1 high DAR 1118 ± 426.8 
Cetuximab 
native 3671 ± 1960 
-DX low DAR 233.3 ± 96.89 high DAR 128.6 ± 57.77 
-LC-DX low DAR 782.0 ± 335.3 high DAR 375.8 ± 148.1 
 
greater activity than CET alone on A431 cells.  Drug loading did not increase cytotoxicity of the 
short chain P-DX conjugates (p=0.543) or the long chain P-LC-DX conjugates (p=0.864).  The 
same was observed for the long chain C-LC-DX conjugates (p=0.065), but a difference was 
observed between the high and low DAR short chain C-DX conjugate (p=0.044).  Differences 
between cytotoxicity of conjugates loaded with either the SC-DX prodrug or the LC-DX prodrug 
were observed high DAR panitumumab-docetaxel conjugates (p=0.0437), low DAR 
panitumumab-docetaxel conjugates (p=0.0492), and high DAR cetuximab-docetaxel conjugates 
(p=0.045), but not between the low DAR cetuximab-docetaxel conjugates (p=0.0581).  
Cytotoxicty of each mAb and DX-ADC was determined by measuring the concentration of mAb 
and mAb-DX that resulted in 50% cell viability (IC50). 
 
 
igure 4-X. ytotoxicity of anti- F  antibody-docetaxel conjugates.  Panitu umab (PAN) or 
cetuximab (CET), short-chain DX-ADCs (P-DX or C-DX), or long-chain DX-ADCs (P-LC-DX 
or C-LC-DX) were exposed to EGFR+++ A431 cells for 4 h and assayed at 72 h for cell viability.  
Cytotoxicity was plotted as % cell viability and normalized to an untreated control. 
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Combined data from MALDI-TOF, SDS-PAGE, Ellman assay, and cytotoxicity strongly 
suggested there was no difference in drug loading between the “high” and “low” panitumumab 
DX-ADCs.  Therefore, stocks of P-DXlow and P-DXhigh were pooled, as were stocks of P-LC-
DXlow and P-LC-DXhigh.  In preparation for in vivo PK and efficacy studies, DX-ADCs were 
analyzed for aggregation, changes in molecular weight, and retained EGFR-specific binding 
following 2-week storage in PBS at 4 ˚C.  MALDI-TOF confirmed no change in molecular 
weight. 
 
Table 5-4. Determination of DAR by MALDI-TOF immediately following synthesis and again 
after 14-day storage in PBS at 4 ˚C 
ADC DAR0 DAR14 
DAR0 – DAR14 
(% loss) 
C-DXlow 1.92 1.97 (2.62) 
C-DXhigh 2.88 2.60 9.60 
C-LC-DXlow 1.97 1.92 2.64 
C-LC-DXhigh 2.54 2.57 (1.26) 
 
P-DXlow 3.07 2.95 ~ 3.7 P-DXhigh 3.05 
P-LC-DXlow 2.98 3.06 ~ (3.6) P-LC-DXhigh 2.92 
 
When analyzed by SE-HPLC, a small fraction of aggregates (<2%) were observed.  Some 
lower molecular weight species were also observed, particularly for DX-ADCs prepared with 
LC-DX, as noted by the shoulder to the right of the main peak in the chromatograms.  These 
artifacts were minor relative to the main peak.  The retention time of DX conjugates did not 
change compared to native PAN and CET. 
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Figure 5-28. SE-HPLC chromatograms of P-DX, P-LC-DX, and the high DAR conjugates of C-
DX and C-LC-DX demonstrated that the DX-ADCs remained both monomeric and intact during 
14-day storage at 4 ˚C. 
 
Pharmacokinetics of the anti-EGFR mAb-DX conjugates were studied in healthy mice.  
No differences were observed between native PAN, P-DX, and P-LC-DX, nor were differences 
observed between CET and its DX-conjugates.  CET and its DX-conjugates cleared modestly 
faster than PAN and its DX-conjugates. 
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Figure 5-29. 14-day pharmacokinetic profile of anti-EGFR mAb-DX conjugates of 
panitumumab (A) or cetuximab (B) in healthy mice.  Mice (3 per group) dosed with 10 mg/kg 
mAb or DX-ADC and assayed for circulating blood concentration at 1, 4, 24, 48, 96, 168, 240, 
and 336 h.  Data were collected by tail nick and blood concentration determined by ELISA using 
a calibration curves with fresh PAN, CET and DX-ADCs. 
 
In vitro cytotoxicity and specificity of EGFR-DX ADCs  
 EGFR+++ A431 cells and EGFR+ U87MG cells were treated with DX-ADCs to study the 
relationship between EGFR expression and cytotoxicity of the DX-ADC.  P-DX was more than 
5-fold more potent in EGFR+++ A431 cells compared to EGFR+ U87MG cells; C-DX was 3-fold 
more potent in EGFR+++ A431 cells compared to EGFR+ U87MG cells.  In the same experiment, 
docetaxel demonstrated EGFR-independent cytotoxic activity.  Differences among groups were 
significant (p<0.0001).  While differences were observed between DX and P-DX (p<0.0001) and 
DX and C-DX (p=0.0453) in U87MG low-EGFR-expressing cells, no differences were observed 
between DX and P-DX or C-DX in A431 high-EGFR-expressing cells.  Moreover, significant 
differences in cytotoxicity were observed for P-DX(p=0.012) and C-DX (0=0.007) when 
incubated with low or high-EGFR expressing cells, but DX exhibited comparable effects on both 
cells lines (p=0.504). 
 
 
  219 
 
Figure 5-30. Cytotoxic activity of anti-EGFR antibody-docetaxel conjugates is EGFR-
dependent, whereas cytotoxic activity of docetaxel alone is not.  EGFR+++ A431 cells (solid lines) 
treated with anti-EGFR P-DX (blue) or anti-EGFR C-DX (green) were more susceptible to the 
DX-ADCs than EGFR+ U87MG (dotted lines) at equal conjugate doses.  Contrarily, docetaxel 
(red) exhibits EGFR-independent cytotoxicity.  Cytotoxicity was plotted as % cell viability and 
normalized to an untreated control. 
 
The EGFR specificity ratio, calculated as the IC50 on EGFR+ U87MG divided by the IC50 
on EGFR+++ A431 cells, and cytotoxicity of each mAb-DX conjugate is listed in Table X. 
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Table 5-5. IC50 values (nM) and the EGFR specificity ratio of anti-EGFR antibody-docetaxel 
conjugates following 4 h treatment with EGFR+ U87MG or EGFR+++ A431 cells 
 U87MG (EGFR
+) 
(nM) 
A431 (EGFR+++) 
(nM) EGFR specificity ratio* 
P-DX (4 h) 1040 ± 125.8 202.8 ± 106.7 5.13 
C-DX (4 h) 433.4 ± 23.5 128.6 ± 57.77 3.37 
DX (72 h) 104.0 ± 38.01 212.4 ± 270.0 0.490 
* calculated by dividing the IC50 (nM) determined in EGFR+ U87MG cells by the IC50 (nM) 
determined in EGFR+++ A431 cells 
 
 Differences in cytotoxicity were significant among anti-EGFR ADCs incubated with 
EGFR+++ A431 cells for 4 h (p<0.0001) or 72 h (p<0.0001).  Anti-EGFR P-DX conjugates 
exposed A431 cells for either 4 h (p=0.956) or 72 h (p=0.847) exhibited equal cytotoxicity as 
DX exposed to A431 cells for 72 h, but a significant difference was observed between PAN and 
DX incubated for 72 h (p=0.001).  Likewise, cytotoxicity differences were not observed between 
anti-EGFR C-DX conjugates exposed to A431 cells for either 4 h (p=0.630) or 72 h (p=0.401) 
compared to DX exposed to A431 cells for 72 h, but a significant difference was observed 
between CET and DX incubated for 72 h (p=0.003).  Extending the exposure time of C-DX 
(p=0.215) or P-DX (0.891) conjugates with A431 cells did not improve cytotoxic activity.  
 
Table 5-6. IC50 values (nM) of anti-EGFR antibody-docetaxel conjugates following 4 h or 72 h 
treatment with EGFR+++ A431 cells 
 DX 
(nM) 
PAN 
(nM) 
P-DX 
(nM) 
CET 
(nM) 
C-DX 
(nM) 
4 h 
 4683 ± 3428 202.8 ± 106.7 3672 ± 1960 128.6 ± 57.77 
72 h 212.4 ± 270.0 4213 ± 489.3 220.7 ± 207.5 4391 ± 123.0 71.08 ± 38.78 
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Figure 5-31. PAN and CET ADC cytotoxicity on EGFR+++ A431 cells.  P-DX (blue) and C-DX 
(green) were exposed to EGFR+++ A431 cells for 4 h (dotted lines) or 72 h (solid lines).  
Cytotoxicity was plotted as % cell viability and normalized to an untreated control. 
 
In vivo efficacy and PK of EGFR-DX ADCs in EGFR-positive tumor-bearing mice 
 EGFR-DX ADCs were evaluated for in vivo efficacy in separate single-dose and multi-
dose studies with mice bearing EGFR+++ A431 tumors.  Prior to initiating those studies, anti-
EGFR antibody-docetaxel conjugates P-DX and C-DX were evaluated for retained EGFR 
binding affinity to A431, MDA-MB-468, and U87MG cells  
 
 
Figure 4-X. PAN and CET ADC cytotoxicity on EGFR+++ A431 cells.  P-DX (blue) and C-DX 
(green) were exposed to EGFR+++ A431 cells for 4 h (dotted lines) or 72 h (solid lines).  
Cytotoxicity was plotted as % cell viability and normalized to an untreated control. 
 
In	vivo	efficacy	and	PK	of	EGFR-DX	ADCs	in	EGFR-positive	tumor-bearing	mice	
 EGFR-DX ADCs were evaluated for in vivo efficacy in separate single-dose and multi-
dose studies with mice bearing EGFR+++ A431 tumors.  Prior to initiating those studies, anti-EGFR 
antibody-docetaxel conjugates P-DX and C-DX  were evaluated for retained EGFR binding 
affinity to A431, MDA-MB-468, and U87MG cells  
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Figure 5-32. Saturation binding of anti-EGFR ADCs to EGFR+++ A431 (A), EGFR++ MDA-MB-
468 (B), and EGFR+ U87MG (C) cells by ELISA.  
 
 Saturation binding curves of anti-EGFR ADCs overlapped their respective native CET 
and PAN saturation binding curves.  With EGFR+++ A431 cells, equilibrium dissociation 
constant (Kd) was determined to be 0.139 nM for CET and 0.325 nM for PAN, compared to 
0.237 nM for C-DX and 0.272 nM for P-DX.  These values were consistent with the Kd 
determined using the MDA-MB-468 cells.  The Kd for U87MG could not be determined.  
After confirming retained affinity to EGFR-overexpressing cells, anti-EGFR ADCs were 
dosed at 10 mg/kg and studied for their tumor growth inhibition.  After 7 days, the single dose 
anti-EGFR ADCs do not appear to exhibit any antitumor effects.  There appears to be no 
difference between the anti-EGFR ADCs and their respective unconjugated mAb, nor head-to-
head between P-DX and C-DX.  This study is on-going. 
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Figure 5-33. Single dose efficacy of P-DX and C-DX in A431 tumor-bearing mice.   
 
 To evaluate the antitumor activity and durability of response to the anti-EGFR ADCs, a 
multi-dose study was designed to evaluate P-DX and C-DX against controls at both a low dose 
(10 mg/kg) and high dose (100 mg/kg).  Mice bearing A431 tumor were dosed with 10 mg/kg or 
100 mg/kg, and measurements of tumor size, body weight, and survival were collected.  After 3 
of 4 doses administered in the study, P-DX and C-DX at 100 mg/kg provide dramatic tumor 
growth inhibition compared to the 10mg/kg dose, equimolar DX dose, and saline control.  C-DX 
in particular, which demonstrated higher in vitro activity, appears to provide modest tumor 
regression compared to controls.  For both anti-EGFR ADCs, the unconjugated mAb alone as 
well as mixture unconjugated mAb + docetaxel at equimolar doses of the ADC provide tumor 
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growth inhibition.  This study is on-going, and it remains to be seen whether the anti-EGFR 
ADCs can separate from controls over the long term. 
 
 
Figure 5-34. Multi-dose efficacy of P-DX and C-DX ADCs administered at low dose (10 
mg/kg) or high dose to A431 tumor-bearing mice. 
 
In addition to studying efficacy, the pharmacokinetics of anti-EGFR ADCs were studied 
in tumor-bearing mice.  A431 tumor-bearing mice dosed with 10 mg/kg PAN or P-DX showed 
near equal elimination rates; however, the concentrations of PAN and P-DX were significantly 
reduced compared to the circulating concentrations in healthy mice.  Contrarily, the circulating 
concentration of C-DX was significantly lower than CET when dosed at 10 mg/kg to A431 
tumor-bearing mice dosed.  While the CET largely followed the same PK profile in A431 tumor-
bearing mice as in healthy mice, the PK profile of C-DX in A431 tumor-bearing mice was 
reduced by approximately one order of magnitude.  This study is on-going. 
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Figure 5-35. 14-day pharmacokinetic profile of anti-EGFR P-DX (A) and C-DX (B) in A431 
tumor-bearing mice. 
  
  226 
Discussion 
Panitumumab and cetuximab are FDA-approved mAb therapies indicated for metastatic 
colorectal, breast, and other EGFR-overexpressing cancers.  As monotherapy, neither 
demonstrates consistent and durable antitumor efficacy; however, when combined with an 
additional chemotherapy like docetaxel, patient outcomes significantly improve.  To this end, we 
studied the effect of directly conjugating docetaxel to the anti-EGFR mAbs panitumumab and 
cetuximab.  We hypothesized and demonstrated the resulting conjugate exhibit antigen-
dependent activity, thereby improving the selectivity of docetaxel to EGFR-expressing cells.  
Given the modest potency of docetaxel and moderate drug loading (DAR 2-3) of the ADCs, we 
did not anticipate observing significantly improved activity in vivo compared to controls.  
However, these proof-of-concept studies encourage further investigation of EGFR-targeted 
ADCs carrying higher potency payloads.  
The short chain docetaxel prodrug (SC-DX) and long chain docetaxel prodrug (LC-DX) 
were more hydrophobic than either docetaxel or the linker.  RP-HPLC showed that conversion of 
the 2’-hydroxyl of docetaxel during synthesis of the SC-DX prodrug increased the 
hydrophobicity of the docetaxel, eluting later in the method at higher organic concentrations.  
The same behavior was observed during the LC-DX synthesis. The SPDP and LC-SPDP linkers 
elute before docetaxel due to the hydrophilic nature of the N-hydroxysuccinimide active ester 
leaving group, which is liberated following esterification of DX.  By elution time on the RP-
HPLC method, the SC-DX prodrug proved to be slightly more hydrophobic than the LC-DX 
prodrug. 
Bioconjugation of LC-DX and SC-DX prodrugs was accomplished using the stepwise 
reduction of PAN or CET disulfide bonds followed by alkylation of the mAb free thiols with the 
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pyridyl disulfide leaving group of the DX prodrug.  The linker bridging DX to the cysteine 
residue of PAN or CET contains two covalent yet cleavable bonds: an ester between DX and the 
linker, and a disulfide between the linker and the mAb.  We hypothesized that the disulfide bond 
would demonstrate greater lability in vivo than the ester, given the strong reducing environment 
within cells and high circulating concentration of the cysteine-containing albumin (typically > 40 
mg/mL) in the blood.  Cleavage of the disulfide bond before hydrolysis of the ester would yield a 
thiolated version of the LC-DX or SC-DX prodrug.  Therefore, cytotoxicity of the prodrugs was 
studied to assess antitumor activity following reduction of the disulfide, as well as identify 
potential safety liabilities that would be incurred due to premature disulfide cleavage and LC-DX 
release during circulation and prior to accumulation at the tumor.  The cytotoxicity SC-DX and 
LC-DX were found to be 10-fold less potent (IC50 ~ 1 µM) than DX (IC50 ~ 100 nM) in vitro, 
likely due to altered DX binding affinity to the microtubules or differences in cell uptake and 
trafficking behavior by cancer cell. 
Synthesis of the anti-EGFR ADCs required optimization of mAb reduction and DX 
prodrug alkylation in conditions amenable to both the DX prodrug and mAb.  Attempts to 
thiolate the mAb by EDC/NHS coupling with a thiol-capped PEG2000 chain resulted in modest 
alkylation, even at conditions 200:1 NHS:mAb.  This approach was studied, though ultimately 
discontinued, due to the low yields in preliminary experiments and non-specific nature of 
bioconjugation to solvent-exposed, chemically reactive mAb lysine residues, of which there are 
of 40-80 in mAb.  Although more common, the NHS-lysine bioconjugation is generally not 
favored, particularly if higher quality conjugation methods are available.  Former studies 
elegantly demonstrated a stepwise reduction-alkylation process of the mAb interchain disulfides 
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[192], which has been shown to yield more homogenous antibody-drug conjugates with 
modifications at less disruptive locations [116]. 
DX bioconjugation to PAN or CET was performed following the general stepwise 
reduction-alkylation protocol.  With no prior literature precedent found, significant effort was 
spent optimizing conditions of the protocol with the primary goal of consistent and predictable 
drug-loading.  First, cetuximab and panitumumab were exposed to various reducing agents 
across a wide range of concentrations.   The mAbs displayed drastically different susceptibility 
to disulfide reduction.  While thiols formed at near stoichiometric ratios during DTT or TCEP 
treatment of CET, PAN was largely resistant to disulfide reduction, requiring an order of 
magnitude more TCEP than CET to yield the same thiol concentration as determined by Ellman 
assay.  TCEP offered the most control over the widest range of concentrations for both mAbs 
and was selected as the reducing agent for the studies.  Effect of time, temperature, and buffer 
were studied to establish the reduction conditions of 1 h at 37 ˚C in borate buffer pH 8.1.  Next, 
studies were performed to determine the precise molar ratio of TCEP-to-mAb that could generate 
a low DAR species (target DAR 1.5) and high DAR species (target DAR 4).  CET and PAN 
were reduced with increasing concentrations of TCEP and assayed for thiol concentration as well 
as studied for intact structure by SDS-PAGE.  Fragmentation of CET was concentration 
dependent and first observed above 1.5 molar equiv of TCEP.  PAN remained wholly intact at 
TCEP concentrations as high as 100 molar equiv, and any number of thiols from 0 to 32 could be 
produced, however PAN rapidly reformed its disulfide bonds after purifying the reduced mAb 
from the reducing agent.  Differences in reducing behavior of the IgG1 cetuximab and IgG2 
panitumumab to were likely a result of their unique disulfide structures [349]. 
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Alkylation was first studied using maleimide-activated methoxy-PEG2000 (mal-PEG-
OCH3) to reduced PAN and CET.  These studies set out to define conditions like time, 
temperature, and molar ratio of alkylating agent to mAb free thiol during preliminary studies, as 
the maleimide reaction with mAb thiol creates a covalent, noncleavable thioether, and the 
reaction mixture can be characterized by SDS-PAGE under reducing conditions to qualitatively 
assess extent of alkylation and distribution of species.  However, these studies failed to inform 
the ideal reaction conditions with the DX conjugates.  In fact, the ideal conditions for the mal-
PEG-OCH3 resulted in undetectable alkylation of DX prodrug to the mAb, likely due to the low 
aqueous solubility of the DX prodrugs. 
Thus, two approaches to increasing the aqueous solubility of DX prodrugs were studied, 
and the winner was deemed as the approach the led to consistent and predictable DX prodrug 
loading to the mAb.  Given the high solubility of the DX prodrugs in DMSO, we hypothesized 
adding DMSO to the alkylation buffer could improve the solubility of DX prodrug.  A 1 mg/mL 
stock of DX prodrug was completely insoluble until the DMSO co-solvent reached 40% (v/v), at 
which point the solubility increased dramatically.  DMSO is widely used in other chemical 
conjugations, with some regularly use at low-to-moderates concentrations in select ADC 
preparations.  Separately, DX prodrug solubility was studied as a function of polysorbate 80 
concentration in a series of DMSO co-solvent alkylation buffer.  Polysorbate 80 is a widely used 
solubilizing agent and one of the additives to the clinical formulation of docetaxel, Taxotere®.  
Given its use in the Taxotere® formulation, we hypothesized polysorbate 80 or polysorbate 80 in 
a DMSO co-solvent solution could improve the aqueous solubility of the DX prodrugs.  
Solubility of a 1 mg/mL stock of DX prodrug steady increased with PS80 concentration; 
however, buffers with high concentration DMSO co-solvent saw a steady decrease in solubility 
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as PS80 increased, perhaps due to saturation and phase separation of the DX prodrug in the 
complex fluid.  After repeated batch head-to-head studies starting from fresh material, 
bioconjugation of DX to reduced PAN and CET with the DMSO cosolvent resulted in higher and 
more consistent drug loading than bioconjugation in the PS80 buffer.  All subsequent ADC 
preparations were carried out following the optimized protocol. 
Synthesis of the CET-DX and PAN-DX conjugates was fickle, but repeated trials resulted 
in more predictable and more consistent DX loading.  Bioanalytical characterization 
demonstrated that PAN-DX conjugates were prepared with an average DAR of 3.05, with no 
difference between the high (n=24) and low(n=8) reducing conditions.  CET-DX conjugates 
were prepared with an average DAR of 1.9 or 2.9 for the low (n=1.5) and high (n=2.75) reducing 
conditions, respectively.  All conjugates remained intact and retained EGFR-specificity and 
affinity compared to unconjugated mAb.  Reduced DX loading and ADC yield was observed 
during batch scale-up for in vivo studies.  This was addressed by performing multiple small batch 
bioconjugations in parallel, and then pooling the resulting mixtures for purification and 
characterization. 
We hypothesized that the in vitro cytotoxicity of DX-ADCs would directly correspond to 
the level of EGFR expression by the cell, where A431 cells (EGFR+++) would exhibit greater 
susceptibility to cell death than MDA-MB-468 cells (EGFR++) and U87MG cells (EGFR+).  DX 
incubated with very-low EGFR expressing U87MG cells or very high EGFR-expressing A431 
cells for 72 h exhibited near identical cytotoxicity.  Contrarily, once covalently conjugated to 
anti-EGFR mAbs PAN or CET, DX exhibited significantly lower activity on U87MG cells yet 
retained activity against A431 cells.  The shift in IC50 curves corresponded with antigen-density 
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on the surface of the cancer cell and provides strong evidence of the role of EGFR in mediating 
cell-specific activity  
 It was also hypothesized that ADCs carrying more DX (high DAR) would exhibit greater 
potency than ADCs with less drug (low DAR).  Numerous studies demonstrate a ADCs with 
higher DAR result in higher cytotoxicity in vitro, presumably due to enhanced intracellular 
delivery of drug to the target cell.  Because the bioanalytical studies determined no difference in 
drug loading between the high and low reducing conditions of PAN ADCs, different in vitro 
cytotoxicity were not expected when the conjugates were screened for in vitro cytotoxicity, and 
this was confirmed.  However, characterization of the CET ADCs did show differences in drug 
loading (2.9 compared to 1.9 for C-DX, and 2.5 compared to 1.9 for C-LC-DX).  While no 
difference was observed between he low and high DX-loaded C-LC-DX ADCs, high DAR C-
DX proved to be more potent than low DAR C-DX.  This important finding confirmed the 
bioanalytical data and provided critical indirect evidence linking cell cytotoxicity to the amount 
of DX delivered to the cell. 
 Finally, due to the specific, high-affinity nature of interaction between the ADC and the 
EGFR-expressing cancer cell, we hypothesized that longer cell incubations with ADC would not 
significantly improve cytotoxicity.  By the proposed mechanism of cytotoxicity, only the DX 
associated with the mAb, bound to the cell surface, internalized, and subsequently released will 
exhibit toxicity.  Incubation for 4 h allows sufficient time for the ADC to engage EGFR on the 
target cell, and increased cytotoxicity after 72 h compared to 4 h could indicate DX drug release 
from unbound ADC during incubation, non-antigen mediated activity, or DX impurities in the 
final ADC preparation.  Instead, no difference in cytotoxicity was observed between 4 h and 72 h 
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for either C-DX or P-DX ADCs.  These data were confirmed in both EGFR+++ A431 as well as 
the EGFR+ U87MG cells.   
In vitro cytotoxicity data demonstrated a robust cytotoxic response by antigen-positive 
cells to the ADC.  ADC cytotoxicity was antigen-specific, as cells with high antigen density 
were more susceptible to cytotoxic cell death.  Moreover, high DX-loaded CET ADC proved to 
be more potent than low DX-loaded CET ADC, which confirmed that it is the delivery of DX to 
the cell, not the mAb carrier, that mediates a cytotoxic response to the ADC.  Based on these 
data, ADCs were evaluated for antitumor efficacy in A431 tumor-bearing mice. 
 
Figure 5-36. P-DX and C-DX efficacy in A431 tumor-bearing mice 
 
A pharmacokinetic study was performed to help address any observed differences 
between the ADC and unconjugated mAb in the efficacy study.  Pharmacokinetic profiles of P-
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DX and C-DX were investigated at the equivalent doses in healthy mice and tumor-bearing mice, 
and each was compared head-to-head to native CET and PAN in both studies.  Due to the target-
mediated drug disposition effect, it was hypothesized that mAb and ADC would experience 
accelerated clearance in tumor-bearing mice compared to in healthy mice.  However, because the 
ADC retained EGFR-specific binding affinity, no difference between the ADC and mAb was 
expected.  The PK data in healthy mice revealed no significant differences in the circulating half-
life of mAb of ADC, regardless of drug or drug loading.  In tumor-bearing mice, the PK profile 
of PAN and P-DX are dramatically lower than the PK profile of PAN and P-DX in healthy mice, 
but the rate of clearance from circulation appears unaffected by the tumor.  Interestingly, in 
tumor-bearing mice C-DX appears to clear faster than CET.  Contrary to the PAN data, however, 
the PK data of CET and C-DX in tumor-bearing mice are not significantly different than the PK 
data in healthy mice.  These data require further analysis. 
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CHAPTER 6: SUMMARY OF CONCLUSIONS AND FUTURE DIRECTION OF 
DISSERTATION RESERACH 
 
CD44 mAb tumor uptake and retention in mice bearing a well-controlled subcutaneous 
xenograft A549 tumor highlights key attributes of mAb that impact tumor targeting, generally, 
but also specifically identifies critical attributes of CD44 mAb that enable efficient tumor 
targeting in a moderately CD44-expressing tumor cell line.  Summarized below, data from the 
study indicate the impact of CD44 mAb antigen affinity, internalization rate, and 
pharmacokinetics on CD44 mAb tumor exposure in CD44+ A549 tumor-bearing mouse. 
 
 
Figure 6-1 Association between antigen affinity and internalization rate (A) and influence of 
antigen affinity (B), internalization rate (C), and pharmacokinetics (D) on CD44+ tumor targeting 
of monoclonal antibody in CD44-overexpressing A549 tumor-bearing mice 
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The study could be improved in number of key ways.  Most notably, it would be 
important to perform association studies between tumor uptake and molecular properties of mAb 
against a novel but validated tumor antigen (1) using cGMP grade mAbs (2).  One of the biggest 
challenges in these studies was procuring enough mAb that demonstrated consistent properties in 
validation assays.  Poor quality reagent grade mAb fail to consistently perform during in vitro 
validation assays and result in irreproducible data and potential to develop false, or difficult to 
justify and validate, conclusions [3, 350].  Standard batch-to-batch variability may be one issue, 
but production, purification and lack of proper validation can also lead to irreproducibility of 
mAb in tumor homing studies.  Commercial grade mAb, produced using standard cGMP 
methods, would significantly enhance the quality and confidence of data and conclusions. 
Access to a panel of mAb of the same isotype and specific to one single epitope would 
enable exquisitely precise studies on the basic molecular properties of mAb that result in 
improved exposure and localization.  Not only would it be seamless to tease out the impact of 
specific molecular attributes like antigen affinity, pharmacokinetic profile, and internalization 
rate separate from the epitope of interest, but these studies would allow for epitope specific 
interrogation of the tumor targeting mAb for a specific biological target on the amino acid 
specific level.  Moreover, mechanistic studies in both broadly expressed antigens as well as 
selectively expressed TAA would allow for better understanding in selection of tumor targeting 
mAb for a receptor with a specific expression profile within a disease or an individual.  Such 
studies would encourage the design and engineering of mAb with specific properties for a 
specific biological target, thereby improving mAb-based targeted therapy from a one-size fits all 
approach to a specific, patient-inspired personalized approach. 
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In these studies, as has been shown in prior literature, in vitro studies failed to predict in 
vivo behavior.  Most in vitro experimental protocols poorly reflect a similar environment as what 
would occur in vivo; for example, many in vitro assays may be performed under constant 
exposure or saturating conditions, whereas flow conditions at a significantly diluted and 
progressively decreasing concentration would better reflect the true in vivo environment.  
Biodistribution studies reveal the most relevant information to tumor targeting, uptake, 
penetration, and retention of tumor homing mAbs, and therefore should serve as the workhorse 
assay for the development and evaluation of tumor targeting mAb.  Critical to the application of 
biodistribution data is a fundamental understanding as to the stability of the label, catabolism or 
metabolism of the radiolabeled mAb, and the resulting distribution of the label compared to the 
mAb active specific pharmacological events.  Cell-based assay should be used to screen for 
changes in binding, uptake, trafficking and efflux after modification of the tumor targeting mAb 
with a radioisotope.  Importantly, tumor uptake mAb labeled with non-residualizing isotopes like 
125I will show significantly reduced tumor uptake than residualizing isotopes like 64Cu or 89Zr.  
This difference is due to the intracellular processing of the radiolabel, rather than differences in 
the uptake and distribution of the mAb.  Lastly, biodistribution with radiolabeled mAb must be 
confirmed by immunohistochemistry, or another assay means that detects the antibody rather 
than the radioactive agent.  
Animal models ideally would represent the median clinical scenario of a tumor homing 
agent, as well as the expression profile of the target antigen.  Rarely do clinical samples reflect 
the order of magnitude expression used in many preclinical models.  While mAb tumor uptake 
and drug delivery studies work exceptionally well in preclinical models, clinical data show very 
low response to targeted therapies, or a response in only a very modest subset of the population.  
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Expression profiles of the target antigen must also be considered.  CD44 expression is observed 
broadly across various healthy tissues of the human body, yet in this study, the A549 tumor 
xenograft was the single CD44-expressing tissue.  Tumor homing and competition studies ought 
to be in models where a targeting agent has equal access to both healthy (low or modest 
expression) and diseased (high expression).  One way to do this is to choose a better animal 
model to perform the study.  Another strategy is to co-implant a high TAA expressing tumor and 
a low-TAA expressing tumor and study tumor uptake and retention in the animal with co-
implanted tumors of varying antigen expression. 
This study was important for a few key reasons.  The dynamic interplay between receptor 
and targeting ligand (a TAA-specific mAb, in this case) remains a poorly understood area of 
research.  Data in the literature continue to demonstrate potent, selective tumor targeting of 
mAb-based therapies and drug delivery carriers, yet most fail to show selective, preferential, or 
even reasonable homing, accumulation, or drug delivery in clinical trials.  Selective, efficient 
tumor targeting remains a critical issue due to the complexity of the selected target antigen.  
Many target antigens are found on healthy tissues, in the blood, or expressed in only a small 
subset of patients.  Moreover, the endogenous life-cycle of the receptor is rarely taken into 
account when selecting a target, let alone the targeting agent to exploit that target for tumor 
homing or drug delivery.  These factors, along with unique exposure and localization 
requirements of therapeutic and drug-loaded mAb, will continue to drive improvements in the 
field of mAb-targeted drug delivery.  Though the “plug-and-play” approach continues today, 
especially with the selection of the highest affinity mAb for tumor targeting and drug delivery, 
newer molecules buck this trend and make clear this approach will not last forever. 
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Data presented in this chapter 4 aided the design and subsequent interpretation of novel 
anti-EGFR mAbs and fragments evaluated in preclinical studies as immunoPET imaging agents.  
Those data continue to be collected and are the subject of three manuscripts in preparation [316-
318]. 
Based on the in vitro experiments we might hypothesize very-low uptake and retention of 
89Zr-DFO-N in U87MG and HT-29 tumors compared to MDA-MB-468 and A431 tumors.  
Moreover, based on the potent and complete competitive equilibrium binding studies, tumor 
uptake of radiolabeled mAb should decrease when co-administered or subsequently administered 
after cold mAb.  Finally, half-to-equal amounts of the total fraction of mAb that binds the EGFR 
in vitro (5-70% with EGFR+++ cells depending on the antigen affinity, or 0.7–8.7% with 89Zr-
DFO-N depending on EGFR expression level) internalize within the cancer cell.  64Cu and 89Zr 
are residualizing radionuclides.  Any radioactivity reaching the tumor and internalizing within 
the cancer cell will largely remain localized at the tumor.  Needless to say, these hypotheses were 
largely unconfirmed by preclinical studies. 
89Zr-DFO-N displayed greater tumor uptake and lower liver uptake than both 89Zr-DFO-P 
and 89Zr-DFO-C in EGFR+++ A431 tumor xenografts.  This was an exciting finding and 
confirmed the proposed hypothesis related to intermediate affinity mAb.  However, two different 
A431 tumor blocking studies in which cold N was co-administered or pre-dosed with 89Zr-DFO-
N, each study executed with 2-3 orders of magnitude more cold N than 89Zr-DFO-N, failed to 
block 89Zr-DFO-N from accumulating at the tumor.  Blocking studies with high-affinity 89Zr-
DFO-C and 89Zr-DFO-P increased tumor uptake.  Moreover, preclinical tumor studies in mice 
bearing A431 (EGFR+++), MDA-MB-468 (EGFR++), or U87MG (EGFR+) tumors were carried 
out with the hypothesis that EGFR immunoPET imaging agents will accumulate in tumors with 
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higher EGFR antigen expression to a greater extent than those of lower EGFR antigen 
expression.  ImmunoPET images taken at 72 h showed significantly higher tumor uptake in 
U87MG compared to MDA-MB-468 and A431 cells.  Lower tumor uptake was not observed 
during a blocking study of 89Zr-DFO-N in U87MG.    Taken together, the preliminary results 
from these preclinical immunoPET studies were, in many cases, striking and unexpected.  In 
fact, much of the data challenged my deeply held initial assumptions related to mAb tumor 
targeting.  However, a retrospective look offers perspective and adds some clarity to the murky 
waters. 
Regardless of antigen affinity, diffusion and convection are the driving forces to tumor 
uptake and penetration [81, 83].  Tumor uptake also tends to trend proportionally with larger, 
faster growing tumors.  In preclinical xenograft models, tumor size, growth rate, and the EPR 
effect should be thought of as the main drivers affecting tumor uptake of mAb and fragments.  
While antigen affinity plays a significant role in tumor retention, cellular processing and 
independent fates of the radionuclide and the mAb can muddy data and mislead interpretation. 
Moreover, tumor uptake in immunoPET studies appears more influenced by injected dose 
and time selected for immunoPET imaging than a specific pharmaceutical property of the 
immunoPET imaging agent.  This can be overcome by taking longitudinal PET images, but this 
experimental design can pose financial and logistic challenges.  In our studies, intact mAb were 
radiolabeled with zirconium-89 while mAb fragments were radiolabeled with copper-64.  The 
half-life of zirconium-89 (78 h) and copper-64 (12 h) appropriately match the half-life of their 
parent compound.  ImmunoPET images of the 89Zr-labeled mAb at 72 h showed greater tumor 
uptake for larger, faster-growing, low EGFR-expressing U87MG tumors compared to smaller, 
slower-growing, moderate EGFR-expressing MDA-MB-468 tumors.  Data may improve by 
  240 
starting the study earlier, when the U87MG tumors are smaller and growing less rapidly.  It’s 
also possible that 72 h was too early in the study to compare tumor uptake differences, and that 
greater tumor uptake in the MDA-MB-468 tumor compared the U87MG tumor might be 
observed at 120 or 168 h, as the circulating concentration decreases.  Use of intact mAb 
immunoPET imaging agents is challenging in a clinical setting, where a patient would be asked 
to return between 1 and 5 days after the dose and subjected to radioactivity for that entire period 
of time.  The impact of injected dose on tumor uptake and retention was not investigated in 
preclinical studies of EGFR immunoPET imaging agents and may be one area of improvement 
for future studies.  Among the panel EGFR mAbs studied, these data suggest none serve as 
especially apt immunoPET imaging agents. 
On the other hand, anti-EGFR mAb fragments hold great promise in imaging studies and 
should be an active area of interest.  Fragments rapidly accumulate at tumor, and yet rapidly 
clear from the body, offering a narrow but sufficient window for immunoPET imaging.  
Fragments do not demonstrate properties of slow uptake and long circulation that plague intact 
mAb in imaging.  Future studies could screen engineered fragments with carefully curated size, 
charge, and affinity attributes.  Engineered fragments could enable improved tumor targeting.  
Moreover, a panel of engineered fragments, each with a unique feature (vary the size, affinity, 
charge, etc.), could be used to evaluate specific hypotheses related to tumor targeting, as well as 
engineered and improved to overcome the pathophysiological barriers to effective immunoPET 
imaging and agent development.  Small fragments tethered together could improve affinity and 
selectivity in some tumor models [106], yet still overcome the disadvantages of large and 
complex bispecific antibodies. 
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Because many cancer cells express the EGF receptor at orders of magnitude greater 
quantity than healthy cells, we hypothesized that an antibody-docetaxel conjugate would 1) limit 
the exposure of healthy tissues to docetaxel in vivo and 2) lower the cytotoxicity of antibody-
docetaxel conjugates to low EGFR-expressing cells in vitro.  Covalent modification of docetaxel 
with the non-cleavable SPDP linker followed by bioconjugation to partially reduced anti-EGFR 
antibody significantly improved the specificity of docetaxel for high-EGFR expressing cancer 
cell lines.  Given the recent trend toward repurposing therapeutic mAbs as targeting agents for 
molecules with extremely poor therapeutic indices, like the auristatins or maytansinoids, we were 
also interested to evaluate whether synergistic effects could be detected with therapeutic mAbs 
conjugated with drugs offering a different mechanism of action.  Anti-EGFR antibody-docetaxel 
conjugates were prepared and evaluated for antitumor efficacy in vitro and in vivo. 
Docetaxel is 2-3 orders of magnitude lower potency than ADC payloads under current 
preclinical and clinical investigation.  As such, we recognized that ADC activity would be 
modest compared to the free drug or free antibody alone.  In the nature of a proof-of-concept 
study, we identified antigen-dependent activity as the key metric to define improvements in the 
safety of anti-EGFR therapy compared to docetaxel alone.  Safety was assessed in vivo due to the 
mAb and ADC dosing requirements needed to reach equimolar doses in mice as docetaxel MTD.  
Therefore, we assessed safety and efficacy as a function of cell surface EGFR density.  
Significant differences in activity were observed between the DX-ADCs and DX alone on 
EGFR+++ A431, EGR++ MDA-MB-468, and EGFR+ U87MG cells. 
While anti-EGFR antibody-drug conjugates have been prepared and evaluated before, the 
novelty of this study was the parallel synthesis and characterization of PAN and CET ADCs.  
Moreover, a docetaxel antibody-drug conjugate has not been reported, nor has the stepwise 
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reduction-alkylation protocol been extended to the anti-EGFR mAbs.  Finally, a literature search 
has thus far not identified a disulfide-linked ADC where the disulfide bond is formed at the 
cysteine residue of the reduced interchain disulfide of the mAb.  The reasons for this are not 
clear, but based on these limited data, two hypotheses could be poor drug loading and impaired 
physicochemical properties of the mAb. 
When combined with standard chemotherapy, drugs targeting EGFR have proven to be 
effective therapies that decrease tumor growth and significantly improve survival.  The ADC 
approach may be one way to improve therapy to EGFR-overexpressing tumor.  In this study, the 
rapid disulfide reformation of PAN and relative fragility of CET posed a challenge to achieving 
high DAR ADCs with these two anti-EGFR mAbs.  Moreover, the study was challenged by 
using a modestly potent DX prodrug, which also exhibited extremely poor aqueous solubility.   
Thus, demonstrating an efficacy profile of the ADC that outperformed drug alone was an uphill 
battle. 
I surmise that the literature might be mostly void CET and PAN ADCs because of the 
issues uncovered during bioconjugation.  And, because the conversion percentage is so low, 
ADCs using drugs at the potency level of docetaxel must carry 8 drugs or more per antibody. 
This can induce precipitation and rapid degradation of the antibody, for one, but other mAbs 
(like CET or PAN) may reduce to fragments or reform or to such high drug loading.  Therefore, 
it’s not surprising therapeutic mAbs are not generally under exploration in ADC platforms.  The 
ideal properties of a therapeutic mAb are unique to its function, just as the antibody element of 
an ADC is unique to its function.  
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